


NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS AND RISK BEHAVIOUR SURVEY REPORT

2004, 2007 AND 2010



Prevalence of HIV, hepatitis C, hepatitis B, sexually transmissible infections, and risk behaviours among Australian prison entrants



Kirby Institute

www.kirby.unsw.edu.au

Postal Address:

The Kirby Institute
The University of New South Wales
CFI Building
Cnr Boundary & West Streets
Darlinghurst NSW 2010

Telephone: 02 9385 0900

Facsimile: 02 9385 0920

Email: recpt@nchechr.unsw.edu.au

NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS & RISK BEHAVIOUR SURVEY 2004, 2007, and 2010

Prevalence of HIV, HBV, HCV, and risk behaviours
among Australian prison entrants

NATIONAL REPORT
2004, 2007, and 2010

Report prepared by Tony Butler, David Lim, Denton Callander

The Kirby Institute (University of New South Wales) and National Drug Research Institute
(Curtin University)

September 2011



Suggested citation:

Butler, T, Lim D, & Callander D. National Prison Entrants' Bloodborne Virus and Risk Behaviour Survey Report 2004, 2007, and 2010. Kirby Institute (University of New South Wales) and National Drug Research Institute (Curtin University). 2011. ISBN: 978-0-7334-3055-8

CONTENTS

CONTENTS	1
ACKNOWLEDGEMENTS.....	3
FOREWORD	5
EXECUTIVE SUMMARY	6
Background.....	6
Methods.....	6
Results.....	7
Implications of the Findings.....	9
INTRODUCTION	12
METHODS	13
Study Sample.....	13
Sample Selection	13
Recruitment.....	13
Survey Sites	14
Screening Procedures	14
Blood Testing	14
Urine Testing.....	15
Questionnaire.....	15
Statistical Analysis	15
Interviewers.....	15
Ethics Approval	15
Reporting of Results.....	16
RESULTS.....	16
Response Rate	16
Summary	19
National	25
HIV antibody prevalence.....	32
HCV antibody prevalence	34
HBV prevalence	41
Chlamydia.....	52
Gonorrhoea.....	52
Syphilis.....	52
New South Wales	53
HIV antibody prevalence.....	60
HCV antibody prevalence	60
HBV prevalence	67
Chlamydia.....	79
Gonorrhoea.....	79
Syphilis.....	79
Northern Territory.....	80
HIV antibody prevalence.....	87
HCV antibody prevalence	87
HBV prevalence	91
Chlamydia.....	97
Gonorrhoea.....	97
Syphilis.....	97
Queensland.....	98
HIV antibody prevalence.....	105
HCV antibody prevalence	105
HBV prevalence	112
Chlamydia.....	123
Gonorrhoea.....	123
Syphilis.....	123

South Australia.....	124
HIV antibody prevalence	131
HCV antibody prevalence.....	131
HBV prevalence	135
Chlamydia.....	141
Gonorrhoea.....	141
Syphilis.....	141
Tasmania	142
HIV antibody prevalence	149
HCV antibody prevalence.....	149
HBV prevalence	156
Chlamydia.....	168
Gonorrhoea.....	168
Syphilis.....	168
Victoria.....	169
HIV antibody prevalence	175
HCV antibody prevalence.....	176
HBV prevalence	183
Chlamydia.....	194
Gonorrhoea.....	194
Syphilis.....	194
Western Australia.....	195
HIV antibody prevalence	202
HCV antibody prevalence.....	202
HBV prevalence	209
Chlamydia.....	220
Gonorrhoea.....	220
Syphilis.....	220
Methodological Notes.....	221
Appendix 1 – Blood Tests, Test Kits and Testing Laboratories.....	223
Appendix 2 – Questionnaire	224
References	226

ACKNOWLEDGEMENTS

We are grateful to the project steering group and the site co-ordinators:

Project steering group:

Professor Tony Butler (National Drug Research Institute & National Centre in HIV Epidemiology & Clinical Research); **ACT:** Professor Michael Levy (ACT Corrections Health); **NSW:** Dr Devon Indig (Justice Health NSW); **NT:** Kiah McGregor, Simon Stafford, and Robyn Hopkins (NT Correctional Services); **Qld:** Dr Alun Richards and Stacy Kambouris (Queensland Health); **SA:** Dr Peter Frost and Karen Harlin (SA Prison Health Service); **Tas:** Dr Chris Wake and Deborah Siddall (Tas Correctional Primary Health Services); **Vic:** Fiona MacFarlane and Michele Gardner (Justice Health Victoria); and **WA:** Holly Beasley (WA Corrective Services).

State and Territory co-ordinators:

ACT: Professor Michael Levy; **NSW:** Dr Devon Indig; **NT:** Simon Stafford and Kiah McGregor; **Qld:** Stacy Kambouris; **SA:** Karen Harlin; **Tas:** Deborah Siddall; **Vic:** Fiona MacFarlane; and **WA:** Holly Beasley.

The following individuals conducted the interviews:

ACT: Jenny Kuzek.

NSW: Phe Affleck, Nicole Ang, Karen Aquilina, Vicki Archer, Shalin Kumar, Helen Pearce, Meredith Picker, Jing Prideaux, Elaine Robinson and Aleta Stevenson.

NT: Jenny Grimes and Gary Lucas.

Qld: Hillary Barrett, Judy Gallie, Lisa Imhoff, Stacy Kambouris, Janelle Kelly, Norma Lane, Shirley Petrie, Katherine Ransley, Jillian Rayfield and Sandra Wolfenden.

SA: Jo Andrews, Jackie Hughes, Robynne Lower, Joanne Peak, Jamie Reed, Sue Rex, Ronnie Richardson, Janice Scott, Catherine Whatson.

Tas: Matthew Chick.

Vic: Jackie Ayad, Nikki Bartolo, Evan Hill, Kelly O'Reilly, Krystyna Ramshaw, Sue Tran, Mel Tyson and Sarah Walsh.

WA: Holly Beasley, Shona Curri, Diane Delaney, Clyde DuBois, Beryl Joines, Gail Jones, Treena Martin, Ian Matthews, Suzanne Mill, Yvonne Morris and David Venables.

We wish to thank everyone who assisted in the development and conduct of the National Prison Entrants' Bloodborne Virus & Risk Behaviour Survey including the participants, health professionals at the survey sites, prison managers and prison officers for their cooperation in

accommodating the survey teams, laboratory staff, and nursing staff involved in providing the results back to participants.

We are grateful for the assistance provided by staff at the Kirby Institute (formerly the National Centre in HIV Epidemiology and Clinical Research), particularly Jenny Ivers and Libby Topp. David Coombe and Errol Banford from the National Centre for Social Applications of GIS, the University of Adelaide assisted with the Accessibility/Remoteness Index of Australia (ARIA). Leng Boonwaat and Linda Garton for assistance with interpreting the hepatitis B immunity results and Basil Donovan for advice on the sexual health component of the survey. Nesin Kok for help with the data entry. Mrs Imelda Butler for proof reading the report.

Financial support:

The cost of the data collection and screening was borne by the jurisdictions. Support for the co-ordination and report writing was provided by Justice Health NSW, Western Australia Department of Corrective Services, Northern Territory Correctional Services, Queensland Health, South Australia Prison Health Service, Tasmania Correctional Primary Health Services, and Justice Health Victoria. Professor Tony Butler is supported by an ARC Future Fellowship (#0991864).

FOREWORD

The first National Prison Entrants' Bloodborne Virus & Risk Behaviour Survey (NPEBBV&RBS) was conducted in 2004 and we are pleased to present the third iteration of this study - the 2010 national report.

The prevalence of hepatitis C is over thirty times higher among prisoners than the general community, highlighting the need to monitor blood-borne viruses in this population. The NPEBBV&RBS fulfils this important role and represents one of the few nationally collaborated prisoner health projects in Australia.

The 2010 survey includes data, for the first time, from all jurisdictions across Australia. It is unique in the world in providing routine surveillance on the prevalence of blood-borne viruses (HIV, hepatitis B, hepatitis C) among this population on a national basis. The NPEBBV&RBS is an important adjunct to the Australian National Needle and Syringe Program Survey on which the survey was originally based. The prison survey screens prisoners who report injecting drug use and also those with no history of injecting who are nonetheless at risk of contracting blood-borne viruses from other routes such as tattooing and other blood-to-blood contact.

The NPEBBV&RBS has several features which enhance our knowledge of blood-borne virus epidemiology in Australia: it provides unique access to groups known to be over-represented in prisons such as Indigenous Australians (25% of Australia's prisoners are Indigenous), the survey tests for hepatitis B immunity in a marginalised group, and venous blood samples are used providing a high degree of test accuracy and permits the test results to be provided back to participants.

Prisoners are known to engage in sexual risk behaviours and thus the 2010 survey was expanded to screen for three sexually transmissible infections - syphilis, gonorrhoea and chlamydia. It is reassuring that the 2010 survey findings did not indicate these infections to be at levels indicating an outbreak among those entering prison. No cases of HIV were detected in 2010 which is reassuring.

Monitoring blood-borne viruses among prisoners is important for the overall community response to preventing the spread of infectious diseases and the planning of appropriate prevention strategies. The utility of this survey is highlighted by its use in all of the Commonwealth Government's recently released national communicable diseases strategies which recognise prisoners as a key population in communicable disease control in Australia.

EXECUTIVE SUMMARY

Background

Prisoner populations are characterised by engagement in a range of risk behaviours, most notably injecting drug use. Consequently they are at an increased risk of exposure to blood-borne viruses such as hepatitis B, hepatitis C and HIV. Previous Australian research has shown that hepatitis C is between thirty to forty times higher among prisoners compared with the general community. Therefore, surveillance of this population to detect the presence of blood-borne pathogens and identify trends in risk behaviours is important in planning effective prevention strategies. This is the third prison entrants' survey to have been conducted; the first was undertaken in 2004 and the second in 2007. The 2010 survey was enhanced to test for three sexually transmissible infections (STI) - chlamydia, gonorrhoea, and syphilis.

Methods

The study represents a consecutive survey of prison entrants conducted over two weeks in October 2004, 2007 and 2010. Participants in 2010 were 873^a of the 1154 consecutive prison entrants in all jurisdictions. Twenty-nine reception centres in the Australian Capital Territory (ACT), New South Wales (NSW), Northern Territory (NT), South Australia (SA), Queensland (Qld), Tasmania (Tas), Victoria (Vic) and Western Australia (WA) participated in the survey (Table 1).

The survey screened for the following markers: HIV antibody and antigen, hepatitis B surface antibody and antigen, hepatitis B core antibodies (IgM and IgG), hepatitis B e-antigen and antibody, hepatitis C antibody, *Treponema pallidum* antibody, *Chlamydia trachomatis* DNA and *Neisseria gonorrhoea* DNA (see Appendix 1).

Test results are made available to participants and appropriate treatment pathways identified including education and advice, hepatitis B vaccination, treatment for sexually transmissible infections, and referrals for hepatitis C treatment.

Risk behaviour and demographic information was collected using a short questionnaire covering injecting and illicit drug use, body piercing and tattooing, sexual activity, hepatitis B and cervical cancer immunisation, and tobacco smoking (see Appendix 2).

^a Nine participants consented to participate in the 2010 survey but were excluded due to missing information for the main classification variable (injecting drug user status) and 53 participants provided a blood and/or urine specimen but no questionnaire information. The 2010 results report the findings for the 811 participants for whom complete data were available.

Results

Demographic & criminographic characteristics

- The overall response rate to the survey was high at 76%.
- In 2010, 32% of the sample was Indigenous which is higher than the national census¹ proportion of Indigenous prisoners (25%). Similarly, women represented 9.5% of the sample which is slightly higher than the proportion of women prisoners in Australia (7.5%).¹
- Only 2% of those with a history of injecting drug use and 3% of non-injectors were classified as primary homeless (i.e. sleeping rough, squat, long grass, boat, or car).
- Most of those taking part in the 2010 survey (79%) lived in 'highly accessible' and 'accessible' areas prior to prison based on the Accessibility/Remoteness Index of Australia². Living in 'highly accessible' and 'accessible' areas was more common among people who reported using injecting drugs (89%) compared with those who did not (72%).
- Consistent with results from the 2004 and 2007 surveys, eight out of ten prisoners in 2010 with a history of injecting drug use reported they had previously been incarcerated. In 2010, six out of ten non-injectors reported a prior incarceration.

Blood-borne viruses

- No cases of HIV were detected among the prisoners screened in 2010. This represents a small decrease from 2004 and 2007, both of which reported less than 1% nationally.
- In 2010, the overall prevalence of hepatitis C antibody was 22%, a decrease from 35% in 2007. Among states where more than 30 prisoners were tested, hepatitis C prevalence was highest in Victoria (33%) and lowest in the Northern Territory (4%).
- As in previous surveys, hepatitis C antibody prevalence was higher among those with a history of injecting drug use compared with those who had not injected (51% versus 1% in 2010) and higher among women who injected compared with men (68% versus 49% in 2010).
- Among Indigenous injecting drug users there was a decrease in the prevalence of hepatitis C antibody between 2007 and 2010 from 64% to 52%.
- Nationally, only 7 prisoners (5%) reported having ever received treatment for hepatitis C.

- Nationally, 19% of those tested were positive for hepatitis B core-antibody. This was highest in the Northern Territory (39%) and lowest in South Australia (9%). Some jurisdictions, notably Tasmania and Queensland, saw an increase in hepatitis B core-antibody prevalence from 9% in 2007 to 17% in 2010 for both jurisdictions.
- While there was an increase in the prevalence of hepatitis B core-antibody among Indigenous injecting drug users between 2004 and 2007 (38% to 48%), 2010 saw a decrease in prevalence to 18%.
- Nationally, 41% of those screened in 2010 showed no evidence of immunity against hepatitis B and are therefore vulnerable to infection. The proportion of prisoners who are unimmunised against hepatitis B infection was highest in Tasmania (57%) and lowest in Queensland (15%).
- Of the 207 tested in 2010 who reported they had been vaccinated against hepatitis B, 72% had hepatitis B surface-antibody levels signifying immunity. Conversely, 135 individuals reported that they had not been vaccinated against hepatitis B but the tests revealed that 25% of them had hepatitis B surface-antibody levels considered as conferring immunity.

Sexually transmissible infections

- Among eligible women (those who would have been 27 years or younger in 2007), 62% reported they had not been vaccinated against cervical cancer with one woman unsure of her vaccination status.
- Rates of sexually transmissible infections were no higher than in the general population - chlamydia (5% of men, 2% of women), and gonorrhoea (1% of men, 0 women). For syphilis, 6% of men and 6% of women had markers consistent with past or present infection, 2% had markers indicating possible current infection, and only 1 had an RPR titre level indicating current infection.

Risk behaviours

- Less than half of those screened in 2010 reported they had ever injected drugs (44%) which is down from 2007 (55%). Of these, 56% had injected in the past month.
- As in 2004 and 2007, amphetamine was the most common drug to be last injected - 58% in 2004, 59% in 2007, and 59% in 2010. Heroin was the second most common drug to be injected at 25%, down slightly from previous years (32% in 2004, 31% in 2007).

- Victoria and the Northern Territory reported the lowest levels of injecting amphetamine as the last drug injected (39% and 33%) and Western Australia reported the highest level at 75%.
- As in previous years, most injecting drug users had done so for more than 3 years (87%) suggesting that the prisoner population is characterised by longer term drug users.
- Most injecting drug users reported using clean needles over the past month for 'all' (69%) or 'most' (21%) of their injections.
- As in 2007, 85% of prisoners reported they were current tobacco smokers. The median age of first tobacco smoking was 14 years. For those with histories of injecting drug use, the median age of first tobacco smoking was 13 years.
- Most prisoners had had sex in the past 3 months (83%).
- A small number of prison entrants reported they had been paid for sex in the past 3 months (2%), of these 63% reported using a condom.
- Prisoners reported inconsistent condom use, regardless of whether with male or female partners. Half of participants reported never using condoms with 'casual' partners in the past 3 months.

Implications of the Findings

- Prison provides an important public health opportunity to monitor high-risk populations for exposure to blood-borne infections and, if appropriate, initiate prevention and treatment measures.
- Given the high prevalence of hepatitis C and hepatitis B in this population compared with the community, it is important that this survey be regularly conducted to inform policy and health services planning for this [at-risk] group at local, state and national level. The findings from the previous surveys are utilised by all of the Commonwealth Government's recently released national communicable diseases strategies and highlight prisoners as a 'priority population. It is therefore appropriate to conduct the NPEBBVS&RBS every two years rather than the current triennial survey.

- Prevention initiatives need to target prison entrants, particularly those with a history of injecting drugs and who are in prison for the first time. This group was less likely to have been exposed to hepatitis C (10% versus 56% for those with 10+ incarcerations) suggesting an important opportunity to intervene and prevent blood-borne virus acquisition.
- Nationally, around 40% of all prison entrants were unimmunised against hepatitis B and therefore vulnerable to infection. This group should be vaccinated as a matter of priority. Accelerated vaccination schedules are effective and should be considered for this population considering their mobility and, in many cases, their inability to complete the recommended six month schedule.
- While the prevalence of HIV has remained low in all jurisdictions across surveys (2004, 2007 and 2010), the NPEBBV&RBS has an important role to play in monitoring this trend. The prisoner population is comprised of highly marginalised individuals (e.g. those with histories of mental illness and Indigenous Australians) who are often excluded from community surveys. The NPEBBV&RBS therefore provides an important opportunity to monitor these population groups.
- In 2004, 18% of those who reported they were negative for hepatitis C tested positive for HCV antibody, in 2007 16% reported they were negative but tested positive, and in 2010 7% reported they were negative but tested positive. This reinforces the benefits of ongoing testing of prisoners for blood-borne pathogens such as hepatitis C to reduce the number who are unaware of their exposure to hepatitis C.
- In previous surveys, the prevalence of hepatitis B core-antibody and hepatitis C antibody among Indigenous injecting drugs users has been high (48% and 64% in 2007). However, in 2010 there were significant drops for both hepatitis B (18%) and hepatitis C (52%) suggesting that programs targeting Indigenous IDU may be effective.
- In 2010, 7 (5%) hepatitis C antibody positive prisoners reported receiving treatment for hepatitis C (*cf.* 1 [0.5%] in 2007 and 2 [2%] in 2004). No Indigenous prisoners reported receiving treatment for hepatitis C in either 2004, 2007 and only 1 NSW Indigenous prisoner reported receiving treatment in 2010. This suggests that this population is underserved with regard to hepatitis C treatment and would benefit from the development of comprehensive prison-based treatment programs. Culturally appropriate treatment programs targeting Indigenous prisoners are recommended.
- Amphetamine remains the most frequently reported drug last injected by prison entrants. Amphetamine substitution therapies should be investigated and service providers need to

ensure that staff receive training in recognising and managing amphetamine withdrawal on entry to prison.

- Tobacco smoking is at epidemic proportions among prisoners with almost 9 out of 10 prisoners reporting they currently smoke. Effective and sustainable (i.e. post-release) smoking cessation programs need to be developed for this population. This needs to be addressed as a matter of national health priority. Incarceration is an important, but underutilised, public health opportunity to initiate quit smoking programs among this group to ensure sustained cessation.

INTRODUCTION

Prisoner populations are characterised by engagement in a range of health risk behaviours, most notably injecting drug use.³⁻⁵ Consequently they are at an increased risk of exposure to blood-borne viruses such as HIV and viral hepatitis.⁶⁻¹¹ Australian and overseas studies have consistently shown prisoner populations to have rates of blood-borne viruses many times that of the community. The prison setting has been shown to be a high risk environment for blood-borne virus transmission from sharing contaminated injecting equipment, tattooing, and other blood-to-blood contact.¹²⁻¹⁴

Monitoring blood-borne virus infections in Australia occurs through ad hoc prevalence surveys^{7,8,15} of prisoners in the states and territories, and through screening of prison receptions¹⁶. However, screening strategies vary across Australia in terms of both scope and coverage. Nationally just under one third of Australian prison entrants (31%) were tested for HIV. This ranged from 15% in South Australia to 45% in Western Australia. No national data are available for hepatitis C and hepatitis B testing among prisoners.

Since 1995, the Kirby Institute (formerly the National Centre in HIV Epidemiology and Clinical Research [NCHECR]) has monitored blood-borne viruses in high-risk groups in the community.¹⁷ Injecting drug users (IDU) at community Needle and Syringe Programs (NSP) are invited to self-complete a risk behaviour questionnaire and to provide a finger-prick sample of blood to test for HIV and hepatitis C. The survey is conducted annually over a one-week period.

Following discussions with NCHECR in 2003, it was agreed to adapt the NSP survey and apply it to the prison setting in an effort to provide systematic information on blood-borne virus prevalence across Australia and to enable comparisons with NSP survey data.

This report presents the findings from the 2004, 2007 and 2010 surveys.

METHODS

Study Sample

The study is a consecutive cross-section of prison entrants over two weeks during October 2010. The prison survey was designed to run at the same time as the community NSP survey to minimise any overlap of participants between the two surveys. Participants were 873 of the 1154 (76%) consecutive prisoners entering Australian correctional centres. However, 53 participants provided a blood and/or urine specimen but no questionnaire information, and 9 participants provided a blood and/or urine sample with some questionnaire information but were excluded due to no information on the main classification variable - injecting drug user status. The 2010 results therefore report the findings for the 811 participants for whom complete data were available.

Sample Selection

New receptions at 29 sentinel sites were invited to participate in the assessment. However, complete data were only available for 27 sites (Table 1). New receptions were defined as individuals entering prison from the community and did not include remanded inmates returning from court appearances or prisoners transiting through the survey site *en route* to other prisons.

Recruitment

We aimed to minimise any disruption to the prison reception process by conducting the survey immediately after the initial health and welfare assessments which are routinely conducted on all individuals received into prison. Those unable to be screened at the time of reception were called up within approximately twenty-four hours of entry into the prison and invited to participate.

Potential participants were given an outline of the project by a member of the survey team. The explanation emphasised the following: involvement was voluntary, the structure of the assessment consisted of a short questionnaire followed by blood testing, there was no obligation to answer any questions deemed intrusive or sensitive, and information would remain confidential. Participants were also informed that every effort would be made to return the blood test results, even if they were in the community, and that post-test counselling would be provided and referrals made to specialist services if necessary. Written consent was obtained from all participants. No payment was made to participants.

Confidentiality was maintained on the questionnaires and serology requests through the use of a code comprising the first two letters of each participant's surname and first name, their date of birth and a unique inmate identifier number.

Survey Sites

Twenty-nine sentinel reception sites in six states and two territories participated in the 2010 study (Table 1). These centres receive both men and women prisoners directly from the community. In all jurisdictions, prisoners are received into the correctional system through a limited number of reception sites. Therefore, by targeting these sites we could be certain that we were accessing most of the eligible prison receptions across the participating jurisdictions. For example, in Victoria all male receptions are processed through the Melbourne Assessment Prison and in New South Wales, the Metropolitan Reception and Remand Centre (MRRC) in Sydney processes approximately two-thirds of the state's prisoners. Overall, the 2010 survey screened 76% of all prisoners entering the Australian correctional system at the reception sites given in Table 1.

Screening Procedures

Screening was divided into several stages to provide a consistent structure to the survey. Broadly, this involved recruiting participants and obtaining consent, administering the questionnaire, providing pre-test counselling for those who consented to blood testing, and collecting the blood specimen. Pre-test discussion included psychological assessment of the person's ability to deal with a positive result, provision of information about the possible consequences of infection with blood-borne viruses, transmission risks, confidentiality and notification requirements related to blood tests and treatment options for those who tested positive. Those who consented to the blood test were also informed that face-to-face post-test counselling would be provided as soon as results became available for both positive and negative test results. In some cases this involved community follow-up.

Blood Testing

Screening for blood-borne viruses included testing for the following markers:

- HIV antibody and antigen
- Hepatitis B surface-antibody
- Hepatitis B surface-antigen, and if positive hepatitis B e-antigen and e-antibody
- Hepatitis B (IgM & IgG) core-antibody
- Hepatitis C antibody
- *Treponema pallidum* (syphilis) antibody

Urine Testing

Screening for sexually transmissible infections included testing for the following markers:

- *Chlamydia trachomatis* (chlamydia) DNA
- *Neisseria gonorrhoea* (gonorrhoea) DNA

Details of test kits used for the blood and urine testing by the various laboratories are provided in Appendix 1.

Questionnaire

The NSP survey questionnaire was originally designed for the community setting to collect behavioural risk factor information on body piercing, tattooing, injecting drug use, sexual activity, and immunisation status. A small number of modifications were made to this screening instrument to adapt it to the correctional setting (Appendix 2). The questionnaire was piloted in each jurisdiction to ensure it was appropriate for a prisoner population, including Indigenous prisoners. In 2010, questions were added on living situation prior to prison, other drug use (not just injecting drug use), and cervical cancer vaccination. The sexual health questions were modified to cover the past 3 months and differentiate male and female sex partners.

Statistical Analysis

All data were analysed using SPSS version 19. Associations between demographic and behavioural variables and exposure to blood-borne viruses and sexually transmissible infections were assessed using the χ^2 test.

Interviewers

Interviewers were recruited from nursing staff within each state's and territory correctional health system. Training of site co-ordinators was undertaken via a number of teleconferences with the principal investigator (TB) who in turn trained the local interviewers. Aboriginal health workers were recruited in Western Australia to facilitate data collection among Indigenous prisoners (around 40% of prisoners in Western Australia are Indigenous).

Ethics Approval

Approval for the project was obtained from the human research and ethics committees in the ACT, NSW, SA, Tas, and WA. In addition to the health-based ethics committees, approval was sought separately from corrective services' ethics committees in NSW, Qld, Vic, and WA. In WA, approval was granted by the Western Australia Aboriginal Health and Information Ethics Committee. The study was also approved by the Curtin University HREC.

Reporting of Results

The following sections present the findings from the survey stratified by injecting drug user status. For this reason, only those for whom we have information regarding injecting drug user status have been included in the analysis. Percentages have been rounded to the nearest whole number. In this report, the prisoners, prison entrant and inmate are used interchangeably as are reception centre and prison.

RESULTS

Response Rate

A number of inmates declined to participate in the survey ('refusers') while others agreed to answer the questionnaire but opted not to provide blood. A small number initially agreed to provide a blood sample but were unable to do so due to poor venous access. Some of the reasons given by the 'refusers' included a perceived lack of personal gain from participation, needle phobia, and feeling fatigued or stressed during the reception process.^b

The response rate was calculated as follows^c:

$$\frac{\text{Total participants}}{\text{Total receptions}} \times 100$$

The overall response rate to the survey was 76% with men being more likely than women to consent to participate (76% versus 69%). The response rate for Aboriginal & Torres Strait Islanders was 86% compared with 71% for non-Aboriginal & Torres Strait Islanders. Screening rates varied between reception sites (Table 1). Low screening rates were often attributable to local conditions at the site such as overcrowding and consequent inmate dissatisfaction, and staff shortages.

^b The reception process is often conducted at the end of the day and sometimes in the early hours of the morning. This is because the courts process people during the day and those receiving a custodial sentence or remanded into custody are taken to the reception prison at the end of the day. Once at the prison there is often a waiting period in a holding cell before they are seen by welfare and medical staff. The high response rate seen in this survey is a credit to the skill of the reception nurses in highlighting the benefits of the survey to prisoners in what is perhaps one of the most stressful and harrowing periods of the participant's life.

^c The response rate includes the 9 individuals who participated in the survey but were not included in the analysis due to missing data for the main classification variable - injector status.

Table 1 Reception centre, sex of prison receptions, participants screened, and total number of receptions, 2010 NPEBBV&RBS

State	Reception Site	Sex of prisoners	Total N° of receptions*	N° screened (%)	N° screened with complete data (%)
ACT	Alexander Maconochie Centre	Men & women	16	15 (94)	13 (81)
NSW	Bathurst CC	Men	7	1 (14)	1 (14)
	Cessnock CC	Men	1	1 (100)	1 (100)
	Grafton CC	Men	18	11 (61)	10 (56)
	Goulburn CC	Men	8	5 (63)	5 (63)
	Metropolitan Remand & Reception Centre	Men	234	213 (91)	212 (91)
	Silverwater Women's CC	Women	26	13 (50)	13 (50)
	Tamworth CC	Men	17	13 (76)	12 (71)
	<i>Total</i>		311	257 (83)	254 (82)
NT	Alice Springs CC	Men & women	41	34 (83)	33 (80)
	Darwin CC	Men & women	42	42 (100)	42 (100)
	<i>Total</i>		83	76 (92)	75 (90)
Qld	Arthur Gorrie CC	Men	86	72 (84)	69 (80)
	Brisbane CC	Men & women	86	78 (91)	77 (90)
	Capricornia CC	Men	21	21 (100)	19 (90)
	Lotus Glenn CC	Men	39	39 (100)	37 (95)
	Townsville CC	Men & women	37	35 (95)	9 (24)
	<i>Total</i>		269	245 (91)	211 (78)
SA	Adelaide Remand Centre	Men	62	18 (29)	17 (27)
	Adelaide Women's Prison	Women	21	11 (52)	11 (52)
	Port Augusta Prison	Men & women	10	9 (90)	8 (80)
	Port Lincoln	Men	1	0 (0)	0 (0)
	Yatala Labour Prison	Men	53	21 (40)	20 (38)
	<i>Total</i>		147	59 (40)	56 (38)
Tas	Hobart Reception Prison	Men & women	23	20 (87)	18 (78)
	Launceston Reception Prison	Men & women	13	8 (62)	3 (23)
	Mary Hutchinson's Women's Prison	Women	1	1 (100)	1 (100)
	Risdon Prison Complex	Men	10	10 (100)	10 (100)
	<i>Total</i>		47	39 (83)	32 (68)
Vic	Dame Phyllis Frost Centre	Women	12	6 (50)	6 (50)
	Melbourne Assessment Prison	Men	126	43 (34)	42 (33)
	<i>Total</i>		138	49 (36)	48 (35)
WA	Bandyup Women's Prison	Women	9	8 (89)	8 (89)
	Hakea Prison	Men	123	114 (93)	114 (93)
	Roebourne Regional Prison	Men & women	11	11 (100)	0 (0)
	<i>Total</i>		143	133 (93)	122 (85)
Total			1154	873 (76)	811 (70)

* Taken from the running sheets provided by jurisdictions for the period: 11th October - 22nd November 2010.

Under half (44%) of all respondents reported current or previous injecting drug use (Table 2).

Table 2 Structure of the study sample by sex and injector status, 2010 NPEBBV&RBS

Sex	Ever Inject Drugs		Total
	No	Yes	
Men	424 (58%)	310 (42%)	734 (100%)
Women	34 (44%)	43 (56%)	77 (100%)
Total	458 (57%)	353 (44%)	811 (100%)

Summary 2010

Table 3 Demographic characteristics of prison entrants by jurisdiction (2010)

	State								Total
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	
N° of sites	1	7	2	5	4	4	2	2	27
N° surveyed	13	254	75	211	56	32	48	122	811
N° (%) Male	11 (85)	241 (95)	72 (96)	180 (85)	43 (77)	31 (97)	42 (88)	114 (93)	734 (91)
Median age (years)	28	31	31	30	32	26	31	29	30
Age range	18 – 53	17 – 79	18 – 56	17 – 66	19 – 80	19 – 59	20 – 75	18 – 74	18 – 80
N° (%) Indigenous	2 (15)	49 (19)	66 (88)	72 (34)	20 (36)	5 (16)	5 (10)	41 (34)	260 (32)
N° (%) Aust. Born	10 (77)	195 (77)	71 (95)	182 (86)	53 (95)	32 (100)	40 (83)	103 (84)	686 (85)

Table 4 Injecting drug use, smoking status, other drug use by jurisdiction (2010)

	State								Total
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	
N° (%) with IDU history	5 (39)	100 (39)	9 (12)	85 (40)	27 (48)	19 (59)	31 (65)	77 (63)	353 (44)
Last drug injected									
Amphetamine	5 (100)	49 (49)	3 (33)	49 (58)	19 (70)	12 (63)	12 (39)	58 (75)	207 (59)
Anabolic steroids	--	1 (1)	--	--	1 (4)	--	--	--	2 (1)
Cocaine	--	2 (2)	--	1 (1)	--	--	--	--	3 (1)
Heroin	--	37 (37)	--	21 (25)	6 (22)	--	14 (45)	10 (13)	88 (25)
Heroin + amphetamine	--	--	--	--	--	--	--	--	--
Heroin + cocaine	--	2 (2)	--	--	--	--	2 (6)	--	4 (1)
Methadone	--	4 (4)	--	--	1 (4)	--	--	--	5 (1)
Morphine	--	2 (2)	2 (22)	5 (6)	--	5 (26)	2 (6)	4 (5)	20 (6)
Others	--	2 (2)	3 (33)	7 (8)	--	2 (11)	1 (3)	4 (5)	19 (5)
Not reported	--	1 (1)	1 (11)	2 (2)	--	--	--	1 (1)	5 (1)
N° (%) injected last month									
No, did not inject	2 (40)	46 (46)	4 (44)	38 (45)	16 (59)	10 (53)	8 (26)	26 (34)	150 (43)
Yes, injected	3 (60)	53 (53)	4 (44)	46 (54)	11 (41)	9 (47)	23 (74)	50 (65)	199 (56)
Not reported	--	1 (1)	1 (11)	1 (1)	--	--	--	1 (1)	4 (1)
Places injected last month (%)**									
Prison	--	--	--	2 (4)	--	--	1 (4)	1 (2)	4 (1)
Own home	2 (40)	34 (64)	3 (75)	28 (61)	7 (64)	4 (44)	15 (65)	27 (55)	120 (34)
Friend's home	3 (60)	15 (28)	2 (50)	20 (43)	3 (27)	4 (44)	8 (35)	23 (47)	78 (22)
Dealer's home	1 (20)	8 (15)	--	8 (17)	1 (9)	1 (11)	3 (13)	5 (10)	27 (8)
Street, park, beach	2 (40)	6 (11)	1 (25)	8 (17)	1 (9)	2 (22)	7 (30)	3 (6)	31 (9)
Car	2 (40)	9 (17)	--	12 (26)	3 (27)	5 (56)	9 (39)	5 (10)	45 (13)
Public toilet	1 (20)	7 (13)	--	11 (24)	1 (9)	2 (22)	6 (26)	3 (6)	31 (9)
Commercial shooting room	--	--	--	1 (2)	--	--	--	--	1 (<1)
MSIC*	--	2 (4)	--	1 (2)	--	--	--	--	3 (1)
Squat	--	--	--	1 (2)	--	--	2 (9)	1 (2)	4 (1)
Other	--	--	--	--	--	--	--	--	--
Use of sterile needles & syringes last month (%)									
All injections	1 (33)	36 (68)	4 (100)	38 (83)	10 (91)	7 (78)	11 (48)	30 (60)	137 (69)
Most of the time	1 (33)	10 (19)	--	4 (9)	1 (9)	2 (22)	9 (39)	15 (30)	42 (21)
Half of the time	1 (33)	--	--	2 (4)	--	--	2 (9)	2 (4)	7 (4)
Some of the time	--	1 (2)	--	--	--	--	1 (4)	1 (2)	3 (2)
None of the time	--	1 (2)	--	1 (2)	--	--	--	1 (2)	3 (2)
Not reported	--	5 (9)	--	1 (2)	--	--	--	1 (2)	7 (4)
Ever smoked a full cigarette (%)									
No	--	18 (7)	6 (8)	13 (6)	2 (4)	1 (3)	2 (4)	9 (7)	51 (6)
Yes	13 (100)	236 (93)	69 (92)	198 (94)	54 (96)	31 (97)	45 (94)	113 (85)	759 (94)
Not reported	--	--	--	--	--	--	1 (2)	--	1 (<1)
Current smoker (%)									
No	--	43 (17)	7 (9)	38 (18)	5 (9)	5 (16)	5 (10)	16 (13)	119 (15)
Yes	13 (100)	211 (83)	68 (91)	173 (82)	50 (89)	27 (84)	42 (88)	106 (87)	690 (85)
Not reported	--	--	--	--	1 (2)	--	1 (2)	--	2 (<1)

Table 4 Injecting drug use, smoking status, other drug use by jurisdiction (2010) (cont.)

	State								Total
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	
Other drugs used last month** (%)									
No drugs in past 4 weeks	1 (8)	114 (45)	46 (61)	70 (33)	12 (21)	9 (28)	8 (17)	25 (21)	285 (37)
Cannabis	7 (70)	98 (70)	25 (89)	93 (75)	32 (80)	18 (78)	20 (77)	79 (83)	372 (77)
Heroin	2 (20)	31 (22)	1 (4)	24 (19)	5 (13)	1 (4)	10 (39)	15 (16)	89 (18)
Cocaine	--	17 (12)	1 (4)	2 (2)	3 (8)	2 (9)	2 (8)	2 (2)	29 (6)
Amphetamine	4 (40)	67 (48)	2 (7)	40 (32)	19 (48)	7 (30)	14 (54)	55 (58)	208 (43)
Other's methadone	--	12 (9)	3 (11)	4 (3)	--	--	3 (12)	1 (1)	23 (5)
Other opiates	--	9 (6)	3 (11)	7 (6)	2 (5)	2 (9)	7 (27)	15 (16)	45 (9)
Other's buprenorphine	1 (10)	6 (4)	--	11 (9)	4 (10)	3 (13)	5 (19)	6 (6)	36 (7)
Steroids	--	4 (3)	1 (4)	1 (<1)	1 (3)	--	2 (8)	--	9 (2)
Hallucinogens	1 (10)	2 (1)	--	1 (<1)	3 (8)	--	3 (12)	2 (2)	12 (2)
Benzodiazepines	1 (10)	21 (15)	2 (7)	19 (15)	7 (18)	6 (26)	10 (39)	11 (12)	77 (16)
Ecstasy/MDA	--	8 (6)	1 (4)	4 (3)	5 (13)	1 (4)	2 (8)	12 (13)	33 (7)
Inhalants (e.g. petrol)	--	1 (<1)	--	--	1 (3)	--	--	--	2 (<1)
Other drug	--	--	1 (4)	1 (<1)	--	--	--	1 (1)	3 (<1)
Not reported	2 (15)	--	1 (1)	17 (8)	5 (9)	--	14 (29)	2 (2)	41 (5)

*Medically Supervised Injecting Centre, Sydney.

** More than one option could be selected.

Table 5 HIV antibody prevalence by jurisdiction and sex (2010)†

	Male		Female		Total	
	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV
ACT	5	0 (0)	1	0 (0)	6	0 (0)
NSW	195	0 (0)	7	0 (0)	202	0 (0)
NT	64	0 (0)	3	0 (0)	67	0 (0)
Qld	162	0 (0)	29	0 (0)	191	0 (0)
SA	29	0 (0)	7	0 (0)	36	0 (0)
Tas	30	0 (0)	1	0 (0)	31	0 (0)
Vic	26	0 (0)	5	0 (0)	31	0 (0)
WA	93	0 (0)	4	0 (0)	97	0 (0)
Total	604	0 (0)	57	0 (0)	661	0 (0)

† Excludes equivocal test results and missing values.

Table 6 HIV antibody prevalence by jurisdiction, sex and injector status (2010)†

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N° tested	N° (%) with HIV
	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV		
ACT	2	0 (0)	3	0 (0)	0	0 (0)	1	0 (0)	6	0 (0)
NSW	72	0 (0)	123	0 (0)	3	0 (0)	4	0 (0)	202	0 (0)
NT	7	0 (0)	57	0 (0)	1	0 (0)	2	0 (0)	67	0 (0)
Qld	59	0 (0)	103	0 (0)	14	0 (0)	15	0 (0)	191	0 (0)
SA	11	0 (0)	18	0 (0)	4	0 (0)	3	0 (0)	36	0 (0)
Tas	18	0 (0)	12	0 (0)	1	0 (0)	0	0 (0)	31	0 (0)
Vic	17	0 (0)	9	0 (0)	3	0 (0)	2	0 (0)	31	0 (0)
WA	60	0 (0)	33	0 (0)	2	0 (0)	2	0 (0)	97	0 (0)
Total	246	0 (0)	358	0 (0)	28	0 (0)	29	0 (0)	661	0 (0)

† Excludes equivocal test results and missing values.

Table 7 Hepatitis C antibody prevalence by jurisdiction and sex (2010)†

	Male		Female		Total	
	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV
ACT	4	2 (50)	1	0 (0)	5	2 (40)
NSW	195	46 (24)	7	2 (29)	202	48 (24)
NT	64	3 (5)	3	0 (0)	67	3 (4)
Qld	160	29 (18)	28	12 (43)	188	41 (22)
SA	26	5 (19)	7	2 (29)	33	7 (21)
Tas	29	8 (28)	1	0 (0)	30	8 (27)
Vic	25	7 (28)	5	3 (60)	30	10 (33)
WA	92	22 (24)	4	0 (0)	96	22 (23)
Total	595	122 (21)	56	19 (34)	651	141 (22)

† Excludes equivocal test results and missing values.

Table 8 Hepatitis C antibody prevalence by jurisdiction, sex and injector status (2010)†

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N° tested	N° (%) with HCV
	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV		
ACT	2	2 (100)	2	0 (0)	0	0 (0)	1	0 (0)	5	2 (40)
NSW	71	44 (62)	124	2 (2)	3	2 (67)	4	0 (0)	202	48 (24)
NT	7	3 (43)	57	0 (0)	1	0 (0)	2	0 (0)	67	3 (4)
Qld	58	29 (50)	102	0 (0)	14	12 (86)	14	0 (0)	188	41 (22)
SA	10	4 (40)	16	1 (6)	4	2 (50)	3	0 (0)	33	7 (21)
Tas	17	8 (47)	12	0 (0)	1	0 (0)	0	0 (0)	30	8 (27)
Vic	15	6 (40)	10	1 (10)	3	3 (100)	2	0 (0)	30	10 (33)
WA	59	22 (37)	33	0 (0)	2	0 (0)	2	0 (0)	96	22 (23)
Total	239	118 (49)	356	4 (1)	28	19 (68)	28	0 (0)	651	141 (22)

† Excludes equivocal test results and missing values.

Table 9 Hepatitis B surface-antigen prevalence by jurisdiction and sex (2010)†

	Male		Female		Total	
	N° tested	N° (%) with Hepatitis B surface-antigen	N° tested	N° (%) with Hepatitis B surface-antigen	N° tested	N° (%) with Hepatitis B surface-antigen
ACT	3	0 (0)	1	0 (0)	4	0 (0)
NSW	197	6 (3)	7	0 (0)	204	6 (3)
NT	51	2 (4)	3	1 (33)	54	3 (6)
Qld	151	2 (1)	28	0 (0)	179	2 (1)
SA	5	1 (20)	4	0 (0)	9	1 (11)
Tas	29	0 (0)	1	0 (0)	30	0 (0)
Vic	27	0 (0)	5	1 (20)	32	1 (3)
WA	93	0 (0)	4	0 (0)	97	0 (0)
Total	556	11 (2)	53	2 (4)	609	13 (2)

† Excludes equivocal test results and missing values.

Table 10 Hepatitis B core-antibody prevalence by jurisdiction and sex (2010)†

	Male		Female		Total	
	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV
ACT	--	--	--	--	--	--
NSW	198	38 (19)	4	0 (0)	202	38 (19)
NT	51	18 (35)	3	3 (100)	54	21 (39)
Qld	80	14 (18)	2	0 (0)	82	14 (17)
SA	27	3 (11)	7	0 (0)	34	3 (9)
Tas	29	5 (17)	1	0 (0)	30	5 (17)
Vic	27	3 (11)	1	1 (100)	28	4 (14)
WA	93	16 (17)	4	0 (0)	97	16 (16)
Total	505	97 (19)	22	4 (18)	527	101 (19)

† Excludes equivocal test results and missing values.

Table 11 Hepatitis B core-antibody prevalence by jurisdiction, sex and injector status (2010)†

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N° tested	N° (%)
	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV		
ACT	--	--	--	--	--	--	--	--	--	--
NSW	72	17 (24)	126	21 (17)	0	0 (0)	4	0 (0)	202	38 (19)
NT	7	2 (29)	44	16 (36)	1	1 (100)	2	2 (100)	54	21 (39)
Qld	32	6 (19)	48	8 (17)	1	0 (0)	1	0 (0)	82	14 (17)
SA	11	2 (18)	16	1 (6)	4	0 (0)	3	0 (0)	34	3 (9)
Tas	17	2 (12)	12	3 (25)	1	0 (0)	--	--	30	5 (17)
Vic	15	2 (13)	12	1 (8)	0	0 (0)	1	1 (100)	28	4 (14)
WA	60	9 (15)	33	7 (21)	2	0 (0)	2	0 (0)	97	16 (16)
Total	214	40 (19)	291	57 (20)	9	2 (14)	13	3 (23)	527	101 (19)

† Excludes equivocal test results and missing values.

Table 12 Hepatitis B virus immune status by jurisdiction (2010)†

	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity
ACT	1	0 (0)	0 (0)	0 (0)	0 (0)
NSW	202	101 (50)	32 (16)	6 (3)	63 (31)
NT	54	18 (33)	18 (33)	3 (6)	15 (28)
Qld	107	16 (15)	14 (13)	2 (2)	75 (70)
SA	33	8 (24)	2 (6)	1 (3)	22 (67)
Tas	28	16 (57)	5 (18)	0 (0)	7 (25)
Vic	33	15 (45)	3 (9)	1 (3)	14 (42)
WA	97	50 (52)	16 (16)	0 (0)	31 (32)
Total	555	225 (41)	90 (16)	13 (2)	227 (41)

† Excludes equivocal test results and missing values.

Table 13 Hepatitis B virus immune status - Males (2010)†

	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity
ACT	1	1 (100)	0 (0)	0 (0)	0 (0)
NSW	198	98 (49)	32 (16)	6 (3)	62 (31)
NT	51	18 (35)	16 (31)	2 (4)	15 (29)
Qld	95	10 (11)	14 (15)	2 (2)	69 (73)
SA	27	7 (26)	2 (7)	1 (4)	17 (63)
Tas	27	16 (59)	5 (19)	0 (0)	6 (22)
Vic	30	15 (50)	3 (10)	0 (0)	12 (40)
WA	93	47 (51)	16 (17)	0 (0)	30 (32)
Total	522	212 (41)	88 (17)	11 (2)	211 (40)

† Excludes equivocal test results and missing values.

Table 14 Hepatitis B virus immune status - Females (2010)†

	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity
ACT	--	--	--	--	--
NSW	4	3 (75)	0 (0)	0 (0)	1 (25)
NT	3	0 (0)	2 (67)	1 (33)	0 (0)
Qld	12	6 (50)	0 (0)	0 (0)	6 (50)
SA	6	1 (17)	0 (0)	0 (0)	5 (83)
Tas	1	0 (0)	0 (0)	0 (0)	1 (100)
Vic	3	0 (0)	0 (0)	1 (33)	2 (67)
WA	4	3 (75)	0 (0)	0 (0)	1 (25)
Total	33	13 (39)	2 (6)	2 (6)	16 (48)

† Excludes equivocal test results and missing values.

Table 15 Genital chlamydia prevalence by jurisdiction and sex (2010)†

	Male		Female		Total	
	N° tested	N° (%) with chlamydia	N° tested	N° (%) with chlamydia	N° tested	N° (%) with chlamydia
ACT	2	0 (0)	1	0 (0)	3	0 (0)
NSW	185	10 (5)	5	0 (0)	190	10 (5)
NT	63	1 (2)	3	0 (0)	66	1 (2)
Qld	158	10 (6)	31	0 (0)	189	10 (5)
SA	29	0 (0)	8	0 (0)	37	0 (0)
Tas	10	0 (0)	--	--	10	0 (0)
Vic	19	1 (5)	6	0 (0)	25	1 (4)
WA	93	5 (5)	5	1 (20)	98	6 (6)
Total	559	27 (5)	59	1 (2)	618	28 (5)

† Excludes missing values.

Table 16 Genital gonorrhoea prevalence by jurisdiction and sex (2010)†

	Male		Female		Total	
	N° tested	N° (%) with gonorrhoea	N° tested	N° (%) with gonorrhoea	N° tested	N° (%) with gonorrhoea
ACT	2	0 (0)	1	0 (0)	3	0 (0)
NSW	184	0 (0)	5	0 (0)	189	0 (0)
NT	63	2 (3)	3	0 (0)	66	2 (3)
Qld	158	2 (1)	31	0 (0)	189	2 (1)
SA	29	0 (0)	8	0 (0)	37	0 (0)
Tas	--	--	--	--	--	--
Vic	19	0 (0)	6	0 (0)	25	0 (0)
WA	93	1 (1)	5	0 (0)	98	1 (1)
Total	548	5 (1)	59	0 (0)	607	5 (1)

† Excludes missing values.

Table 17 Syphilis markers by jurisdiction and sex (2010)†

	Male			Female			Total
	N° tested	N° (%) with syphilis antibodies	N° (%) with reactive RPR	N° tested	N° (%) with syphilis antibodies	N° (%) with reactive RPR	N° (%) with any marker for syphilis
ACT	3	0 (0)	0 (0)	1	0 (0)	0 (0)	0 (0)
NSW	195	4 (2)	0 (0)	7	0 (0)	0 (0)	4 (2)
NT	64	13 (20)	5 (8)	3	1 (33)	0 (0)	14 (21)
Qld	161	15 (9)	7 (4)	29	2 (7)	1 (3)	17 (11)
SA	25	2 (8)	0 (0)	--	--	--	2 (8)
Tas	5	0 (0)	0 (0)	--	--	--	0 (0)
Vic	27	1 (4)	0 (0)	6	0 (0)	0 (0)	1 (4)
WA	93	2 (2)	2 (2)	4	0 (0)	0 (0)	2 (2)
Total	573	45 (8)	14 (2)	50	3 (6)	3 (<1)	40 (7)

† Excludes missing values.

National
2004, 2007, 2010

Table 18 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 8		N = 17		N = 27	
N ^o surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458
Sex (%)						
Male	118 (93)	228 (92)	354 (87)	315 (94)	310 (88)	424 (93)
Female	9 (7)	19 (8)	52 (13)	19 (6)	43 (12)	34 (7)
Transgender	--	--	--	--	--	--
Sexual identity (%)						
Heterosexual	341 (96)	240 (97)	385 (95)	328 (98)	336 (95)	441 (96)
Bisexual	11 (3)	3 (1)	6 (2)	2 (<1)	8 (2)	7 (2)
Homosexual	5 (1)	3 (1)	9 (2)	1 (<1)	6 (2)	3 (1)
Unsure	--	--	2 (<1)	--	1 (<1)	2 (0)
Not reported	--	1 (<1)	4 (<1)	3 (<1)	2 (1)	5 (1)
Age and duration of injection (years)						
Median age (years)	30	34	32	29	33	28
Age range	17 – 58	17 – 75	18 – 54	17 – 77	18 – 79	16 – 80
Age group (%)						
<25 years	95 (27)	69 (28)	70 (17)	120 (36)	71 (20)	160 (35)
25+ years	260 (72)	178 (72)	335 (83)	214 (64)	281 (80)	298 (65)
Not reported	2 (<1)	--	1 (<1)	--	1 (<1)	--
Median age 1 st IDU (years)	18	--	18	--	18	--
Age range	9 – 41	--	8 – 44	--	7 – 42	--
Not reported	8	--	9	--	13	--
Median years IDU	10	--	12	--	13	--
Range	<1 – 37	--	<1 – 36	--	<1 – 40	--
Duration of drug injection (%)						
<3 years	36 (10)	--	24 (6)	--	33 (9)	--
3+ years	311 (87)	--	372 (92)	--	306 (87)	--
Not reported	10 (3)	--	10 (2)	--	14 (4)	--
Aboriginal and Torres Strait Islander origin (%)						
No	285 (80)	209 (85)	320 (79)	283 (85)	260 (74)	291 (64)
Yes	64 (18)	36 (15)	78 (19)	50 (15)	93 (26)	167 (36)
Not reported	8 (2)	2 (<1)	8 (2)	1 (<1)	--	--
Living situation prior to prison (%)*						
Not homeless	n/a	n/a	n/a	n/a	223 (63)	260 (57)
Primary homelessness	n/a	n/a	n/a	n/a	12 (3)	10 (2)
Secondary homelessness	n/a	n/a	n/a	n/a	56 (16)	113 (25)
Tertiary homelessness	n/a	n/a	n/a	n/a	23 (7)	11 (2)
Not reported	n/a	n/a	n/a	n/a	39 (11)	64 (14)
Residential remoteness in 12 months before prison (%)						
Highly accessible/accessible	325 (91)	215 (87)	362 (89)	286 (86)	313 (89)	329 (72)
Moderately accessible	9 (3)	6 (2)	11 (3)	14 (4)	15 (4)	22 (5)
Remote/very remote	13 (4)	14 (6)	11 (3)	11 (3)	14 (4)	84 (18)
Not reported	10 (3)	12 (5)	22 (5)	23 (7)	11 (3)	23 (5)
Region/Country of birth (%)						
Australia	310 (87)	182 (74)	354 (87)	263 (79)	314 (89)	372 (81)
Other Oceania	12 (3)	17 (7)	9 (2)	13 (4)	15 (4)	29 (6)
Asia	13 (4)	14 (6)	19 (5)	20 (6)	9 (3)	22 (5)
UK & Ireland	8 (2)	9 (4)	7 (2)	7 (2)	7 (2)	6 (1)
Other	13 (4)	23 (9)	15 (4)	27 (8)	7 (2)	29 (6)
Not reported	1 (<1)	2 (<1)	2 (<1)	4 (1)	1 (<1)	--
Main language spoke at home by parents (%)						
English	328 (92)	208 (84)	365 (90)	268 (80)	332 (94)	367 (80)
Non-English	28 (8)	37 (15)	40 (10)	64 (19)	17 (5)	65 (14)
Not reported	--	2 (<1)	1 (<1)	2 (<1)	4 (1)	26 (6)

* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers' accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010.

Table 18 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)						
No	302 (85)	149 (60)	336 (83)	161 (48)	290 (82)	262 (57)
Yes	55 (15)	98 (40)	69 (17)	171 (51)	61 (17)	190 (41)
Not reported	--	--	1 (<1)	2 (<1)	2 (1)	6 (1)
Lifetime imprisonments (%)						
One	55 (15)	98 (40)	69 (17)	171 (51)	118 (33)	285 (62)
Two to four	178 (50)	117 (47)	163 (40)	119 (36)	115 (33)	109 (24)
Five to nine	87 (24)	17 (7)	95 (23)	23 (7)	72 (20)	43 (9)
Ten or more	32 (9)	3 (1)	60 (15)	10 (3)	46 (13)	15 (3)
Not reported	5 (1)	12 (5)	19 (5)	11 (3)	2 (1)	6 (1)
Imprisonment in last year (%)						
No	129 (36)	137 (55)	113 (34)	47 (29)	160 (45)	277 (60)
Yes	220 (62)	98 (40)	214 (64)	111 (68)	180 (51)	153 (33)
Not reported	8 (2)	12 (5)	10 (3)	5 (3)	13 (4)	28 (6)
Frequency of injection last month (%)						
Not last month	125 (35)	--	152 (37)	--	150 (42)	--
Less than weekly	47 (13)	--	54 (13)	--	68 (19)	--
Weekly not daily	28 (8)	--	52 (13)	--	23 (7)	--
Daily or more	154 (43)	--	142 (35)	--	108 (31)	--
Not reported	3 (<1)	--	6 (2)	--	4 (1)	--
Ever smoked a full cigarette (%)*						
No	n/a	n/a	14 (3)	45 (14)	7 (2)	44 (10)
Yes	n/a	n/a	392 (97)	289 (87)	346 (98)	413 (90)
Not reported	n/a	n/a	--	--	--	1 (<1)
Median age first smoked (years)	n/a	n/a	14	14	13	15
Age range	n/a	n/a	5 – 36	4 – 31	3 – 37	6 – 50
Current smoker (%)*						
No	n/a	n/a	26 (6)	85 (25)	20 (6)	99 (22)
Yes	n/a	n/a	379 (93)	249 (75)	333 (94)	357 (86)
Not reported	n/a	n/a	1 (<1)	--	--	2 (<1)
Smoking frequency (%)*						
Occasional – weekly or less	n/a	n/a	13 (3)	22 (9)	11 (3)	12 (3)
5 to 10 cigarettes a day	n/a	n/a	98 (26)	60 (24)	106 (32)	152 (42)
11 to 20 cigarettes a day	n/a	n/a	154 (41)	85 (34)	144 (43)	104 (29)
Over 20 cigarettes a day	n/a	n/a	113 (30)	81 (33)	70 (21)	88 (25)
Not reported	n/a	n/a	2 (<1)	1 (<1)	2 (1)	1 (<1)
Other drugs used last month (%)**						
No drugs in past 4 weeks	n/a	n/a	n/a	n/a	63 (19)	222 (52)
Cannabis	n/a	n/a	n/a	n/a	205 (74)	167 (80)
Heroin	n/a	n/a	n/a	n/a	78 (28)	11 (5)
Cocaine	n/a	n/a	n/a	n/a	18 (6)	11 (5)
Amphetamine	n/a	n/a	n/a	n/a	159 (57)	49 (23)
Other's methadone	n/a	n/a	n/a	n/a	23 (8)	--
Other opiates	n/a	n/a	n/a	n/a	43 (16)	2 (1)
Other's buprenorphine	n/a	n/a	n/a	n/a	33 (12)	3 (1)
Steroids	n/a	n/a	n/a	n/a	7 (3)	2 (1)
Hallucinogens	n/a	n/a	n/a	n/a	7 (3)	5 (2)
Benzodiazepines	n/a	n/a	n/a	n/a	62 (22)	15 (7)
Ecstasy/MDA	n/a	n/a	n/a	n/a	17 (6)	16 (8)
Inhalants (e.g. petrol)	n/a	n/a	n/a	n/a	1 (<1)	1 (<1)
Other drug	n/a	n/a	n/a	n/a	2 (1)	1 (<1)
Not reported	n/a	n/a	n/a	n/a	13 (4)	28 (6)

* Smoking questions not asked in 2004.

** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 19 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010
Last drug injected (%)	N = 357	N = 406	N = 353
Amphetamine (Speed, Ice)	206 (58)	238 (59)	207 (59)
Anabolic steroids	1 (<1)	--	2 (1)
Cocaine	7 (2)	7 (2)	3 (1)
Heroin	115 (32)	126 (31)	88 (25)
Heroin + amphetamine	--	10 (2)	--
Heroin + cocaine	2 (<1)	1 (<1)	4 (1)
Methadone	7 (2)	6 (1)	5 (1)
Morphine	9 (3)	12 (3)	20 (6)
Other	8 (2)	5 (1)	19 (5)
Not reported	--	1 (<1)	5 (1)
N° Injected last month	N = 232	N = 248	N = 199
Places injected last month (%)*			
Prison	8 (3)	7 (3)	4 (2)
Own home	181 (78)	199 (80)	120 (61)
Friend's home	117 (50)	137 (55)	78 (40)
Dealer's home	51 (22)	74 (30)	27 (14)
Street, park, beach	73 (31)	95 (38)	30 (15)
Car	82 (35)	112 (45)	45 (23)
Public toilet	56 (24)	69 (28)	31 (16)
Commercial injecting room	8 (3)	7 (3)	1 (<1)
Medically Supervised Injecting Centre, Sydney	9 (4)	10 (4)	3 (2)
Squat	19 (8)	14 (6)	4 (2)
Other place	5 (2)	12 (5)	1 (<1)
Use of sterile needles & syringes last month (%)			
All injections	160 (69)	162 (65)	137 (69)
Most of the time	38 (16)	52 (21)	42 (21)
Half of the time	14 (6)	11 (4)	7 (4)
Some of the time	17 (7)	18 (7)	3 (2)
Not last month	2 (<1)	--	3 (2)
Not reported	1 (<1)	5 (2)	7 (4)
Re-used someone else's used needle & syringe last month (%)			
None	196 (84)	198 (80)	157 (79)
Once	6 (3)	10 (4)	11 (6)
Twice	14 (6)	10 (4)	9 (5)
3-5 times	7 (3)	7 (3)	7 (4)
>5 times	7 (3)	19 (8)	9 (5)
Not reported	2 (<1)	4 (2)	6 (3)
Number of people needle & syringe was re-used after last month (%)			
None	197 (85)	198 (78)	156 (78)
One	20 (9)	31 (12)	16 (8)
Two	7 (3)	3 (1)	6 (3)
Three to five	4 (2)	4 (2)	2 (1)
More than five	2 (<1)	--	4 (2)
Don't know how many	--	5 (2)	7 (4)
Not reported	2 (<1)	13 (5)	8 (4)
Relationship to people needle & syringe was re-used after last month (%)*			
Regular sex partner	18 (8)	25 (10)	20 (10)
Casual sex partner	2 (<1)	2 (<1)	3 (2)
Close friend	7 (3)	13 (5)	7 (4)
Acquaintance	5 (2)	5 (2)	6 (3)
Other	5 (2)	5 (2)	4 (2)
Equipment used after someone else last month (%)*			
Spoon	49 (21)	76 (30)	50 (25)
Water	39 (17)	63 (25)	39 (20)
Filter	34 (15)	57 (23)	40 (20)
Tourniquet	18 (8)	31 (13)	26 (13)
Drug mix	33 (14)	49 (20)	36 (18)

* More than one option could be selected.

Table 20 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment for drug use	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458
Any treatment/therapy for drug use (%)						
No	195 (55)	228 (92)	125 (31)	182 (54)	157 (44)	397 (87)
Yes	161 (45)	17 (7)	250 (62)	42 (13)	194 (55)	56 (12)
Not reported	1 (<1)	2 (<1)	31 (8)	110 (33)	2 (1)	4 (1)
History of methadone maintenance treatment (%)						
Currently	53 (15)	3 (1)	50 (12)	--	48 (14)	1 (<1)
Previously	76 (21)	2 (<1)	92 (23)	--	51 (14)	4 (1)
Never	226 (63)	240 (97)	225 (55)	--	250 (71)	449 (98)
Not reported	2 (<1)	2 (<1)	39 (10)	--	4 (1)	4 (1)
History of other pharmacotherapy treatment (%)						
Currently	19 (5)	3 (1)	28 (7)	--	32 (9)	4 (1)
Previously	49 (14)	1 (<1)	95 (23)	--	44 (12)	4 (1)
Never	284 (80)	241 (98)	268 (66)	--	276 (78)	447 (98)
Not reported	5 (1)	2 (<1)	15 (4)	--	1 (<1)	3 (1)

Table 21 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010
N° surveyed	N = 233	N = 248	N = 353
From an NSP last month (%)			
Daily or almost daily	31 (13)	30 (12)	26 (7)
A couple of times each week	38 (16)	57 (22)	37 (10)
Less than weekly	33 (14)	38 (15)	40 (11)
Weekly	n/a	n/a	19 (5)
Once last month	39 (17)	29 (12)	12 (3)
Not in the last month	57 (24)	45 (18)	154 (44)
Not reported	35 (15)	52 (21)	65 (18)
From a chemist last month (%)			
Daily or almost daily	17 (7)	14 (6)	17 (5)
A couple of times each week	36 (16)	32 (13)	29 (8)
Less than weekly	51 (22)	35 (14)	38 (11)
Weekly	n/a	n/a	36 (10)
Once last month	38 (17)	32 (13)	--
Not in the last month	86 (37)	84 (34)	173 (49)
Not reported	2 (<1)	51 (21)	60 (17)

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 22 Number (%) of respondents by body piercing and tattoos

Body piercing and tattoos	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458
Body or ear piercings (%)						
No	184 (52)	161 (65)	179 (44)	198 (59)	205 (58)	297 (65)
Yes	172 (48)	85 (34)	224 (55)	133 (40)	147 (42)	161 (35)
Not reported	1 (<1)	1 (<1)	3 (1)	3 (1)	1 (<1)	--
Pierced in past 12 mths (%)						
No	121 (70)	49 (58)	170 (76)	95 (72)	103 (69)	108 (66)
Yes	22 (13)	9 (10)	25 (11)	15 (11)	18 (12)	22 (13)
Not reported	29 (17)	27 (32)	29 (13)	23 (17)	28 (19)	33 (20)
Who did piercing (%)*						
Chemist/hairdresser/beauty salon	5 (23)	3 (33)	3 (12)	5 (31)	2 (11)	5 (23)
Professional piercer / studio	9 (41)	4 (44)	10 (40)	2 (13)	5 (28)	10 (45)
Tattooist / parlour	1 (5)	2 (22)	4 (16)	3 (19)	3 (17)	2 (9)
Friend	2 (9)	--	1 (4)	1 (6)	3 (17)	2 (9)
Prison inmate	1 (5)	--	1 (6)	1 (4)	1 (6)	--
Self	5 (23)	--	3 (12)	4 (25)	5 (28)	--
Family member	--	--	2 (8)	--	1 (6)	--
Other	--	--	--	--	--	--
Needle used by other (%)						
No	21 (95)	9 (100)	3 (12)	1 (7)	9 (50)	11 (50)
Yes	1 (5)	--	--	2 (13)	--	--
Unsure	--	--	--	--	--	--
Not reported	--	--	22 (88)	12 (80)	9 (50)	11 (50)
Tattoos (%)						
No	96 (27)	137 (55)	111 (27)	170 (51)	72 (20)	238 (52)
Yes	261 (73)	109 (44)	294 (72)	164 (49)	275 (78)	209 (46)
Not reported	--	1 (<1)	1 (<1)	--	6 (2)	11 (2)
Tattoos in past 12 mths (%)						
No	205 (79)	91 (83)	220 (75)	100 (61)	197 (72)	132 (63)
Yes	53 (20)	17 (15)	74 (25)	62 (38)	75 (27)	73 (35)
Not reported	3 (1)	1 (2)	1 (<1)	2 (1)	3 (1)	4 (2)
Who did tattooing (%)*						
Professional tattooist	32 (60)	10 (59)	41 (55)	47 (76)	40 (53)	47 (64)
Friend	11 (21)	2 (12)	21 (28)	10 (16)	24 (32)	21 (29)
Prison inmate	11 (21)	2 (12)	16 (22)	2 (3)	7 (9)	2 (3)
Self	7 (13)	2 (12)	4 (5)	4 (7)	4 (5)	4 (5)
Family member	1 (2)	1 (6)	--	1 (2)	7 (9)	--
Other	--	--	--	--	--	--

* More than one option could be selected.

Table 23 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sexual behaviour	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458
Sex last month / last 3 months (%)**						
No	93 (26)	75 (30)	107 (26)	84 (25)	41 (12)	80 (17)
Yes	263 (74)	168 (68)	298 (73)	248 (74)	307 (87)	368 (80)
Not reported	1 (<1)	4 (2)	1 (<1)	2 (<1)	5 (1)	10 (2)
Male sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	1	1
Range	n/a	n/a	n/a	n/a	0 – 300	0 – 10
Female sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	1	1
Range	n/a	n/a	n/a	n/a	0 – 90	0 – 26
Condom use at last sex (%)						
No	270 (76)	175 (71)	327 (81)	239 (72)	n/a	n/a
Yes	87 (24)	69 (28)	75 (18)	94 (28)	n/a	n/a
Not reported	--	3 (1)	4 (<1)	1 (<1)	n/a	n/a
Condom use with regular sex partner(s) last month (%)*						
No	160 (86)	112 (81)	189 (84)	149 (74)	n/a	n/a
Sometimes	14 (7)	12 (9)	24 (11)	31 (15)	n/a	n/a
Always	13 (7)	14 (10)	12 (5)	22 (11)	n/a	n/a
Condom use with new sex partner(s) last month (%)*						
No	27 (55)	9 (47)	44 (59)	11 (28)	n/a	n/a
Sometimes	8 (16)	3 (16)	14 (19)	15 (38)	n/a	n/a
Always	14 (29)	7 (37)	16 (22)	14 (35)	n/a	n/a
Condom use with casual sex partner(s) last month (%)*						
No	41 (49)	18 (47)	66 (69)	19 (35)	n/a	n/a
Sometimes	14 (17)	6 (16)	15 (16)	18 (33)	n/a	n/a
Always	28 (34)	14 (37)	15 (16)	17 (31)	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	30 (79)	18 (64)
Sometimes	n/a	n/a	n/a	n/a	5 (13)	4 (14)
Always	n/a	n/a	n/a	n/a	3 (8)	6 (21)
Condom use last sex - casual male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	8 (57)	4 (57)
Sometimes	n/a	n/a	n/a	n/a	2 (14)	2 (29)
Always	n/a	n/a	n/a	n/a	4 (29)	1 (14)
Condom use last sex - regular female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	157 (79)	168 (62)
Sometimes	n/a	n/a	n/a	n/a	26 (13)	47 (17)
Always	n/a	n/a	n/a	n/a	16 (8)	57 (21)
Condom use last sex - casual female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	55 (53)	41 (37)
Sometimes	n/a	n/a	n/a	n/a	28 (27)	25 (22)
Always	n/a	n/a	n/a	n/a	20 (19)	46 (41)
Sex work last month (%)						
No	349 (98)	240 (97)	392 (97)	323 (97)	340 (96)	442 (97)
Yes	6 (2)	2 (<1)	10 (2)	5 (1)	10 (3)	3 (1)
Not reported	2 (<1)	5 (2)	4 (<1)	6 (2)	3 (1)	13 (3)
Condom used at last sex work last month (%)						
No	3 (43)	1 (50)	4 (40)	1 (20)	2 (20)	1 (33)
Yes	4 (57)	1 (50)	5 (50)	2 (40)	5 (50)	2 (67)
Not reported	--	--	1 (10)	2 (40)	3 (30)	--
Ever had cervical cancer vaccine (women only)*** (%)						
No	n/a	n/a	n/a	n/a	11 (65)	7 (58)
Yes	n/a	n/a	n/a	n/a	6 (35)	4 (33)
Unsure	n/a	n/a	n/a	n/a	--	1 (8)

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

*** Proportion of eligible women i.e. those under 27 years of age in 2007.

Table 24 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458
Previous HIV test (%)						
Yes, last year	168 (47)	46 (19)	182 (45)	80 (24)	160 (45)	125 (27)
>1 year ago	117 (33)	72 (29)	159 (39)	99 (30)	109 (31)	105 (23)
Never tested	71 (20)	126 (51)	61 (15)	155 (46)	82 (23)	225 (49)
Not reported	1 (<1)	3 (1)	4 (1)	--	2 (1)	3 (1)
HBV infection (%)						
No	278 (78)	226 (91)	329 (81)	311 (93)	306 (87)	411 (90)
Yes	51 (14)	5 (2)	47 (12)	6 (2)	25 (7)	8 (2)
Don't know	28 (8)	16 (6)	29 (7)	12 (4)	21 (6)	36 (8)
Not reported	--	--	1 (<1)	5 (1)	1 (<1)	3 (1)
HBV vaccination (%)*						
No	82 (27)	116 (48)	125 (31)	162 (49)	96 (27)	186 (41)
Yes	188 (61)	78 (32)	239 (59)	124 (37)	203 (58)	164 (36)
Don't know	36 (12)	44 (18)	35 (9)	45 (13)	53 (15)	103 (22)
Not reported	--	4 (2)	7 (2)	3 (1)	1 (<1)	5 (1)
Previous HCV test (%)						
Yes, last year	155 (43)	42 (17)	178 (44)	75 (22)	164 (46)	111 (24)
>1 year ago	138 (39)	48 (20)	180 (44)	83 (25)	123 (35)	104 (23)
Never tested	61 (17)	154 (63)	48 (12)	174 (52)	61 (17)	241 (53)
Unsure	2 (1)	1 (<1)	--	1 (<1)	1 (<1)	--
Not reported	1 (<1)	2 (<1)	--	1 (<1)	4 (1)	2 (<1)
Any HCV treatment (%)**	N = 149	N = 7	N = 197	N = 11	N = 137	N = 4
Interferon	--	--	1 (<1)	--	4 (3)	--
Interferon & Ribavirin	1 (<1)	1 (14)	1 (<1)	--	3 (2)	--
Other	--	--	--	--	--	--
No treatment	148 (99)	6 (86)	195 (99)	11 (100)	130 (99)	4 (100)
Not reported	--	--	--	--	--	--
Current HCV treatment						
Interferon	--	--	--	--	1 (<1)	--
Interferon & Ribavirin	1 (<1)	1 (14)	1 (<1)	--	1 (<1)	--
Other	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Number (%) of those testing positive for hepatitis C antibodies.

HIV antibody prevalence

Table 25 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	240	2 (<1)	23	0 (0)	263	2 (<1)
Non-IDU	172	1 (<1)	12	0 (0)	184	1 (<1)
p value		0.8		--		0.8
2007						
IDU	287	2 (<1)	37	1 (3)	324	3 (<1)
Non-IDU	246	1 (<1)	16	0 (0)	262	1 (<1)
p value		0.7		0.5		0.4
2010						
IDU	246	0 (0)	28	0 (0)	274	0 (0)
Non-IDU	358	0 (0)	29	0 (0)	387	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 26 HIV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heterosexual	407	1 (<1)	30	0 (0)	437	1 (<1)
Bisexual	2	1 (50)	5	0 (0)	7	1 (14)
Homosexual	3	1 (33)	--	--	3	1 (33)
Unsure	--	--	--	--	--	--
p value		<0.001		--		<0.001
2007						
Heterosexual	522	2 (<1)	44	1 (2)	566	3 (<1)
Bisexual	1	0 (0)	4	0 (0)	5	0 (0)
Homosexual	6	1 (17)	1	0 (0)	7	1 (14)
Unsure	1	0 (0)	1	0 (0)	2	0 (0)
p value		<0.001		1.0		<0.001
2010						
Heterosexual	588	0 (0)	45	0 (0)	633	0 (0)
Bisexual	4	0 (0)	9	0 (0)	13	0 (0)
Homosexual	4	0 (0)	3	0 (0)	7	0 (0)
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 27 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Non-Indigenous	340	1 (<1)	25	0 (0)	365	1 (<1)
Indigenous	68	2 (3)	10	0 (0)	78	2 (3)
p value		0.06		--		0.08
2007						
Non-Indigenous	433	3 (<1)	35	1 (3)	468	4 (<1)
Indigenous	93	0 (0)	17	0 (0)	110	0 (0)
p value		0.4		0.5		0.3
2010						
Non-Indigenous	398	0 (0)	39	0 (0)	437	0 (0)
Indigenous	206	0 (0)	18	0 (0)	224	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 28 HIV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Highly accessible/accessible	372	3 (100)	30	0 (0)	402	3 (100)
Moderately accessible	9	0 (0)	1	0 (0)	10	0 (0)
Remote/very remote	18	0 (0)	2	0 (0)	20	0 (0)
p value		0.9		--		0.9
2007						
Highly accessible/accessible	470	3 (1)	45	1 (2)	515	4 (1)
Moderately accessible	16	0 (0)	1	0 (0)	17	0 (0)
Remote/very remote	20	0 (0)	1	0 (0)	21	0 (0)
p value		0.9		1.0		0.9
2010						
Highly accessible/accessible	471	0 (0)	46	0 (0)	517	0 (0)
Moderately accessible	27	0 (0)	4	0 (0)	31	0 (0)
Remote/very remote	80	0 (0)	5	0 (0)	85	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 29 Self-reported HIV status versus HIV serology by sex†

Self-report HIV	HIV Serology					
	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Positive	1	1(100)	--	--	1	1(100)
Negative	240	2 (<1)	23	0 (0)	263	2 (<1)
Not sure	19	0 (0)	4	0 (0)	23	0 (0)
p value		<0.001		--		<0.001
2007						
Positive	6	0 (0)	--	--	6	0 (0)
Negative	334	2 (<1)	36	1 (3)	370	3 (<1)
Not sure	25	0 (0)	5	0 (0)	30	0 (0)
p value		0.9		0.7		0.9
2010						
Positive	0	0 (0)	0	0 (0)	0	0 (0)
Negative	324	0 (0)	36	0 (0)	360	0 (0)
Not sure	30	0 (0)	2	0 (0)	32	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 30 HCV antibody prevalence by sex, injector status and survey year†

Injector status	HCV antibody prevalence					
	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	242	130 (54)	23	19 (83)	265	149 (56)
Non-IDU	174	7 (4)	12	0 (0)	186	7 (4)
p value		<0.001		<0.001		<0.001
2007						
IDU	287	166 (58)	40	31 (78)	327	197 (60)
Non-IDU	247	9 (4)	15	2 (13)	262	11 (4)
p value		<0.001		<0.001		<0.001
2010						
IDU	239	118 (49)	28	19 (68)	267	137 (51)
Non-IDU	356	4 (1)	28	0 (0)	384	4 (1)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

Table 31 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	411	136 (33)	31	16 (52)	442	152 (34)
Bisexual	2	0 (0)	4	3 (75)	6	3 (50)
Homosexual	3	1 (33)	--	--	3	1 (33)
Unsure	--	--	--	--	--	--
p value		0.6		0.4		0.7
2007						
Heterosexual	523	172 (33)	45	24 (53)	568	196 (35)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Homosexual	6	2 (33)	2	2 (100)	8	4 (50)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.8		0.4		0.3
2010						
Heterosexual	579	120 (21)	44	12 (27)	623	132 (21)
Bisexual	4	0 (0)	9	5 (56)	13	5 (38)
Homosexual	4	2 (50)	3	2 (67)	7	4 (57)
Unsure	--	--	--	--	--	--
p value		0.2		0.1		0.03

† Excludes equivocal test results and missing values.

Table 32 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	36	1 (3)	1	0 (0)	37	1 (3)
20 – 24	91	25 (27)	4	2 (50)	95	27 (28)
25 – 29	89	28 (31)	9	6 (67)	98	34 (35)
30 + years	205	84 (41)	20	9 (45)	225	93 (41)
p value		<0.001		0.5		<0.001
2007						
< 20 years	35	2 (6)	1	0 (0)	36	2 (6)
20 – 24	117	22 (19)	6	4 (67)	123	26 (21)
25 – 29	114	44 (39)	16	11 (69)	130	55 (42)
30 + years	267	107 (40)	32	18 (56)	299	125 (42)
p value		<0.001		0.5		<0.001
2010						
< 20 years	65	1 (2)	4	1 (25)	69	2 (3)
20 – 24	127	19 (15)	7	1 (14)	134	20 (15)
25 – 29	126	24 (19)	11	5 (45)	137	29 (21)
30 + years	277	78 (28)	34	12 (35)	311	90 (29)
p value		<0.001		0.6		<0.001

† Excludes equivocal test results and missing values.

Table 33 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	28	1 (4)	1	0 (0)	29	1 (3)
3 to 5 years	25	11 (44)	2	1 (50)	27	12 (44)
6 to 10 years	75	34 (45)	7	6 (86)	82	40 (49)
10 + years	111	84 (76)	12	11 (92)	123	95 (77)
p value		<0.001		0.1		<0.001
2007						
<3 years	19	4 (21)	1	1 (100)	20	5 (25)
3 to 5 years	29	12 (41)	3	2 (67)	32	14 (44)
6 to 10 years	69	28 (41)	17	12 (71)	86	40 (47)
10 + years	161	116 (72)	19	16 (84)	180	132 (73)
p value		<0.001		0.7		<0.001
2010						
<3 years	28	3 (11)	2	0 (0)	30	3 (10)
3 to 5 years	22	6 (27)	4	1 (25)	26	7 (27)
6 to 10 years	47	24 (51)	7	4 (57)	54	28 (52)
10 + years	133	81 (61)	14	13 (93)	147	94 (64)
p value		<0.001		<0.01		<0.001

† Excludes equivocal test results and missing values.

Table 34 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	22	1 (5)	129	65 (50)	151	66 (44)
Heroin	1	0 (0)	75	63 (84)	76	63 (83)
More than one	5	0 (0)	23	15 (65)	28	15 (54)
Other/not reported	1	0 (0)	5	5(100)	6	5 (83)
p value		1.0		<0.001		<0.001
2007						
Amphetamine (Speed, Ice)	17	3 (18)	178	83 (47)	195	86 (44)
Heroin	3	2 (67)	90	76 (84)	93	78 (84)
More than one	--	--	11	10 (91)	11	10 (91)
Other/not reported	--	--	19	17 (89)	19	17 (89)
p value		0.07		<0.001		<0.001
2010						
Amphetamine (Speed, Ice)	19	1 (5)	136	67 (49)	155	68 (44)
Heroin	5	1 (20)	52	39 (75)	57	40 (70)
More than one	--	--	8	1 (13)	8	1 (13)
Other/not reported	6	1 (17)	31	22 (71)	37	23 (62)
p value		0.5		<0.001		<0.001

† Excludes equivocal test results and missing values.

Table 35 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	11	0 (0)	40	30 (75)	51	30 (59)
Daily or more	9	1 (11)	101	70 (69)	110	71 (65)
p value		0.3		0.2		0.1
2007						
Less than daily	3	1 (33)	77	45 (58)	80	46 (58)
Daily or more	5	2 (40)	110	86 (78)	115	88 (77)
p value		0.9		<0.01		<0.001
2010						
Less than daily	12	1 (8)	56	34 (61)	68	35 (51)
Daily or more	9	2 (22)	68	46 (68)	77	48 (62)
p value		0.4		0.4		0.2

† Excludes equivocal test results and missing values.

Table 36 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	19	1 (5)	103	76 (74)	122	77 (63)
Yes	2	0 (0)	38	25 (66)	40	25 (63)
p value		0.1		0.7		0.8
2007						
No	8	3 (38)	143	97 (68)	151	100 (66)
Yes	--	--	36	28 (78)	36	28 (78)
p value		--		0.3		0.2
2010						
No	16	1 (6)	95	59 (62)	111	60 (54)
Yes	4	2 (50)	18	12 (67)	22	14 (64)
p value		0.03		0.7		0.4

† Excludes equivocal test results and missing values.

Table 37 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	12	0 (0)	80	51 (64)	92	51 (55)
Yes	17	1 (6)	148	94 (64)	165	95 (58)
p value		0.4		1.0		0.7
2007						
No	5	1 (20)	86	53 (62)	91	54 (59)
Yes	6	3 (50)	156	114 (73)	162	117 (72)
p value		0.3		0.07		0.04
2010						
No	16	1 (6)	96	49 (51)	112	50 (45)
Yes	13	2 (15)	123	75 (61)	136	77 (57)
p value		0.4		0.1		0.06

† Excludes equivocal test results and missing values.

Table 38 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	104	14 (13)	11	1 (9)	115	15 (13)
2 to 4	211	68 (32)	17	11 (65)	228	79 (35)
5 to 9	68	38 (56)	4	4 (100)	72	42 (58)
10 +	23	16 (70)	3	3 (100)	26	19 (73)
p value		<0.001		0.001		<0.001
2007						
1	170	9 (5)	21	9 (43)	191	18 (9)
2 to 4	210	66 (31)	20	13 (65)	230	79 (34)
5 to 9	82	54 (66)	8	7 (88)	90	61 (68)
10 +	52	39 (75)	4	3 (75)	56	42 (75)
p value		<0.001		0.1		<0.001
2010						
1	301	26 (9)	33	8 (24)	334	34 (10)
2 to 4	169	41 (24)	14	8 (57)	183	49 (27)
5 to 9	78	31 (40)	6	1 (17)	84	32 (38)
10 +	42	23 (55)	3	2 (67)	45	25 (56)
p value		<0.001		0.07		<0.001

† Excludes equivocal test results and missing values.

Table 39 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	345	112 (32)	24	13 (54)	369	125 (34)
Indigenous	68	24 (35)	10	5 (50)	78	29 (37)
p value		0.7		0.8		0.5
2007						
Non-Indigenous	435	136 (31)	36	19 (53)	471	155 (33)
Indigenous	92	34 (37)	18	13 (72)	110	47 (43)
p value		0.3		0.2		0.05
2010						
Non-Indigenous	392	88 (22)	39	13 (33)	431	101 (23)
Indigenous	203	34 (17)	17	6 (35)	220	40 (18)
p value		0.1		0.9		0.1

† Excludes equivocal test results and missing values.

Table 40 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	156	5 (3)	210	119 (57)	366	124 (34)
Indigenous	28	1 (4)	49	28 (57)	77	29 (38)
p value		0.9		0.9		0.6
2007						
Non-Indigenous	221	9 (4)	250	146 (58)	471	155 (33)
Indigenous	40	2 (5)	70	45 (64)	110	47 (43)
p value		0.8		0.4		0.05
2010						
Non-Indigenous	237	2 (1)	194	99 (51)	431	101 (23)
Indigenous	147	2 (1)	73	38 (52)	220	40 (18)
p value		0.6		0.9		0.1

† Excludes equivocal test results and missing values.

Table 41 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	375	128 (34)	31	18 (58)	406	146 (36)
Moderately accessible	10	2 (20)	1	0 (0)	11	2 (18)
Remote/very remote	18	2 (11)	2	0 (0)	20	2 (10)
p value		0.09		0.2		0.03
2007						
Highly accessible/accessible	471	161 (34)	47	28 (60)	518	189 (36)
Moderately accessible	16	2 (13)	1	0 (0)	17	2 (12)
Remote/very remote	20	3 (15)	1	0 (0)	21	3 (14)
p value		0.04		0.2		0.01
2010						
Highly accessible/accessible	466	107 (23)	46	18 (39)	512	125 (24)
Moderately accessible	25	6 (24)	4	1 (25)	29	7 (24)
Remote/very remote	78	5 (6)	4	0 (0)	82	5 (6)
p value		0.04		0.3		0.01

† Excludes equivocal test results and missing values.

Table 42 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	338	118 (35)	33	19 (58)	371	137 (37)
Other Oceania	23	2 (9)	--	--	23	2 (9)
Asia	18	10 (56)	2	0 (0)	20	10 (50)
UK & Ireland	9	2 (22)	--	--	9	2 (22)
Other	27	5 (19)	--	--	27	5 (19)
p value		<0.01		0.1		<0.01
2007						
Australia	450	149 (33)	47	28 (60)	497	177 (36)
Other Oceania	17	3 (18)	2	1 (50)	19	4 (21)
Asia	29	14 (48)	3	1 (33)	32	15 (47)
UK & Ireland	9	3 (33)	1	1 (100)	10	4 (40)
Other	27	5 (19)	2	2 (100)	29	7 (24)
p value		0.2		0.6		0.3
2010						
Australia	512	109 (21)	46	17 (37)	558	126 (23)
Other Oceania	33	8 (24)	2	0 (0)	35	8 (23)
Asia	20	2 (10)	4	0 (0)	24	2 (8)
UK & Ireland	6	0 (0)	1	1 (100)	7	1 (14)
Other	24	3 (13)	3	1 (33)	27	4 (15)
p value		0.4		0.3		0.4

† Excludes equivocal test results and missing values.

Table 43 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	368	120 (33)	31	17 (55)	399	137 (34)
Non-English	47	17 (36)	4	2 (50)	51	19 (37)
p value		0.6		0.9		0.7
2007						
English	464	150 (32)	50	30 (60)	514	180 (35)
Non-English	69	24 (35)	5	3 (60)	74	27 (36)
p value		0.3		1.0		0.4
2010						
English	517	116 (22)	50	18 (36)	567	134 (24)
Non-English	55	6 (11)	4	1 (25)	59	7 (12)
p value		<0.01		0.5		0.04

† Excludes equivocal test results and missing values.

Table 44 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	88	87 (99)	16	16 (100)	104	103 (99)
Negative	138	25 (18)	7	1 (14)	145	26 (18)
Not sure	22	13 (59)	2	1 (50)	24	14 (58)
p value		<0.001		<0.001		<0.001
2007						
Positive	125	120 (96)	29	28 (97)	154	148 (96)
Negative	211	33 (16)	13	2 (15)	224	35 (16)
Not sure	25	10 (40)	4	2 (50)	29	12 (41)
p value		<0.001		<0.001		<0.001
2010						
Positive	79	78 (99)	19	19 (100)	98	97 (99)
Negative	231	17 (7)	21	0 (0)	252	17 (7)
Not sure	35	11 (31)	1	0 (0)	36	11 (31)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 45 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	244	12 (5)	24	1 (4)	268	13 (5)
Non-IDU	172	0 (0)	12	0 (0)	184	0 (0)
p value		<0.01		0.5		<0.01
2007						
IDU	288	9 (3)	38	2 (5)	326	11 (3)
Non-IDU	247	3 (1)	14	0 (0)	261	3 (1)
p value		0.1		0.4		0.08
2010						
IDU	232	3 (1)	25	0 (0)	257	3 (1)
Non-IDU	324	8 (2)	28	2 (7)	352	10 (3)
p value		0.3		0.2		0.2

† Excludes equivocal test results and missing values.

Table 46 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	239	64 (27)	23	7 (30)	264	71 (27)
Non-IDU	172	14 (8)	10	3 (30)	182	17 (9)
p value		<0.001		1.0		<0.001
2007						
IDU	272	83 (31)	39	13 (33)	311	96 (31)
Non-IDU	239	22 (9)	16	2 (13)	255	24 (9)
p value		<0.001		0.1		<0.001
2010						
IDU	214	40 (19)	9	1 (11)	223	41 (18)
Non-IDU	291	57 (20)	13	3 (23)	304	60 (20)
p value		0.8		0.5		0.7

† Excludes equivocal test results and missing values.

Table 47 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	406	78 (19)	29	9 (31)	435	87 (20)
Bisexual	2	0 (0)	4	1 (25)	6	1 (17)
Homosexual	3	0 (0)	--	--	3	0 (0)
Unsure	--	--	--	--	--	--
p value		0.6		0.8		0.7
2007						
Heterosexual	501	104 (21)	45	12 (27)	546	116 (21)
Bisexual	1	0 (0)	4	0 (0)	5	0 (0)
Homosexual	5	1 (20)	2	1 (50)	7	2 (29)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.9		0.2		0.5
2010						
Heterosexual	494	93 (19)	16	4 (25)	510	97 (19)
Bisexual	4	1 (25)	4	0 (0)	8	1 (13)
Homosexual	2	1 (50)	2	0 (0)	4	1 (25)
Unsure	--	--	--	--	--	--
p value		0.5		0.4		0.9

† Excludes equivocal test results and missing values.

Table 48 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	37	1 (3)	1	0 (0)	38	1 (3)
20 – 24	89	11 (12)	5	2 (40)	94	13 (14)
25 – 29	89	17 (19)	8	2 (25)	97	19 (20)
30 + years	201	49 (24)	19	6 (32)	220	55 (25)
p value		<0.01		0.9		<0.01
2007						
< 20 years	32	2 (6)	1	0 (0)	33	2 (6)
20 – 24	115	11 (10)	6	0 (0)	121	11 (9)
25 – 29	110	24 (22)	15	2 (13)	125	26 (21)
30 + years	253	68 (27)	33	13 (39)	286	81 (28)
p value		<0.001		0.09		<0.001
2010						
< 20 years	54	3 (6)	1	0 (0)	55	3 (6)
20 – 24	107	6 (6)	4	0 (0)	111	6 (5)
25 – 29	106	19 (18)	3	1 (33)	109	20 (18)
30 + years	238	69 (29)	14	3 (21)	252	72 (29)
p value		<0.001		0.6		<0.001

† Excludes equivocal test results and missing values.

Table 49 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	29	2 (7)	1	0 (0)	30	2 (7)
3 to 5 years	23	2 (9)	3	1 (33)	26	3 (12)
6 to 10 years	76	18 (24)	7	3 (43)	83	21 (25)
10 + years	108	41 (38)	12	3 (25)	120	44 (37)
p value		<0.01		0.8		<0.01
2007						
<3 years	19	2 (11)	1	0 (0)	20	2 (10)
3 to 5 years	29	5 (17)	3	0 (0)	32	5 (16)
6 to 10 years	66	17 (26)	17	4 (24)	83	21 (25)
10 + years	149	55 (37)	18	9 (50)	167	64 (38)
p value		0.02		0.2		<0.01
2010						
<3 years	25	1 (4)	1	0 (0)	26	1 (4)
3 to 5 years	19	3 (16)	2	1 (50)	21	4 (19)
6 to 10 years	41	5 (12)	3	0 (0)	44	5 (11)
10 + years	123	29 (24)	3	0 (0)	126	29 (23)
p value		0.08		0.3		0.07

† Excludes equivocal test results and missing values.

Table 50 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	23	2 (9)	130	38 (22)	153	40 (26)
Heroin	1	0 (0)	70	22 (31)	71	22 (31)
More than one	5	0 (0)	23	7 (30)	28	7 (25)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value		0.9		0.9		0.8
2007						
Amphetamine (Speed, Ice)	17	2 (12)	165	41 (25)	182	43 (24)
Heroin	3	0 (0)	87	35 (40)	90	35 (39)
More than one	--	--	11	5 (45)	11	5 (45)
Other/not reported	--	--	19	9 (47)	19	9 (47)
p value		0.5		0.02		0.01
2010						
Amphetamine (Speed, Ice)	16	0 (0)	119	22 (18)	135	22 (16)
Heroin	4	0 (0)	39	13 (33)	43	13 (30)
More than one	--	--	6	1 (17)	6	1 (17)
Other/not reported	6	1 (17)	27	2 (7)	33	3 (9)
p value		0.2		0.06		0.09

† Excludes equivocal test results and missing values.

Table 51 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	11	1 (19)	41	20 (49)	52	21 (40)
Daily or more	10	0 (0)	99	26 (26)	109	26 (24)
p value		0.3		0.01		0.02
2007						
Less than daily	3	0 (0)	73	24 (33)	76	24 (32)
Daily or more	6	0 (0)	102	39 (38)	108	39 (36)
p value		--		0.5		0.5
2010						
Less than daily	10	0 (0)	52	11 (21)	62	11 (18)
Daily or more	8	0 (0)	54	8 (15)	62	8 (13)
p value		--		0.4		0.5

† Excludes equivocal test results and missing values.

Table 52 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	20	1 (5)	101	33 (33)	121	34 (28)
Yes	2	0 (0)	39	13 (33)	41	13 (32)
p value		0.7		0.9		0.8
2007						
No	9	0 (0)	135	47 (35)	144	47 (33)
Yes	--	--	32	13 (41)	32	13 (41)
p value		--		0.5		0.4
2010						
No	15	0 (0)	81	15 (19)	96	15 (16)
Yes	2	0 (0)	15	1 (7)	17	1 (6)
p value		--		0.3		0.3

† Excludes equivocal test results and missing values.

Table 53 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	12	0 (0)	79	29 (37)	91	29 (32)
Yes	18	2 (11)	145	37 (26)	163	39 (24)
p value		0.2		0.2		0.6
2007						
No	5	2 (40)	81	25 (31)	86	27 (31)
Yes	6	0 (0)	148	49 (33)	154	49 (32)
p value		0.9		0.7		0.9
2010						
No	14	0 (0)	84	17 (20)	98	17 (17)
Yes	11	1 (9)	100	19 (19)	111	20 (18)
p value		0.3		0.8		0.9

† Excludes equivocal test results and missing values.

Table 54 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	103	9 (9)	9	3 (33)	112	12 (11)
2 to 4	211	40 (19)	17	4 (24)	228	44 (19)
5 to 9	67	22 (33)	4	1 (25)	71	23 (32)
10 +	22	6 (27)	3	2 (67)	25	8 (32)
p value		<0.01		0.5		<0.01
2007						
1	163	15 (9)	21	6 (29)	184	21 (11)
2 to 4	204	44 (22)	21	2 (10)	225	46 (20)
5 to 9	76	24 (32)	7	4 (57)	83	28 (34)
10 +	48	16 (33)	4	1 (25)	52	17 (33)
p value		<0.01		0.08		<0.01
2010						
1	250	31 (12)	12	3 (25)	262	34 (13)
2 to 4	145	33 (23)	7	0 (0)	152	33 (22)
5 to 9	67	21 (31)	3	1 (33)	70	22 (31)
10 +	38	12 (32)	--	--	38	12 (32)
p value		<0.001		0.3		<0.01

† Excludes equivocal test results and missing values.

Table 55 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	340	57 (17)	23	7 (30)	363	64 (18)
Indigenous	68	20 (29)	9	2 (22)	77	22 (29)
p value		0.02		0.6		0.03
2007						
Non-Indigenous	416	67 (16)	36	8 (22)	452	75 (17)
Indigenous	88	37 (42)	18	7 (39)	106	44 (42)
p value		<0.001		0.2		<0.001
2010						
Non-Indigenous	342	53 (15)	14	2 (14)	356	55 (15)
Indigenous	163	44 (27)	8	2 (25)	171	46 (27)
p value		<0.01		0.5		<0.01

† Excludes equivocal test results and missing values.

Table 56 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	154	14 (9)	206	50 (24)	360	64 (18)
Indigenous	26	3 (12)	50	19 (38)	76	22 (29)
p value		0.7		0.05		0.03
2007						
Non-Indigenous	215	12 (6)	237	63 (27)	452	75 (17)
Indigenous	39	12 (31)	67	32 (48)	106	44 (42)
p value		<0.001		0.01		<0.001
2010						
Non-Indigenous	194	25 (13)	162	30 (19)	356	55 (15)
Indigenous	110	35 (32)	61	11 (18)	171	46 (27)
p value		<0.001		0.9		<0.01

† Excludes equivocal test results and missing values.

Table 57 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	370	66 (18)	28	8 (29)	398	74 (19)
Moderately accessible	10	1 (10)	1	0 (0)	11	1 (9)
Remote/very remote	18	7 (39)	2	0 (0)	20	7 (35)
p value		0.06		0.6		0.1
2007						
Highly accessible/accessible	454	89 (20)	47	13 (28)	501	102 (20)
Moderately accessible	15	1 (7)	1	0 (0)	16	1 (6)
Remote/very remote	17	7 (41)	1	1 (100)	18	8 (44)
p value		0.04		0.2		0.02
2010						
Highly accessible/accessible	411	68 (17)	16	2 (13)	427	70 (16)
Moderately accessible	19	5 (26)	1	0 (0)	20	5 (25)
Remote/very remote	56	20 (36)	3	2 (67)	59	22 (37)
p value		<0.01		0.09		<0.01

† Excludes equivocal test results and missing values.

Table 58 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	337	63 (19)	31	8 (26)	368	71 (19)
Other Oceania	23	6 (26)	--	--	23	6 (26)
Asia	15	6 (40)	2	2 (100)	17	8 (47)
UK & Ireland	9	1 (11)	--	--	9	1 (11)
Other	26	2 (8)	--	--	26	2 (8)
p value		0.1		0.07		0.02
2007						
Australia	431	86 (20)	47	11 (23)	478	97 (20)
Other Oceania	17	5 (29)	2	1 (50)	19	6 (32)
Asia	29	7 (24)	3	1 (33)	32	8 (25)
UK & Ireland	8	3 (38)	1	0 (0)	9	3 (33)
Other	24	4 (17)	2	2 (100)	26	6 (23)
p value		0.6		0.2		0.7
2010						
Australia	431	74 (17)	18	2 (11)	449	76 (17)
Other Oceania	26	7 (27)	--	--	26	7 (27)
Asia	20	8 (40)	3	2 (67)	23	10 (43)
UK & Ireland	5	0 (0)	--	--	5	0 (0)
Other	23	8 (35)	1	0 (0)	24	8 (33)
p value		0.01		0.06		<0.01

† Excludes equivocal test results and missing values.

Table 59 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	367	66 (18)	29	7 (24)	396	73 (18)
Non-English	43	12 (28)	4	3 (75)	47	15 (32)
p value		0.1		0.04		0.03
2007						
English	444	86 (19)	49	12 (24)	493	98 (20)
Non-English	66	18 (27)	6	3 (50)	72	21 (29)
p value		0.1		0.2		0.07
2010						
English	442	76 (17)	18	0 (0)	460	76 (17)
Non-English	53	17 (32)	2	2 (100)	55	19 (35)
p value		<0.01		<0.001		<0.01

† Excludes equivocal test results and missing values.

Table 60 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	270	117 (43)	60 (22)	13 (5)	80 (30)
Non-IDU	185	134 (72)	17 (9)	0 (0)	34 (18)
p value					<0.001
2007					
IDU	308	111 (36)	90 (29)	10 (3)	97 (31)
Non-IDU	246	166 (67)	21 (9)	3 (1)	56 (23)
p value					<0.001
2010					
IDU	236	80 (34)	38 (16)	3 (1)	115 (49)
Non-IDU	319	145 (45)	52 (16)	10 (3)	112 (35)
p value					<0.01

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 61 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	445	245 (55)	76 (17)	13 (3)	111 (25)
Bisexual	7	4 (57)	1 (14)	0 (0)	2 (29)
Homosexual	3	2 (67)	0 (0)	0 (0)	1 (33)
Unsure	--	--	--	--	--
p value					--
2007					
Heterosexual	534	269 (50)	108 (20)	11 (2)	146 (27)
Homosexual	5	2 (40)	--	--	3 (60)
Bisexual	7	3 (43)	1 (14)	1 (14)	2 (29)
Unsure	2	1 (50)	1 (50)	--	146 (27)
p value					0.4
2010					
Heterosexual	534	218 (41)	86 (16)	13 (2)	217 (41)
Homosexual	4	2 (50)	1 (25)	0 (0)	1 (25)
Bisexual	11	2 (18)	1 (9)	0 (0)	8 (73)
Unsure	--	--	--	--	--
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 62 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	38	23 (61)	0 (0)	1 (3)	14 (37)
20 – 24	96	53 (55)	10 (10)	4 (4)	29 (30)
25 – 29	100	57 (57)	16 (16)	3 (3)	24 (24)
30 + years	226	123 (54)	51 (23)	5 (2)	47 (21)
p value					0.02
2007					
< 20 years	34	21 (62)	3 (9)	0 (0)	10 (29)
20 – 24	117	59 (50)	9 (8)	2 (2)	47 (40)
25 – 29	121	54 (45)	24 (20)	3 (2)	40 (33)
30 + years	281	142 (51)	75 (27)	8 (3)	56 (20)
p value					<0.001
2010					
< 20 years	59	23 (39)	3 (5)	0 (0)	33 (56)
20 – 24	110	49 (45)	6 (5)	0 (0)	55 (50)
25 – 29	120	53 (44)	16 (13)	5 (4)	46 (38)
30 + years	266	100 (38)	65 (24)	8 (3)	93 (35)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 63 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	115	85 (74)	10 (9)	2 (2)	18 (16)
2 to 4	232	124 (53)	39 (17)	8 (3)	61 (26)
5 to 9	74	25 (34)	21 (28)	1 (1)	27 (36)
10 +	25	11 (44)	6 (24)	2 (8)	6 (24)
p value					<0.001
2007					
1	182	130 (71)	19 (10)	3 (2)	30 (16)
2 to 4	215	109 (51)	42 (20)	5 (2)	59 (27)
5 to 9	83	16 (19)	27 (33)	3 (4)	37 (45)
10 +	52	13 (25)	15 (29)	2 (4)	22 (42)
p value					<0.001
2010					
1	277	143 (52)	28 (10)	6 (2)	100 (36)
2 to 4	154	51 (33)	31 (20)	3 (2)	69 (45)
5 to 9	75	22 (29)	20 (27)	2 (3)	31 (41)
10 +	44	6 (14)	11 (25)	2 (5)	25 (57)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 64 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	372	223 (60)	57 (15)	9 (2)	83 (22)
Indigenous	78	26 (33)	18 (23)	4 (5)	30 (38)
p value					<0.001
2007					
Non-Indigenous	442	242 (55)	70 (16)	8 (2)	122 (28)
Indigenous	104	32 (31)	40 (38)	5 (5)	27 (26)
p value					<0.001
2010					
Non-Indigenous	370	174 (47)	48 (13)	7 (2)	141 (38)
Indigenous	185	51 (28)	42 (23)	6 (3)	86 (46)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 65 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly	409	231 (56)	64 (16)	12 (3)	102 (25)
Moderately accessible	11	6 (55)	1 (9)	0 (0)	4 (36)
Remote/very remote	20	7 (35)	7 (35)	0 (0)	6 (30)
p value					0.2
2007					
Highly	494	248 (50)	92 (19)	13 (3)	141 (29)
Moderately accessible	14	13 (93)	1 (7)	0 (0)	0 (0)
Remote/very remote	15	3 (20)	9 (60)	0 (0)	3 (20)
p value					<0.001
2010					
Highly	447	191 (43)	64 (14)	6 (1)	186 (42)
Moderately accessible	25	9 (36)	4 (16)	2 (8)	10 (40)
Remote/very remote	64	17 (27)	18 (28)	5 (8)	24 (38)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 66 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	403	222 (55)	65 (16)	9 (2)	107 (27)
Non-English	51	28 (55)	12 (24)	4 (8)	7 (14)
p value					0.02
2007					
English	482	248 (51)	94 (20)	8 (2)	132 (27)
Non-English	71	29 (41)	16 (23)	5 (7)	21 (30)
p value					0.02
2010					
English	485	205 (42)	72 (15)	6 (1)	202 (42)
Non-English	57	18 (32)	13 (23)	6 (11)	20 (35)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 67 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	128	14 (11)	8	3 (38)	136	17 (13)
Yes	163	81 (50)	12	5 (42)	175	86 (49)
Not sure	46	9 (20)	6	2 (33)	52	11 (21)
p value		<0.001		0.9		<0.001
2007						
No	144	17 (12)	21	4 (19)	165	21 (13)
Yes	196	111 (57)	18	11 (61)	214	122 (57)
Not sure	47	9 (19)	1	0 (0)	48	9 (19)
p value		<0.001		0.02		<0.001
2010						
No	135	34 (25)	7	1 (14)	142	35 (25)
Yes	207	149 (72)	21	15 (71)	228	164 (72)
Not sure	78	27 (35)	1	0 (0)	79	27 (34)
p value		<0.001		0.4		<0.001

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 68 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	559	27 (5)
Female	59	1 (2)
p value		0.3

† Excludes missing values.

Gonorrhoea

Table 69 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	548	5 (1)
Female	59	0 (0)
p value		0.5

† Excludes missing values.

Syphilis

Table 70 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	573	37 (6)	14 (2)	37 (6)
Female	50	3 (6)	1 (2)	3 (6)
p value		0.9	0.9	0.9

† Excludes missing values.

**New South Wales
2004, 2007, 2010**

Table 71 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 2		N = 3		N = 7	
N° surveyed	N = 183	N = 127	N = 132	N = 113	N = 100	N = 154
Sex (%)						
Male	152 (83)	118 (93)	101 (77)	103 (91)	92 (92)	149 (97)
Female	30 (16)	9 (7)	31 (23)	10 (9)	8 (8)	5 (3)
Transgender	1 (<1)	--	--	--	--	--
Sexual identity (%)						
Heterosexual	171 (93)	123 (97)	120 (91)	110 (97)	99 (99)	152 (99)
Bisexual	7 (4)	1 (<1)	4 (3)	--	--	1 (<1)
Homosexual	5 (3)	2 (2)	5 (4)	--	1 (1)	--
Unsure	--	--	--	--	--	--
Not reported	--	1 (<1)	3 (2)	3 (3)	--	1 (<1)
Age and duration of injection (years)						
Median age (years)	30	32	31	31	34	27
Age range	18 – 58	18 – 75	19 – 53	18 – 71	18 – 79	17 – 72
Age group (%)						
<25 years	47 (26)	39 (31)	22 (17)	37 (33)	9 (9)	55 (36)
25+ years	136 (74)	88 (69)	109 (83)	76 (67)	91 (91)	99 (64)
Not reported	--	--	1 (<1)	0 (0)	--	--
Median age 1 st IDU (years)	18	--	18	--	19	--
Age range	9 – 41	--	8 – 35	--	7 – 40	--
Not reported	4	--	3	--	4	--
Median years IDU	10	--	13	--	14	--
Range	<1 – 31	--	<1 – 36	--	<1 – 38	--
Duration of drug injection (%)						
<3 years	16 (9)	--	6 (5)	--	9 (9)	--
3+ years	163 (89)	--	122 (92)	--	87 (87)	--
Not reported	4 (2)	--	4 (3)	--	4 (4)	--
Aboriginal and Torres Strait Islander origin (%)						
No	155 (85)	118 (93)	93 (70)	97 (86)	80 (80)	126 (81)
Yes	28 (15)	9 (7)	33 (25)	15 (13)	20 (20)	29 (19)
Not reported	--	--	6 (5)	1 (<1)	--	--
Living situation prior to prison (%)*						
Not homeless	n/a	n/a	n/a	n/a	67 (67)	104 (68)
Primary homelessness	n/a	n/a	n/a	n/a	2 (2)	2 (1)
Secondary homelessness	n/a	n/a	n/a	n/a	22 (22)	46 (30)
Tertiary homelessness	n/a	n/a	n/a	n/a	9 (9)	2 (1)
Not reported	n/a	n/a	n/a	n/a	--	--
Residential remoteness in 12 months before prison (%)						
Highly accessible/accessible	174 (95)	117 (92)	121 (92)	104 (92)	139 (90)	92 (92)
Moderately accessible	3 (2)	2 (2)	1 (1)	1 (1)	5 (3)	6 (6)
Remote/very remote	3 (2)	--	--	--	4 (3)	1 (1)
Not reported	3 (2)	8 (6)	10 (8)	8 (7)	6 (4)	1 (1)
Region/Country of birth (%)						
Australia	156 (85)	87 (69)	118 (89)	73 (65)	85 (85)	110 (71)
Other Oceania	3 (2)	8 (6)	2 (2)	9 (8)	8 (8)	13 (8)
Asia	11 (6)	11 (9)	7 (5)	13 (12)	4 (4)	16 (10)
UK & Ireland	3 (2)	5 (4)	1 (<1)	2 (2)	1 (1)	1 (1)
Other	10 (5)	16 (13)	3 (2)	13 (12)	2 (2)	14 (9)
Not reported	--	--	1 (<1)	3 (3)	--	--
Main language spoke at home by parents (%)						
English	159 (87)	99 (78)	115 (87)	74 (65)	91 (91)	122 (79)
Non-English	24 (13)	28 (22)	17 (13)	39 (35)	9 (9)	31 (20)
Not reported	--	--	--	--	--	1 (1)

* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers' accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010.

Table 71 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)						
No	157 (86)	59 (46)	112 (85)	63 (56)	84 (84)	86 (56)
Yes	26 (14)	68 (54)	19 (14)	50 (44)	14 (14)	64 (42)
Not reported	--	--	1 (<1)	--	2 (2)	4 (3)
Lifetime imprisonments (%)						
One	26 (14)	68 (54)	19 (14)	50 (44)	30 (30)	96 (62)
Two to four	84 (46)	44 (35)	50 (38)	49 (43)	30 (30)	39 (25)
Five to nine	50 (27)	9 (7)	32 (24)	7 (6)	22 (22)	13 (8)
Ten or more	20 (11)	2 (2)	27 (20)	3 (3)	16 (16)	2 (1)
Not reported	3 (2)	4 (3)	4 (3)	4 (4)	2 (2)	4 (3)
Imprisonment in last year (%)						
No	84 (46)	97 (76)	35 (31)	14 (22)	50 (50)	94 (61)
Yes	99 (54)	27 (21)	76 (67)	48 (76)	48 (48)	56 (36)
Not reported	--	3 (2)	2 (2)	1 (2)	2 (2)	4 (3)
Frequency of injection last month (%)						
Not last month	55 (30)	--	44 (33)	--	46 (46)	--
Less than weekly	29 (16)	--	22 (17)	--	18 (18)	--
Weekly not daily	14 (8)	--	14 (11)	--	7 (7)	--
Daily or more	83 (45)	--	49 (37)	--	28 (28)	--
Not reported	2 (1)	--	3 (2)	--	1 (1)	--
Ever smoked a full cigarette (%)*						
No	n/a	n/a	4 (3)	10 (9)	3 (3)	15 (10)
Yes	n/a	n/a	128 (97)	103 (91)	97 (97)	139 (90)
Not reported	n/a	n/a	--	--	--	--
Median age first smoked (years)	n/a	n/a	13	14	14	15
Age range	n/a	n/a	6 – 30	4 – 31	7 – 28	6 – 34
Current smoker (%)*						
No	n/a	n/a	8 (6)	27 (24)	6 (6)	37 (24)
Yes	n/a	n/a	124 (94)	86 (76)	94 (94)	117 (76)
Not reported	n/a	n/a	--	--	--	--
Smoking frequency (%)*						
Occasional – weekly or less	n/a	n/a	4 (3)	10 (12)	2 (2)	--
5 to 10 cigarettes a day	n/a	n/a	26 (21)	16 (19)	26 (28)	45 (38)
11 to 20 cigarettes a day	n/a	n/a	61 (49)	31 (36)	48 (51)	45 (38)
Over 20 cigarettes a day	n/a	n/a	32 (26)	29 (34)	18 (19)	27 (23)
Not reported	n/a	n/a	1 (<1)	--	--	--
Other drugs used last month (%)**						
No drugs in past 4 weeks	n/a	n/a	n/a	n/a	24 (24)	90 (58)
Cannabis	n/a	n/a	n/a	n/a	52 (68)	46 (72)
Heroin	n/a	n/a	n/a	n/a	25 (33)	6 (9)
Cocaine	n/a	n/a	n/a	n/a	9 (12)	8 (13)
Amphetamine	n/a	n/a	n/a	n/a	42 (55)	25 (39)
Other's methadone	n/a	n/a	n/a	n/a	12 (16)	--
Other opiates	n/a	n/a	n/a	n/a	9 (12)	--
Other's buprenorphine	n/a	n/a	n/a	n/a	5 (7)	1 (2)
Steroids	n/a	n/a	n/a	n/a	3 (4)	1 (2)
Hallucinogens	n/a	n/a	n/a	n/a	1 (1)	1 (2)
Benzodiazepines	n/a	n/a	n/a	n/a	15 (20)	6 (9)
Ecstasy/MDA	n/a	n/a	n/a	n/a	--	8 (13)
Inhalants (e.g. petrol)	n/a	n/a	n/a	n/a	--	1 (2)
Other drug	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	--	--

* Smoking questions not asked in 2004.

** Other drugs used in the last month not asked in 2004 and 2007. More than one option could be selected.

Table 72 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010
Last drug injected (%)	N = 183	N = 132	N = 100
Amphetamine (Speed, Ice)	73 (40)	64 (48)	49 (49)
Anabolic steroids	1 (1)	--	1 (1)
Cocaine	7 (4)	5 (4)	2 (2)
Heroin	86 (47)	53 (40)	37 (37)
Heroin + amphetamine	--	3 (2)	--
Heroin + cocaine	2 (1)	1 (1)	2 (2)
Methadone	6 (3)	4 (3)	4 (4)
Morphine	1 (1)	2 (2)	2 (2)
Other	7 (4)	--	2 (2)
Not reported	--	--	1 (1)
N° Injected last month	N = 128	N = 88	N = 53
Places injected last month (%)*			
Prison	3 (2)	3 (3)	--
Own home	99 (77)	65 (76)	34 (64)
Friend's home	54 (42)	46 (54)	15 (28)
Dealer's home	21 (16)	23 (27)	8 (15)
Street, park, beach	40 (31)	38 (45)	6 (11)
Car	37 (29)	36 (42)	9 (17)
Public toilet	29 (23)	25 (29)	7 (13)
Commercial injecting room	6 (5)	7 (8)	--
Medically Supervised Injecting Centre, Sydney	5 (4)	10 (12)	2 (4)
Squat	10 (8)	8 (9)	--
Other place	5 (4)	--	--
Use of sterile needles & syringes last month (%)			
All injections	86 (67)	49 (58)	36 (68)
Most of the time	20 (16)	16 (19)	10 (19)
Half of the time	8 (6)	7 (8)	--
Some of the time	12 (9)	10 (12)	1 (2)
Not last month	2 (2)	--	1 (2)
Not reported	--	3 (4)	5 (9)
Re-used someone else's used needle & syringe last month (%)			
None	116 (91)	68 (80)	38 (72)
Once	4 (3)	7 (8)	2 (4)
Twice	3 (2)	2 (2)	3 (6)
3-5 times	4 (3)	3 (4)	4 (8)
>5 times	1 (<1)	4 (5)	2 (4)
Not reported	--	1 (1)	4 (8)
Number of people needle & syringe was re-used after last month (%)			
None	117 (91)	68 (77)	37 (70)
One	8 (6)	12 (14)	9 (17)
Two	2 (2)	--	1 (2)
Three to five	1 (<1)	--	--
More than five	--	--	--
Don't know how many	--	--	1 (2)
Not reported	--	8 (9)	5 (9)
Relationship to people needle & syringe was re-used after last month (%)*			
Regular sex partner	4 (3)	7 (8)	6 (11)
Casual sex partner	1 (<1)	--	1 (2)
Close friend	3 (2)	2 (2)	1 (2)
Acquaintance	3 (2)	2 (2)	1 (2)
Other	1 (<1)	1 (1)	1 (2)
Equipment used after someone else last month (%)*			
Spoon	28 (22)	26 (31)	11 (21)
Water	19 (15)	23 (27)	9 (17)
Filter	17 (13)	20 (24)	8 (15)
Tourniquet	10 (8)	11 (13)	10 (19)
Drug mix	18 (14)	17 (20)	8 (15)

* More than one option could be selected.

Table 73 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment for drug use	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 183	N = 127	N = 132	N = 113	N = 100	N = 154
Any treatment/therapy for drug use (%)						
No	89 (49)	118 (93)	24 (18)	76 (67)	29 (29)	128 (83)
Yes	93 (51)	9 (7)	100 (76)	15 (13)	70 (70)	26 (17)
Not reported	1 (<1)	--	8 (6)	22 (19)	1 (1)	--
History of methadone maintenance treatment (%)						
Currently	44 (24)	--	25 (19)	--	25 (25)	1 (1)
Previously	50 (27)	2 (2)	39 (30)	--	17 (17)	3 (2)
Never	88 (48)	125 (98)	57 (43)	--	55 (55)	150 (97)
Not reported	1 (<1)	--	11 (8)	--	3 (3)	--
History of other pharmacotherapy treatment (%)						
Currently	9 (5)	--	4 (3)	--	18 (18)	2 (1)
Previously	31 (17)	1 (<1)	35 (27)	--	13 (13)	3 (2)
Never	139 (77)	126 (98)	89 (67)	--	69 (69)	149 (97)
Not reported	1 (<1)	--	4 (3)	--	--	--

Table 74 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010
N° surveyed	N = 129	N = 85	N = 53
From an NSP last month (%)			
Daily or almost daily	17 (6)	11 (13)	8 (15)
A couple of times each week	21 (7)	18 (21)	11 (21)
Less than weekly	14 (5)	13 (15)	11 (21)
Weekly	n/a	n/a	--
Once last month	24 (8)	15 (18)	13 (25)
Not in the last month	28 (9)	12 (14)	10 (19)
Not reported	25 (8)	16 (19)	--
From a chemist last month (%)			
Daily or almost daily	5 (2)	5 (6)	3 (6)
A couple of times each week	17 (6)	8 (9)	5 (9)
Less than weekly	30 (10)	9 (11)	7 (13)
Weekly	n/a	n/a	8 (15)
Once last month	19 (6)	11 (13)	--
Not in the last month	54 (17)	37 (44)	30 (57)
Not reported	4 (3)	15 (18)	--

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 75 Number (%) of respondents by body piercing and tattoos

Body piercing and tattoos	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 183	N = 127	N = 132	N = 113	N = 100	N = 154
Body or ear piercings (%)						
No	93 (51)	84 (66)	43 (33)	59 (52)	59 (59)	94 (61)
Yes	90 (49)	42 (33)	88 (67)	52 (46)	41 (41)	60 (39)
Not reported	--	1 (1)	1 (1)	2 (2)	--	--
Pierced in past 12 mths (%)						
No	74 (82)	30 (71)	73 (82)	43 (82)	41 (100)	47 (78)
Yes	11 (12)	5 (12)	13 (15)	6 (12)	--	12 (20)
Not reported	5 (6)	7 (17)	2 (3)	3 (6)	--	1 (2)
Who did piercing (%)*						
Chemist/hairdresser/beauty salon	2 (18)	3 (60)	1 (8)	1 (17)	--	1 (8)
Professional piercer / studio	7 (64)	1 (20)	4 (31)	1 (17)	--	6 (50)
Tattooist / parlour	--	--	4 (31)	1 (17)	--	1 (8)
Friend	--	--	--	1 (17)	--	2 (17)
Prison inmate	--	--	1 (8)	--	--	--
Self	1 (9)	--	--	2 (33)	--	--
Family member	--	--	2 (15)	--	--	--
Other	--	--	--	--	--	--
Needle used by other (%)						
No	2 (18)	--	--	--	--	10 (83)
Yes	--	--	--	2 (33)	--	--
Unsure	--	--	--	--	--	--
Not reported	9 (82)	5 (100)	13 (100)	4 (67)	--	2 (17)
Tattoos (%)						
No	48 (26)	67 (53)	25 (19)	44 (39)	20 (20)	64 (42)
Yes	135 (74)	59 (46)	107 (81)	69 (61)	80 (80)	90 (58)
Not reported	--	1 (1)	--	--	--	--
Tattoos in past 12 mths (%)						
No	114 (84)	48 (80)	81 (76)	44 (64)	64 (80)	55 (61)
Yes	21 (16)	10 (17)	26 (24)	24 (35)	16 (20)	35 (39)
Not reported	--	1 (3)	--	1 (1)	--	--
Who did tattooing (%)*						
Professional tattooist	12 (57)	4 (40)	14 (54)	18 (75)	9 (56)	23 (80)
Friend	5 (24)	1 (10)	7 (27)	4 (17)	6 (38)	6 (17)
Prison inmate	5 (24)	2 (20)	6 (23)	--	1 (6)	--
Self	3 (14)	1 (10)	1 (4)	2 (8)	--	1 (3)
Family member	1 (5)	--	--	1 (4)	--	--
Other	--	--	--	--	--	--

* More than one option could be selected.

Table 76 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sexual behaviour	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 183	N = 127	N = 132	N = 113	N = 100	N = 154
Sex last month / last 3 months (%)**						
No	47 (26)	38 (30)	39 (30)	28 (25)	17 (17)	28 (18)
Yes	136 (74)	86 (68)	93 (70)	84 (74)	83 (83)	123 (80)
Not reported	--	--	--	1 (<1)	--	--
Male sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	1	1
Range	n/a	n/a	n/a	n/a	0 – 23	0 – 20
Female sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	1	1
Range	n/a	n/a	n/a	n/a	0 – 1	0 – 10
Condom use at last sex (%)						
No	136 (74)	85 (67)	114 (86)	90 (80)	n/a	n/a
Yes	47 (26)	39 (31)	15 (11)	22 (19)	n/a	n/a
Not reported			3 (2)	1 (<1)	n/a	n/a
Condom use with regular sex partner(s) last month (%)*						
No	83 (84)	57 (81)	69 (88)	57 (77)	n/a	n/a
Sometimes	8 (8)	7 (10)	8 (10)	9 (12)	n/a	n/a
Always	8 (8)	6 (9)	1 (<1)	8 (11)	n/a	n/a
Condom use with new sex partner(s) last month (%)*						
No	6 (27)	2 (22)	17 (63)	5 (36)	n/a	n/a
Sometimes	6 (27)	1 (11)	5 (19)	5 (36)	n/a	n/a
Always	10 (45)	6 (67)	5 (19)	4 (29)	n/a	n/a
Condom use with casual sex partner(s) last month (%)*						
No	17 (40)	8 (40)	17 (74)	6 (43)	n/a	n/a
Sometimes	9 (21)	4 (20)	4 (17)	5 (36)	n/a	n/a
Always	17 (40)	8 (40)	2 (9)	3 (21)	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	6 (86)	3 (60)
Sometimes	n/a	n/a	n/a	n/a	1 (14)	1 (20)
Always	n/a	n/a	n/a	n/a	--	1 (20)
Condom use last sex - regular male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	6 (86)	3 (60)
Sometimes	n/a	n/a	n/a	n/a	1 (14)	1 (20)
Always	n/a	n/a	n/a	n/a	--	1 (20)
Condom use last sex - regular female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	47 (78)	57 (62)
Sometimes	n/a	n/a	n/a	n/a	7 (12)	12 (13)
Always	n/a	n/a	n/a	n/a	6 (10)	23 (25)
Condom use last sex - casual female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	7 (28)	15 (36)
Sometimes	n/a	n/a	n/a	n/a	11 (44)	10 (24)
Always	n/a	n/a	n/a	n/a	7 (28)	17 (40)
Sex work last month (%)						
No	178 (97)	122 (96)	126 (95)	103 (91)	97 (97)	151 (98)
Yes	5 (3)	--	3 (2)	5 (4)	2 (2)	--
Not reported	--	5 (4)	3 (2)	5 (4)	1 (1)	3 (2)
Condom used at last sex work last month (%)						
No	2 (50)	--	--	1 (20)	--	--
Yes	3 (60)	--	2 (67)	2 (40)	--	--
Not reported	--	--	1 (33)	2 (40)	2 (100)	--
Ever had cervical cancer vaccine (women only)*** (%)						
No	n/a	n/a	n/a	n/a	--	--
Yes	n/a	n/a	n/a	n/a	--	--
Unsure	n/a	n/a	n/a	n/a	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

*** Proportion of eligible women i.e. those under 27 years of age in 2007.

Table 77 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 183	N = 127	N = 132	N = 113	N = 100	N = 154
Previous HIV test (%)						
Yes, last year	96 (52)	23 (18)	52 (39)	25 (22)	41 (41)	31 (20)
>1 year ago	59 (32)	31 (25)	62 (47)	34 (30)	40 (40)	35 (23)
Never tested	27 (15)	72 (57)	17 (13)	54 (48)	19 (19)	88 (57)
Not reported	1 (<1)	--	1 (<1)	--	--	--
HBV infection (%)						
No	131 (72)	115 (91)	97 (73)	106 (94)	82 (82)	140 (91)
Yes	34 (19)	3 (2)	26 (20)	4 (4)	11 (11)	1 (1)
Don't know	18 (10)	9 (7)	8 (6)	3 (3)	7 (7)	13 (8)
Not reported	--	--	1 (<1)	--	--	--
HBV vaccination (%)*						
No	65 (36)	58 (46)	43 (33)	60 (53)	27 (27)	50 (32)
Yes	87 (48)	33 (26)	70 (53)	36 (32)	52 (52)	50 (32)
Don't know	30 (16)	33 (26)	13 (10)	15 (13)	21 (21)	51 (33)
Not reported	--	3 (2)	6 (5)	2 (2)	--	3 (2)
Previous HCV test (%)						
Yes, last year	23 (13)	84 (67)	43 (33)	22 (19)	14 (14)	100 (65)
>1 year ago	85 (46)	23 (18)	77 (58)	30 (27)	41 (41)	24 (16)
Never tested	72 (39)	17 (13)	12 (9)	59 (52)	44 (44)	30 (19)
Unsure	--	--	--	1 (<1)	--	--
Not reported	2 (1)	1 (<1)	--	1 (<1)	1 (1)	--
Any HCV treatment (%)**	N = 85	N = 2	N = 80	N = 3	N = 46	N = 2
Interferon	--	--	--	--	3 (7)	--
Interferon & Ribavirin	1 (1)	--	--	--	2 (4)	--
Pegasys & Ribavirin	--	--	--	--	--	--
Other	--	--	--	--	--	--
No treatment	84 (99)	2 (100)	80 (100)	3 (100)	46 (100)	2 (100)
Not reported	--	--	--	--	--	--
Current HCV treatment						
Interferon	--	--	--	--	--	--
Interferon & Ribavirin	--	--	--	--	--	--
Pegasys & Ribavirin	--	--	--	--	--	--
Other	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Number (%) of those testing positive for hepatitis C antibodies.

HIV antibody prevalence

Table 78 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	104	2 (2)	16	0 (0)	120	2 (2)
Non-IDU	75	0 (0)	5	0 (0)	80	0 (0)
p value		0.2		--		0.2
2007						
IDU	84	1 (1)	27	1 (4)	111	2 (2)
Non-IDU	75	1 (1)	10	0 (0)	85	1 (1)
p value		0.9		0.5		0.7
2010						
IDU	72	0 (0)	3	0 (0)	75	0 (0)
Non-IDU	123	0 (0)	4	0 (0)	127	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 79 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	108	72 (67)	16	13 (81)	124	85 (69)
Non-IDU	75	2 (3)	5	0 (0)	80	2 (3)
p value		<0.001		<0.01		<0.001
2007						
IDU	84	57 (68)	28	23 (82)	112	80 (71)
Non-IDU	76	2 (3)	9	1 (11)	85	3 (3)
p value		<0.001		<0.001		<0.001
2010						
IDU	71	44 (62)	3	2 (67)	74	46 (62)
Non-IDU	124	2 (2)	4	0 (0)	128	2 (2)
p value		<0.001		0.05		<0.001

† Excludes equivocal test results and missing values.

Table 80 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	180	73 (41)	18	11 (61)	198	84 (42)
Bisexual	--	--	3	2 (67)	3	2 (67)
Homosexual	3	1 (33)	--	--	3	1 (33)
Unsure	--	--	--	--	--	--
p value		0.8		0.9		0.7
2007						
Heterosexual	155	59 (38)	29	16 (55)	184	75 (41)
Bisexual	1	0 (0)	3	3 (100)	4	3 (75)
Homosexual	2	0 (0)	2	2 (100)	4	2 (50)
Unsure	--	--	--	--	--	--
p value		0.4		0.2		0.4
2010						
Heterosexual	194	46 (24)	7	2 (29)	201	48 (24)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value	0.3			--		0.6

† Excludes equivocal test results and missing values.

Table 81 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	13	0 (0)	1	0 (0)	14	0 (0)
20 – 24	44	16 (36)	3	2 (67)	47	18 (38)
25 – 29	40	14 (35)	4	3 (75)	44	17 (39)
30 + years	86	44 (51)	13	8 (62)	99	52 (53)
p value		0.003		0.6		0.002
2007						
< 20 years	8	1 (13)	1	0 (0)	9	1 (11)
20 – 24	32	5 (16)	6	4 (67)	38	9 (24)
25 – 29	31	11 (35)	11	9 (82)	42	20 (48)
30 + years	88	42 (48)	19	11 (58)	107	53 (50)
p value		0.005		0.3		0.03
2010						
< 20 years	22	0 (0)	--	--	22	0 (0)
20 – 24	34	2 (6)	--	--	34	2 (6)
25 – 29	42	9 (21)	--	--	42	9 (21)
30 + years	97	35 (36)	7	2 (29)	104	37 (36)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 82 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	11	1 (9)	1	0 (0)	12	1 (8)
3 to 5 years	11	7 (64)	2	1 (50)	13	8 (62)
6 to 10 years	35	20 (57)	5	4 (80)	40	24 (60)
10 + years	50	44 (88)	8	8 (100)	58	52 (90)
p value		<0.001		0.06		<0.001
2007						
<3 years	4	3 (75)	1	1 (100)	5	4 (80)
3 to 5 years	5	3 (60)	2	1 (50)	7	4 (57)
6 to 10 years	17	7 (41)	14	11 (79)	31	18 (58)
10 + years	55	43 (78)	11	10 (91)	66	53 (80)
p value		0.04		0.5		0.1
2010						
<3 years	6	1 (17)	1	0 (0)	7	1 (14)
3 to 5 years	5	0 (0)	--	--	5	0 (0)
6 to 10 years	11	7 (64)	--	--	11	7 (64)
10 + years	47	35 (74)	2	2 (100)	49	37 (76)
p value		<0.01		0.08		<0.001

† Excludes equivocal test results and missing values.

Table 83 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	6	1 (17)	42	26 (62)	48	27 (56)
Heroin	1	0 (0)	55	47 (85)	56	47 (84)
More than one	--	--	9	6 (67)	6	5 (83)
Other/not reported	1	0 (0)	5	5 (100)	15	8 (53)
p value		0.6		0.03		0.008
2007						
Amphetamine (Speed, Ice)	3	3 (100)	49	28 (57)	52	31 (60)
Heroin	2	1 (50)	43	36 (84)	45	37 (82)
More than one	--	--	4	4 (100)	4	4 (100)
Other/not reported	--	--	8	7 (88)	8	7 (88)
p value		0.2		0.01		0.003
2010						
Amphetamine (Speed, Ice)	2	0 (0)	37	22 (59)	39	22 (56)
Heroin	4	1 (25)	17	13 (76)	21	14 (67)
More than one	--	--	2	1 (50)	2	1 (50)
Other/not reported	1	0 (0)	9	8 (89)	10	8 (80)
p value		0.7		0.3		0.5

† Excludes equivocal test results and missing values.

Table 84 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	6	0 (0)	21	17 (81)	27	17 (63)
Daily or more	2	1 (50)	52	39 (75)	54	40 (74)
p value		0.08		0.8		0.2
2007						
Less than daily	2	1 (50)	24	17 (71)	26	18 (69)
Daily or more	1	1 (100)	42	33 (79)	43	34 (79)
p value		0.4		0.5		0.5
2010						
Less than daily	2	0 (0)	17	16 (94)	19	16 (84)
Daily or more	3	1 (33)	14	10 (71)	17	11 (65)
p value		0.4		0.09		0.2

† Excludes equivocal test results and missing values.

Table 85 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	8	1 (13)	53	44 (83)	61	45 (74)
Yes	1	0 (0)	20	12 (60)	21	12 (57)
p value		0.7		0.01		0.02
2007						
No	3	2 (67)	50	39 (78)	53	41 (77)
Yes	--	--	12	8 (67)	12	8 (67)
p value		--		0.4		0.4
2010						
No	3	0 (0)	21	17 (81)	24	17 (71)
Yes	2	1 (50)	6	6 (100)	8	7 (88)
p value		0.2		0.3		0.4

† Excludes equivocal test results and missing values.

Table 86 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	6	0 (0)	53	39 (74)	59	39 (66)
Yes	6	1 (17)	58	45 (78)	64	46 (72)
p value		0.3		0.6		0.5
2007						
No	1	1 (100)	30	22 (73)	31	23 (74)
Yes	2	2 (100)	58	45 (78)	60	47 (78)
p value		--		0.7		0.7
2010						
No	5	0 (0)	29	17 (59)	34	17 (50)
Yes	2	1 (50)	34	26 (76)	36	27 (75)
p value		0.1		0.1		0.03

† Excludes equivocal test results and missing values.

Table 87 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	61	9 (15)	6	1 (17)	67	10 (15)
2 to 4	72	33 (46)	10	7 (70)	82	40 (49)
5 to 9	32	19 (59)	3	3 (100)	35	22 (63)
10 +	15	12 (80)	2	2 (100)	17	14 (82)
p value		<0.001		0.04		<0.001
2007						
1	40	5 (13)	13	5 (38)	53	10 (19)
2 to 4	67	19 (28)	14	10 (71)	81	29 (36)
5 to 9	25	18 (72)	5	5 (100)	30	23 (77)
10 +	22	16 (73)	4	3 (75)	26	19 (73)
p value		<0.001		0.07		<0.001
2010						
1	103	8 (8)	6	2 (33)	109	10 (9)
2 to 4	52	14 (27)	1	0 (0)	53	14 (26)
5 to 9	23	12 (52)	--	--	23	12 (52)
10 +	13	11 (85)	--	--	13	11 (85)
p value		<0.001		0.5		<0.001

† Excludes equivocal test results and missing values.

Table 88 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	163	63 (39)	17	10 (59)	180	73 (41)
Indigenous	20	11 (55)	4	3 (75)	24	14 (58)
p value		0.2		0.6		0.1
2007						
Non-Indigenous	124	38 (31)	24	12 (50)	148	50 (34)
Indigenous	30	16 (53)	12	11 (92)	42	27 (64)
p value		0.02		0.01		<0.001
2010						
Non-Indigenous	159	38 (24)	3	0 (0)	162	38 (23)
Indigenous	36	8 (22)	4	2 (50)	40	10 (25)
p value		0.8		0.2		0.8

† Excludes equivocal test results and missing values.

Table 89 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	77	2 (3)	103	71 (69)	180	73 (41)
Indigenous	3	0 (0)	21	14 (67)	24	14 (58)
p value		0.8		0.8		0.1
2007						
Non-Indigenous	74	2 (3)	74	48 (65)	148	50 (34)
Indigenous	10	1 (10)	32	26 (81)	42	27 (64)
p value		0.2		0.09		<0.001
2010						
Non-Indigenous	103	1 (1)	59	37 (63)	162	38 (23)
Indigenous	25	1 (4)	15	9 (60)	40	10 (25)
p value		0.3		0.9		0.8

† Excludes equivocal test results and missing values.

Table 90 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison, and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	171	70 (41)	21	13 (62)	192	83 (43)
Moderately accessible	3	1 (33)	--	--	3	1 (33)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.6
2007						
Highly accessible/accessible	151	55 (36)	30	19 (63)	181	74 (41)
Moderately accessible	1	0 (0)	1	0 (0)	2	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.5		0.2		0.2
2010						
Highly accessible/accessible	181	41 (23)	5	2 (40)	186	43 (23)
Moderately accessible	8	4 (50)	1	0 (0)	9	4 (44)
Remote/very remote	3	1 (33)	--	--	3	1 (33)
p value		0.2		0.4		0.3

† Excludes equivocal test results and missing values.

Table 91 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	138	60 (43)	19	13 (68)	157	73 (46)
Other Oceania	7	0 (0)	--	--	7	0 (0)
Asia	14	8 (57)	2	0 (0)	16	8 (50)
UK & Ireland	5	2 (40)	--	--	5	2 (40)
Other	19	4 (21)	--	--	19	4 (21)
p value		0.04		0.06		0.04
2007						
Australia	127	52 (41)	32	21 (66)	159	73 (46)
Other Oceania	8	1 (13)	1	1 (100)	9	2 (22)
Asia	14	5 (36)	2	0 (0)	16	5 (31)
UK & Ireland	--	--	--	--	--	--
Other	9	0 (0)	2	2 (100)	11	2 (18)
p value		0.08		0.1		0.1
2010						
Australia	151	38 (25)	5	2 (40)	156	40 (26)
Other Oceania	16	5 (31)	--	--	16	5 (31)
Asia	15	1 (7)	1	0 (0)	16	1 (6)
UK & Ireland	2	0 (0)	--	--	2	0 (0)
Other	11	2 (18)	1	0 (0)	12	2 (17)
p value		0.4		0.6		0.4

† Excludes equivocal test results and missing values.

Table 92 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	146	59 (40)	18	12 (67)	164	71 (43)
Non-English	37	15 (41)	3	1 (33)	40	16 (40)
p value		1.0		0.3		0.7
2007						
English	121	48 (40)	33	22 (67)	154	70 (45)
Non-English	39	11 (28)	4	2 (50)	43	13 (30)
p value		0.2		0.5		0.07
2010						
English	162	41 (25)	7	2 (29)	169	43 (25)
Non-English	32	5 (16)	--	--	32	5 (16)
p value		0.4		--		0.2

† Excludes equivocal test results and missing values.

Table 93 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	45	44 (98)	12	12 (100)	57	56 (98)
Negative	45	12 (27)	4	1 (25)	49	13 (27)
Not sure	14	9 (64)	1	0 (0)	15	9 (60)
p value		<0.001		0.002		<0.001
2007						
Positive	44	42 (95)	20	19 (95)	64	61 (95)
Negative	55	8 (15)	9	2 (22)	64	10 (16)
Not sure	5	4 (80)	4	2 (50)	9	6 (67)
p value		<0.001		<0.001		<0.001
2010						
Positive	36	36 (100)	2	2 (100)	38	38 (100)
Negative	55	6 (11)	4	0 (0)	59	6 (10)
Not sure	5	1 (20)	--	--	5	1 (20)
p value		<0.001		0.014		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 94 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	108	6 (6)	16	0 (0)	124	6 (5)
Non-IDU	75	0 (0)	5	0 (0)	80	0 (0)
p value		0.04		--		0.05
2007						
IDU	85	1 (1)	27	2 (7)	112	3 (3)
Non-IDU	76	3 (4)	10	0 (0)	86	3 (3)
p value		0.3		0.4		0.7
2010						
IDU	72	2 (3)	3	0 (0)	75	2 (3)
Non-IDU	125	4 (3)	4	0 (0)	129	4 (3)
p value		0.9		--		0.9

† Excludes equivocal test results and missing values.

Table 95 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	105	35 (33)	16	3 (19)	121	38 (31)
Non-IDU	74	6 (8)	5	3 (60)	79	9 (11)
p value		<0.001		0.08		0.001
2007						
IDU	85	33 (39)	28	9 (32)	113	42 (37)
Non-IDU	76	11 (14)	10	1 (10)	86	12 (14)
p value		0.001		0.2		0.0
2010						
IDU	72	17 (24)	--	--	72	17 (24)
Non-IDU	126	21 (17)	4	0 (0)	130	21 (16)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 96 HBV core-antibody prevalence by sexual identity, sex and survey year

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	176	41 (23)	18	5 (28)	194	46 (24)
Bisexual	--	--	3	1 (33)	3	1 (33)
Homosexual	3	0 (0)	--	--	3	0 (0)
Unsure	--	--	--	--	--	--
p value		0.3		0.8		0.6
2007						
Heterosexual	156	44 (28)	30	8 (27)	186	52 (28)
Bisexual	1	0 (0)	3	0 (0)	4	0 (0)
Homosexual	2	0 (0)	2	1 (50)	4	1 (25)
Unsure	--	--	--	--	--	--
p value		0.6		0.4		0.5
2010						
Heterosexual	197	38 (19)	4	0 (0)	201	38 (19)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 97 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	13	0 (0)	1	0 (0)	14	0 (0)
20 – 24	43	9 (21)	3	1 (33)	46	10 (22)
25 – 29	40	8 (20)	4	0 (0)	44	8 (18)
30 + years	83	24 (29)	13	5 (38)	96	29 (30)
p value		0.1		0.5		0.06
2007						
< 20 years	8	0 (0)	1	0 (0)	9	0 (0)
20 – 24	32	5 (16)	6	0 (0)	38	5 (13)
25 – 29	31	7 (23)	11	2 (18)	42	9 (21)
30 + years	89	32 (36)	20	8 (40)	109	40 (37)
p value		0.03		0.2		0.01
2010						
< 20 years	22	2 (9)	--	--	22	2 (9)
20 – 24	34	6 (6)	--	--	34	2 (6)
25 – 29	43	9 (21)	--	--	43	9 (21)
30 + years	99	25 (25)	4	0 (0)	103	25 (24)
p value		0.05		--		0.07

† Excludes equivocal test results and missing values.

Table 98 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	11	0 (0)	1	0 (0)	12	0 (0)
3 to 5 years	9	2 (22)	2	0 (0)	11	2 (18)
6 to 10 years	35	12 (34)	5	1 (20)	40	13 (33)
10 + years	49	21 (43)	8	2 (25)	57	23 (40)
p value		0.05		0.8		0.04
2007						
<3 years	4	0 (0)	1	0 (0)	5	0 (0)
3 to 5 years	5	1 (20)	2	0 (0)	7	1 (14)
6 to 10 years	17	6 (35)	14	3 (21)	31	9 (29)
10 + years	56	25 (45)	11	6 (55)	67	31 (46)
p value		0.2		0.2		0.05
2010						
<3 years	6	0 (0)	--	--	6	0 (0)
3 to 5 years	5	2 (40)	--	--	5	2 (40)
6 to 10 years	11	2 (18)	--	--	11	2 (18)
10 + years	48	12 (25)	--	--	48	12 (25)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 99 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	6	0 (0)	42	16 (38)	48	16 (33)
Heroin	1	0 (0)	52	18 (35)	53	18 (34)
More than one	4	0 (0)	9	3 (33)	13	3 (23)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		0.9		0.7
2007						
Amphetamine (Speed, Ice)	3	0 (0)	50	16 (32)	53	16 (30)
Heroin	2	0 (0)	43	18 (42)	45	18 (40)
More than one	--	--	4	2 (50)	4	2 (50)
Other/not reported	--	--	8	5 (63)	8	5 (63)
p value		--		0.4		0.3
2010						
Amphetamine (Speed, Ice)	2	0 (0)	38	8 (21)	40	8 (20)
Heroin	3	0 (0)	16	7 (44)	19	7 (37)
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	1	0 (0)	9	1 (11)	10	1 (10)
p value		--		0.2		0.3

† Excludes equivocal test results and missing values.

Table 100 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	6	0 (0)	21	10 (48)	27	10 (37)
Daily or more	2	0 (0)	50	14 (28)	52	14 (27)
p value		--		0.1		0.4
2007						
Less than daily	2	0 (0)	25	6 (24)	27	6 (22)
Daily or more	1	0 (0)	42	18 (43)	43	18 (42)
p value		--		0.2		0.1
2010						
Less than daily	2	0 (0)	17	4 (24)	19	4 (21)
Daily or more	2	0 (0)	14	2 (14)	16	2 (13)
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 101 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	8	0 (0)	51	16 (31)	59	16 (27)
Yes	1	0 (0)	20	8 (40)	21	8 (38)
p value		--		0.5		0.3
2007						
No	3	0 (0)	51	18 (35)	54	18 (33)
Yes	--	--	12	5 (42)	12	5 (42)
p value		--		0.7		0.6
2010						
No	3	0 (0)	21	4 (19)	24	4 (17)
Yes	1	0 (0)	6	1 (17)	7	1 (14)
p value		--		0.9		0.9

† Excludes equivocal test results and missing values.

Table 102 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	52	20 (38)	58	20 (34)
Yes	6	0 (0)	56	18 (32)	62	18 (29)
p value		--		0.5		0.6
2007						
No	1	0 (0)	30	11 (37)	31	11 (35)
Yes	2	0 (0)	59	26 (44)	61	26 (43)
p value		--		0.5		0.5
2010						
No	4	0 (0)	27	8 (30)	31	8 (26)
Yes	2	0 (0)	35	8 (23)	37	8 (22)
p value		--		0.6		0.7

† Excludes equivocal test results and missing values.

Table 103 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	60	4 (7)	6	3 (50)	66	7 (11)
2 to 4	72	19 (26)	10	1 (10)	82	20 (24)
5 to 9	31	13 (42)	3	1 (33)	34	14 (41)
10 +	14	5 (36)	2	1 (50)	16	6 (38)
p value		0.001		0.3		0.003
2007						
1	40	3 (8)	13	4 (31)	53	7 (13)
2 to 4	67	20 (30)	15	1 (7)	82	21 (26)
5 to 9	26	10 (38)	5	3 (60)	31	13 (42)
10 +	22	10 (45)	4	1 (25)	26	11 (42)
p value		0.004		0.01		0.008
2010						
1	103	13 (13)	3	0 (0)	106	13 (12)
2 to 4	55	14 (25)	1	0 (0)	56	14 (25)
5 to 9	23	5 (22)	--	--	23	5 (22)
10 +	13	6 (46)	--	--	13	6 (46)
p value		0.02		--		0.01

† Excludes equivocal test results and missing values.

Table 104 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	158	33 (21)	17	5 (29)	175	38 (22)
Indigenous	21	8 (38)	4	1 (25)	25	9 (36)
p value		0.08		0.9		0.1
2007						
Non-Indigenous	125	29 (23)	25	6 (24)	150	35 (23)
Indigenous	30	15 (50)	12	4 (33)	42	19 (45)
p value		0.003		0.5		0.005
2010						
Non-Indigenous	162	30 (19)	2	0 (0)	164	30 (18)
Indigenous	36	8 (22)	2	0 (0)	38	8 (21)
p value		0.6		--		0.7

† Excludes equivocal test results and missing values.

Table 105 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	76	9 (12)	99	29 (29)	175	38 (22)
Indigenous	3	0 (0)	22	9 (41)	25	9 (36)
p value		0.5		0.3		0.1
2007						
Non-Indigenous	75	8 (11)	75	27 (36)	150	35 (23)
Indigenous	10	4 (40)	32	15 (47)	42	19 (45)
p value		0.01		0.3		0.005
2010						
Non-Indigenous	105	16 (15)	59	14 (24)	164	30 (18)
Indigenous	25	5 (20)	13	3 (23)	38	8 (21)
p value		0.6		1.0		0.7

† Excludes equivocal test results and missing values.

Table 106 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	167	39 (23)	21	6 (29)	188	45 (24)
Moderately accessible	3	0 (0)	--	--	3	0 (0)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.5		--		0.5
2007						
Highly accessible/accessible	152	40 (26)	31	9 (29)	183	49 (27)
Moderately accessible	1	0 (0)	1	0 (0)	2	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.6		0.5		0.4
2010						
Highly accessible/accessible	183	33 (18)	2	0 (0)	185	33 (18)
Moderately accessible	8	3 (38)	1	0 (0)	9	3 (33)
Remote/very remote	4	1 (25)	--	--	4	1 (25)
p value		0.4		--		0.5

† Excludes equivocal test results and missing values.

Table 107 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	138	32 (23)	19	4 (21)	157	36 (23)
Other Oceania	7	3 (43)	--	--	7	3 (43)
Asia	11	4 (36)	2	2 (100)	13	6 (46)
UK & Ireland	5	1 (20)	--	--	5	1 (20)
Other	18	1 (6)	--	--	18	1 (6)
p value		0.2		0.02		0.08
2007						
Australia	128	35 (27)	33	6 (18)	161	41 (25)
Other Oceania	8	3 (38)	1	1 (100)	9	4 (44)
Asia	14	3 (21)	2	1 (50)	16	4 (25)
UK & Ireland	--	--	--	--	--	--
Other	9	3 (33)	2	2 (100)	11	5 (45)
p value		0.8		0.02		0.4
2010						
Australia	153	23 (15)	2	0 (0)	155	23 (15)
Other Oceania	16	4 (25)	--	--	16	4 (25)
Asia	15	7 (47)	1	0 (0)	16	7 (44)
UK & Ireland	2	0 (0)	--	--	2	0 (0)
Other	12	4 (33)	1	0 (0)	13	4 (31)
p value		0.02		--		0.04

† Excludes equivocal test results and missing values.

Table 108 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	146	32 (22)	18	4 (22)	164	36 (22)
Non-English	33	9 (27)	3	2 (67)	36	11 (31)
p value		0.5		0.1		0.3
2007						
English	122	34 (28)	33	7 (21)	155	41 (26)
Non-English	39	10 (26)	5	3 (60)	44	13 (30)
p value		0.8		0.07		0.7
2010						
English	164	12 (36)	4	0 (0)	168	26 (15)
Non-English	33	26 (16)	--	--	33	12 (36)
p value		0.006		--		0.005

† Excludes equivocal test results and missing values.

Table 109 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	124	60 (40)	33 (27)	6 (5)	25 (20)
Non-IDU	80	62 (78)	9 (11)	0 (0)	9 (11)
p value					<0.001
2007					
IDU	112	36 (32)	39 (35)	3 (3)	34 (30)
Non-IDU	86	53 (62)	9 (10)	3 (3)	21 (24)
p value					<0.001
2010					
IDU	72	27 (38)	15 (21)	2 (3)	28 (39)
Non-IDU	130	74 (57)	17 (13)	4 (3)	35 (27)
p value					0.06

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 110 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	198	119 (60)	41 (21)	6 (3)	32 (16)
Bisexual	3	1 (33)	1 (33)	0 (0)	1 (33)
Homosexual	3	2 (37)	0 (0)	0 (0)	1 (33)
Unsure	--	--	--	--	--
p value					0.9
2007					
Heterosexual	185	85 (46)	47 (25)	5 (3)	48 (26)
Homosexual	4	1 (25)	0 (0)	1 (25)	2 (50)
Bisexual	4	1 (25)	0 (0)	0 (0)	3 (75)
Unsure	--	--	--	--	--
p value					0.4
2010					
Heterosexual	201	101 (50)	32 (16)	6 (3)	62 (31)
Homosexual	--	--	--	--	--
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	--	--	--	--	--
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 111 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	14	11 (79)	0 (0)	0 (0)	3 (21)
20 – 24	46	27 (59)	8 (17)	2 (4)	9 (20)
25 – 29	44	29 (66)	7 (16)	1 (2)	7 (16)
30 + years	100	55 (55)	27 (27)	3 (3)	15 (15)
p value					0.5
2007					
< 20 years	9	7 (78)	0 (0)	0 (0)	2 (22)
20 – 24	38	21 (55)	4 (11)	1 (3)	12 (32)
25 – 29	41	14 (34)	8 (20)	1 (2)	18 (44)
30 + years	109	46 (42)	36 (33)	4 (4)	23 (21)
p value					0.02
2010					
< 20 years	22	7 (32)	2 (9)	0 (0)	13 (59)
20 – 24	34	23 (68)	2 (6)	0 (0)	9 (26)
25 – 29	43	20 (47)	8 (19)	1 (2)	14 (33)
30 + years	103	51 (50)	20 (19)	5 (5)	27 (26)
p value					0.05

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 112 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	67	52 (78)	6 (9)	1 (1)	8 (12)
2 to 4	83	46 (55)	17 (20)	4 (4)	16 (19)
5 to 9	35	14 (40)	14 (40)	0 (0)	7 (20)
10 +	16	8 (50)	5 (31)	1 (6)	2 (13)
p value					<0.01
2007					
1	53	37 (70)	6 (11)	1 (2)	9 (17)
2 to 4	81	41 (51)	18 (22)	3 (4)	19 (23)
5 to 9	31	2 (6)	11 (35)	2 (6)	16 (52)
10 +	26	6 (23)	11 (42)	0 (0)	9 (35)
p value					<0.001
2010					
1	106	69 (65)	10 (9)	3 (3)	24 (23)
2 to 4	56	20 (36)	12 (21)	2 (4)	22 (39)
5 to 9	23	8 (35)	5 (22)	0 (0)	10 (43)
10 +	13	1 (8)	5 (38)	1 (8)	6 (46)
p value					0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 113 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	179	112 (63)	35 (20)	4 (2)	28 (16)
Indigenous	25	10 (40)	7 (28)	2 (8)	6 (24)
p value					0.1
2007					
Non-Indigenous	149	76 (51)	32 (21)	3 (2)	38 (26)
Indigenous	42	10 (24)	16 (38)	3 (7)	13 (31)
p value					<0.01
2010					
Non-Indigenous	164	86 (52)	25 (15)	5 (3)	48 (29)
Indigenous	38	15 (39)	7 (18)	1 (3)	15 (39)
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 114 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	192	115 (60)	40 (21)	6 (3)	31 (16)
Moderately accessible	3	2 (67)	0 (0)	0 (0)	1 (33)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					0.4
2007					
Highly accessible/accessible	182	84 (46)	43 (24)	6 (3)	49 (27)
Moderately accessible	2	2 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	--	--	--	--	--
p value					0.5
2010					
Highly accessible/accessible	185	95 (51)	28 (15)	5 (3)	57 (31)
Moderately accessible	9	3 (33)	2 (22)	1 (11)	3 (33)
Remote/very remote	4	1 (25)	1 (25)	0 (0)	2 (50)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 115 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	164	98 (60)	33 (20)	3 (2)	30 (18)
Non-English	40	24 (60)	9 (23)	3 (8)	4 (10)
p value					0.2
2007					
English	154	74 (48)	38 (25)	3 (2)	39 (25)
Non-English	44	15 (34)	10 (23)	3 (7)	16 (36)
p value					0.1
2010					
English	168	89 (53)	24 (14)	2 (1)	53 (32)
Non-English	33	12 (36)	8 (24)	4 (12)	9 (27)
p value					0.002

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 116 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	56	5 (9)	3	1 (33)	59	6 (10)
Yes	50	19 (38)	10	4 (40)	60	23 (38)
Not sure	34	4 (12)	2	1 (50)	36	5 (14)
p value		<0.001		0.9		<0.001
2007						
No	49	8 (16)	13	3 (23)	62	11 (18)
Yes	54	30 (56)	13	9 (69)	67	39 (58)
Not sure	12	4 (33)	--	--	12	4 (33)
p value		<0.001		0.02		<0.001
2010						
No	47	6 (13)	2	0 (0)	49	6 (12)
Yes	65	41 (63)	1	1 (100)	66	42 (64)
Not sure	47	15 (32)	1	0 (0)	48	15 (31)
p value		<0.001		0.1		<0.001

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 117 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	185	10 (5)
Female	5	0 (0)
p value		0.6

† Excludes missing values.

Gonorrhoea

Table 118 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	184	0 (0)
Female	5	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 119 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	195	4 (2)	0 (0)	4 (2)
Female	7	0 (0)	0 (0)	0 (0)
p value		0.7	--	0.7

† Excludes missing values.

Northern Territory 2010

Table 120 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographic characteristics	2010	
	IDU	Non-IDU
Number of sites surveyed	N = 2	
N ^o surveyed	N = 9	N = 66
Sex (%)		
Male	8 (89)	64 (97)
Female	1 (11)	2 (3)
Transgender	--	--
Sexual identity (%)		
Heterosexual	9 (100)	62 (94)
Bisexual	--	2 (3)
Homosexual	--	1 (2)
Unsure	--	1 (2)
Not reported	--	--
Age and duration of injection (years)		
Median age (years)	34	30
Age range	25 – 21	18 – 56
Age group (%)		
<25 years	--	19 (29)
25+ years	9 (100)	47 (71)
Not reported	--	--
Median age 1 st IDU (years)	25	--
Age range	14 – 42	--
Not reported	1	--
Median years IDU	11	--
Range	1 – 32	--
Duration of drug injection (%)		
<3 years	1 (11)	--
3+ years	7 (78)	--
Not reported	1 (11)	--
Aboriginal and Torres Strait Islander origin (%)		
No	4 (44)	5 (8)
Yes	5 (56)	61 (92)
Not reported	--	--
Living situation prior to prison (%)*		
Not homeless	5 (56)	11 (17)
Primary homelessness	--	1 (2)
Secondary homelessness	1 (11)	22 (33)
Tertiary homelessness	--	1 (2)
Not reported	3 (33)	31 (47)
Residential remoteness in 12 months before prison (%)		
Highly accessible/accessible	5 (56)	11 (17)
Moderately accessible	--	1 (2)
Remote/very remote	4 (44)	47 (71)
Not reported	--	7 (11)
Region/Country of birth (%)		
Australia	7 (78)	64 (97)
Other Oceania	1 (11)	--
Asia	1 (11)	2 (3)
UK & Ireland	--	--
Other	--	--
Not reported	--	--
Main language spoke at home by parents (%)		
English	6 (67)	34 (52)
Non-English	1 (11)	10 (15)
Not reported	2 (22)	22 (33)

* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers' accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010.

Table 120 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographic characteristics	2010	
	IDU	Non-IDU
First time in prison (%)		
No	7 (78)	52 (79)
Yes	2 (22)	14 (21)
Not reported	--	--
Lifetime imprisonments (%)		
One	3 (33)	29 (44)
Two to four	3 (33)	20 (30)
Five to nine	3 (33)	14 (21)
Ten or more	--	3 (5)
Not reported	--	--
Imprisonment in last year (%)		
No	4 (44)	27 (41)
Yes	5 (56)	29 (44)
Not reported	--	10 (15)
Frequency of injection last month (%)		
Not last month	4 (44)	--
Less than weekly	1 (11)	--
Weekly not daily	--	--
Daily or more	3 (33)	--
Not reported	1 (11)	--
Ever smoked a full cigarette (%)*		
No	--	6 (9)
Yes	9 (100)	60 (91)
Not reported	--	---
<i>Median age first smoked (years)</i>		
	15	17
<i>Age range</i>		
	5 – 17	10 – 27
Current smoker (%)*		
No	--	7 (11)
Yes	9 (100)	59 (89)
Not reported	--	--
Smoking frequency (%)*		
Occasional – weekly or less	--	3 (5)
5 to 10 cigarettes a day	4 (44)	19 (32)
11 to 20 cigarettes a day	1 (11)	7 (12)
Over 20 cigarettes a day	4 (44)	30 (51)
Not reported	--	--
Other drugs used last month (%)**		
No drugs in past 4 weeks	--	46 (71)
Cannabis	6 (67)	19 (100)
Heroin	1 (11)	--
Cocaine	1 (11)	--
Amphetamine	2 (22)	--
Other's methadone	3 (33)	--
Other opiates	3 (33)	--
Other's buprenorphine	--	--
Steroids	1 (11)	--
Hallucinogens	--	--
Benzodiazepines	1 (11)	1 (5)
Ecstasy/MDA	1 (11)	--
Inhalants (e.g. petrol)	--	--
Other drug	1 (11)	--
Not reported	--	1 (2)

* Smoking questions not asked in 2004.

** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 121 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2010
Last drug injected (%)	N = 9
Amphetamine (Speed, Ice)	3 (33)
Anabolic steroids	--
Cocaine	--
Heroin	--
Heroin + amphetamine	--
Heroin + cocaine	--
Methadone	--
Morphine	2 (22)
Other	3 (33)
Not reported	1 (11)
N° Injected last month	N = 4
Places injected last month (%)*	
Prison	--
Own home	3 (75)
Friend's home	2 (50)
Dealer's home	--
Street, park, beach	1 (25)
Car	--
Public toilet	--
Commercial injecting room	--
Medically Supervised Injecting Centre, Sydney	--
Squat	--
Other place	--
Use of sterile needles & syringes last month (%)	
All injections	4 (100)
Most of the time	--
Half of the time	--
Some of the time	--
Not last month	--
Not reported	--
Re-used someone else's used needle & syringe last month (%)	
None	4 (100)
Once	--
Twice	--
3-5 times	--
>5 times	--
Not reported	--
Number of people needle & syringe was re-used after last month (%)	
None	4 (100)
One	--
Two	--
Three to five	--
More than five	--
Don't know how many	--
Not reported	--
Relationship to people needle & syringe was re-used after last month (%)*	
Regular sex partner	--
Casual sex partner	--
Close friend	--
Acquaintance	--
Other	--
Equipment used after someone else last month (%)*	
Spoon	--
Water	--
Filter	--
Tourniquet	--
Drug mix	--

* More than one option could be selected.

Table 122 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment for drug use	2010	
	IDU	Non-IDU
N ^o surveyed	N = 9	N = 66
Any treatment/therapy for drug use (%)		
No	3 (33)	64 (97)
Yes	6 (67)	2 (3)
Not reported	--	--
History of methadone maintenance treatment (%)		
Currently	1 (11)	--
Previously	3 (33)	--
Never	5 (56)	66 (100)
Not reported	--	--
History of other pharmacotherapy treatment (%)		
Currently	--	--
Previously	2 (22)	--
Never	7 (78)	66 (100)
Not reported	--	--

Table 123 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2010
N ^o surveyed	N = 8
From an NSP last month (%)	
Daily or almost daily	--
A couple of times each week	1 (13)
Less than weekly	1 (13)
Weekly	--
Once last month	1 (13)
Not in the last month	4 (50)
Not reported	1 (13)
From a chemist last month (%)	
Daily or almost daily	--
A couple of times each week	1 (11)
Less than weekly	--
Weekly	--
Once last month	--
Not in the last month	6 (67)
Not reported	1 (11)

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 124 Number (%) of respondents by body piercing and tattoos

Body piercing and tattoos	2010	
	IDU	Non-IDU
N° surveyed	N = 9	N = 66
Body or ear piercings (%)		
No	6 (67)	56 (85)
Yes	3 (33)	10 (15)
Not reported	--	--
Pierced in past 12 mths (%)		
No	1 (33)	7 (70)
Yes	--	2 (20)
Not reported	2 (67)	1 (10)
Chemist/hairdresser/beauty salon	--	1 (50)
Professional piercer / studio	--	--
Tattooist / parlour	--	--
Friend	--	--
Prison inmate	--	--
Self	--	--
Family member	--	--
Other	--	--
Needle used by other (%)		
No	--	--
Yes	--	--
Unsure	--	--
Not reported	--	2 (100)
Tattoos (%)		
No	2 (22)	55 (83)
Yes	7 (78)	10 (15)
Not reported	--	1 (2)
Tattoos in past 12 mths (%)		
No	6 (86)	5 (50)
Yes	1 (14)	4 (40)
Not reported	--	1 (10)
Who did tattooing (%)*		
Professional tattooist	1 (100)	3 (75)
Friend	--	--
Prison inmate	--	1 (25)
Self	--	--
Family member	--	--
Other	--	--

* More than one option could be selected.

Table 125 Number (%) of respondents by sexual behaviour, injector status and survey year

Sexual behaviour	2010	
	IDU	Non-IDU
N ^o surveyed	N = 9	N = 66
Sex last 3 months (%)		
No	1 (11)	8 (12)
Yes	8 (89)	57 (86)
Not reported	--	1 (2)
Male sex partners in last 3 months		
Median	--	0
Range	--	0 – 1
Female sex partners in last 3 months		
Median	1	1
Range	0 – 90	0 – 7
Condom use last sex - regular male partners - last 3 months (%)		
Never	1 (100)	2 (100)
Sometimes	--	--
Always	--	--
Condom use last sex - casual male partners - last 3 months (%)		
Never	--	1 (33)
Sometimes	--	1 (33)
Always	--	1 (33)
Condom use last sex - regular female partners - last 3 months (%)		
Never	4 (80)	25 (61)
Sometimes	--	4 (10)
Always	1 (20)	12 (29)
Condom use last sex - casual female partners - last 3 months (%)		
Never	2 (100)	7 (37)
Sometimes	--	3 (16)
Always	--	9 (47)
Sex work last month (%)		
No	8 (89)	63 (95)
Yes	1 (11)	2 (3)
Not reported	--	1 (2)
Condom used at last sex work last month (%)		
No	1 (100)	1 (50)
Yes	--	1 (50)
Not reported	--	--
Ever had cervical cancer vaccine (women only)*** (%)		
No	--	--
Yes	--	--
Unsure	--	--

*** Proportion of eligible women i.e. those under 27 years of age in 2007.

Table 126 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and survey year

Testing & treatment	2010	
	IDU	Non-IDU
N° surveyed	N = 9	N = 66
Previous HIV test (%)		
Yes, last year	4 (44)	10 (15)
>1 year ago	1 (11)	14 (21)
Never tested	4 (44)	42 (64)
Not reported	--	--
HBV infection (%)		
No	8 (89)	61 (92)
Yes	--	--
Don't know	1 (11)	4 (6)
Not reported	--	1 (2)
HBV vaccination (%)*		
No	4 (44)	48 (73)
Yes	5 (56)	12 (18)
Don't know	--	5 (8)
Not reported	--	1 (2)
Previous HCV test (%)		
Yes, last year	4 (44)	6 (9)
>1 year ago	1 (11)	18 (27)
Never tested	3 (33)	42 (64)
Unsure	--	--
Not reported	1 (11)	--
Any HCV treatment (%)**	N = 3	N = 0
Interferon	--	--
Interferon & Ribavirin	--	--
Pegasys & Ribavirin	--	--
Other	--	--
No treatment	3 (100)	--
Not reported	--	--
Current HCV treatment		
Interferon	--	--
Interferon & Ribavirin	--	--
Pegasys & Ribavirin	--	--
Other	--	--

* Number (%) among participants with no history of HBV infection.

** Number (%) of those testing positive for hepatitis C antibodies.

HIV antibody prevalence

Table 127 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2010						
IDU	7	0 (0)	1	0 (0)	59	0 (0)
Non-IDU	57	0 (0)	2	0 (0)	8	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 128 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	No with HCV (%)	No tested	No with HCV (%)	No tested	No with HCV (%)
2010						
IDU	7	3 (43)	1	0 (0)	8	3 (38)
Non-IDU	57	0 (0)	2	0 (0)	59	0 (0)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 129 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Heterosexual	61	3 (5)	3	0 (0)	64	3 (5)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	--	--	--	--	--	--
p value		0.1		--		0.9

† Excludes equivocal test results and missing values.

Table 130 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
< 20 years	6	0 (0)	--	--	6	0 (0)
20 – 24	12	0 (0)	--	--	12	0 (0)
25 – 29	13	0 (0)	--	--	13	0 (0)
30 + years	33	3 (9)	--	--	36	3 (8)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 131 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	--	--	1	0 (0)	1	0 (0)
6 to 10 years	--	--	--	--	--	--
10 + years	5	3 (60)	--	--	5	3 (60)
p value		0.3		--		0.4

† Excludes equivocal test results and missing values.

Table 132 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Amphetamine (Speed, Ice)	--	--	3	2 (67)	3	2 (67)
Heroin	--	--	--	--	--	--
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.2		0.3

† Excludes equivocal test results and missing values.

Table 133 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Less than daily	--	--	1	1 (100)	1	1 (100)
Daily or more	--	--	3	1 (33)	3	1 (33)
p value		--		0.3		0.3

† Excludes equivocal test results and missing values.

Table 134 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	--	--	4	2 (50)	4	2 (50)
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 135 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	--	--	3	2 (67)	3	2 (67)
Yes	1	0 (0)	3	1 (33)	4	1 (25)
p value		--		0.4		0.3

† Excludes equivocal test results and missing values.

Table 136 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
1	26	1 (4)	2	0 (0)	28	1 (4)
2 to 4	21	1 (5)	--	--	21	1 (5)
5 to 9	14	1 (7)	1	1 (100)	15	1 (7)
10 +	3	0 (0)	--	--	3	0 (0)
p value		1.0		--		1.0

† Excludes equivocal test results and missing values.

Table 137 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	7	2 (29)	1	0 (0)	8	2 (25)
Indigenous	57	1 (2)	2	0 (0)	59	1 (2)
p value		0.002		--		0.003

† Excludes equivocal test results and missing values.

Table 138 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	4	0 (0)	4	2 (50)	8	2 (25)
Indigenous	55	0 (0)	4	1 (25)	59	1 (2)
p value		--		0.5		0.003

† Excludes equivocal test results and missing values.

Table 139 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Highly accessible/accessible	14	1 (7)	1	0 (0)	15	1 (7)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	43	2 (5)	2	0 (0)	45	2 (4)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 140 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Australia	61	2 (3)	2	0 (0)	63	2 (3)
Other Oceania	1	1 (100)	--	--	1	1 (100)
Asia	2	0 (0)	1	0 (0)	3	0 (0)
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 141 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
English	37	3 (8)	--	--	37	3 (8)
Non-English	8	0 (0)	1	0 (0)	9	0 (0)
p value		0.3		--		0.4

† Excludes equivocal test results and missing values.

Table 142 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Positive	2	2 (100)	--	--	2	2 (100)
Negative	24	0 (0)	--	--	24	0 (0)
Not sure	--	--	1	0 (0)	1	0 (0)
p value		<0.001				<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 143 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	7	0 (0)	1	0 (0)	8	0 (0)
Non-IDU	44	2 (5)	2	1 (50)	46	3 (7)
p value		0.6		0.4		0.5

† Excludes equivocal test results and missing values.

Table 144 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	7	2 (29)	1	1 (100)	8	3 (38)
Non-IDU	44	16 (36)	2	2 (100)	46	18 (39)
p value		0.7		--		0.9

† Excludes equivocal test results and missing values.

Table 145 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Heterosexual	49	17 (35)	3	0 (0)	52	20 (38)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.5		--		0.4

† Excludes equivocal test results and missing values.

Table 146 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
< 20 years	6	1 (17)	--	--	6	1 (17)
20 – 24	10	1 (10)	--	--	10	1 (10)
25 – 29	9	3 (33)	--	--	9	3 (33)
30 + years	26	13 (50)	3	3 (100)	29	16 (55)
p value		0.1		--		0.04

† Excludes equivocal test results and missing values.

Table 147 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
<3 years	1	1 (100)	--	--	1	1 (100)
3 to 5 years	--	--	1	1 (100)	1	1 (100)
6 to 10 years	1	0 (0)	--	--	1	0 (0)
10 + years	5	1 (20)	--	--	5	1 (20)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 148 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Amphetamine (Speed, Ice)	--	--	3	1 (33)	3	1 (33)
Heroin	--	--	--	--	--	--
More than one	--	--	2	1 (50)	2	1 (50)
Other/not reported	1	1 (100)	2	0 (0)	3	1 (33)
p value		--		0.5		0.9

† Excludes equivocal test results and missing values.

Table 149 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Less than daily	--	--	1	1 (100)	1	1 (100)
Daily or more	--	--	3	1 (33)	3	1 (33)
p value		--		0.3		0.3

† Excludes equivocal test results and missing values.

Table 150 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	--	--	4	2 (50)	4	2 (50)
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 151 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	--	--	3	0 (0)	3	0 (0)
Yes	1	1 (100)	4	2 (50)	5	3 (60)
p value		--		0.2		0.1

† Excludes equivocal test results and missing values.

Table 152 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
1	21	5 (24)	2	2 (100)	23	7 (30)
2 to 4	15	5 (33)	--	--	15	5 (33)
5 to 9	12	6 (50)	1	1 (100)	13	7 (54)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.3		--		0.4

† Excludes equivocal test results and missing values.

Table 153 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	7	1 (14)	1	1 (100)	8	2 (25)
Indigenous	44	17 (39)	2	2 (100)	46	19 (41)
p value		0.2		--		0.4

† Excludes equivocal test results and missing values.

Table 154 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	4	0 (0)	4	2 (50)	8	2 (25)
Indigenous	42	18 (43)	4	1 (25)	46	19 (41)
p value		0.09		0.5		0.4

† Excludes equivocal test results and missing values.

Table 155 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Highly accessible/accessible	15	6 (40)	1	1 (100)	16	7 (44)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	32	12 (38)	2	2 (100)	34	14 (41)
p value		0.9		--		0.9

† Excludes equivocal test results and missing values.

Table 156 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Australia	48	17 (35)	2	2 (100)	50	19 (38)
Other Oceania	1	1 (100)	--	--	1	1 (100)
Asia	2	0 (0)	1	1 (100)	3	1 (33)
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		0.2		--		0.4

† Excludes equivocal test results and missing values.

Table 157 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
English	36	11 (31)	--	--	36	11 (31)
Non-English	7	3 (43)	1	1 (100)	8	4 (50)
p value		0.5		--		0.3

† Excludes equivocal test results and missing values.

Table 158 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
IDU	8	1 (13)	3 (38)	0 (0)	4 (50)
Non-IDU	46	17 (37)	15 (33)	3 (7)	11 (24)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 159 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Heterosexual	52	18 (35)	17 (33)	3 (6)	14 (27)
Homosexual	--	--	--	--	--
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	--	--	--	--	--
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 160 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
< 20 years	6	4 (67)	1 (17)	0 (0)	1 (17)
20 – 24	10	3 (30)	1 (10)	0 (0)	6 (60)
25 – 29	9	3 (33)	1 (11)	2 (22)	3 (33)
30 + years	29	8 (28)	15 (52)	1 (3)	5 (17)
p value					0.02

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 161 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
1	23	10 (43)	5 (22)	2 (9)	6 (26)
2 to 4	15	6 (40)	5 (33)	0 (0)	4 (27)
5 to 9	13	2 (15)	6 (46)	1 (8)	4 (31)
10 +	3	0 (0)	2 (67)	0 (0)	1 (33)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 162 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Non-Indigenous	8	4 (50)	2 (25)	0 (0)	2 (25)
Indigenous	46	14 (33)	16 (35)	3 (7)	13 (28)
p value					0.7

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 163 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Highly accessible/accessible	16	3 (19)	7 (44)	0 (0)	6 (38)
Moderately accessible	--	--	--	--	--
Remote/very remote	34	11 (32)	11 (32)	3 (9)	9 (26)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 164 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
English	36	15 (42)	10 (28)	1 (3)	10 (28)
Non-English	8	1 (13)	3 (38)	1 (13)	3 (38)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 165 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2010						
No	23	9 (39)	--	--	23	9 (39)
Yes	8	5 (63)	--	--	8	5 (63)
Not sure	1	0 (0)	--	--	1	0 (0)
p value		1.0		--		0.3

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 166 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	63	1 (2)
Female	3	0 (0)
p value		0.8

† Excludes missing values.

Gonorrhoea

Table 167 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	63	2 (3)
Female	3	0 (0)
p value		0.8

† Excludes missing values.

Syphilis

Table 168 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	64	13 (20)	5 (8)	13 (20)
Female	3	1 (33)	0 (0)	1 (33)
p value		0.6	0.4	0.6

† Excludes missing values.

Queensland
2004, 2007, 2010

Table 169 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 1		N = 1		N = 5	
N ^o surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126
Sex (%)						
Male	80 (100)	58 (100)	91 (100)	66 (100)	70 (82)	110 (87)
Female	--	--	--	--	15 (18)	16 (13)
Transgender	--	--	--	--	--	--
Sexual identity (%)						
Heterosexual	81 (99)	56 (97)	90 (99)	66 (100)	76 (89)	123 (98)
Bisexual	1 (1)	2 (3)	--	--	5 (6)	1 (1)
Homosexual	--	--	--	--	2 (2)	--
Unsure	--	--	--	--	--	1 (1)
Not reported	--	--	1 (1)	--	2 (2)	1 (1)
Age and duration of injection (years)						
Median age (years)	29	36	29	27	30	30
Age range	17 – 53	17 – 67	18 – 47	17 – 63	18 – 52	17 – 66
Age group (%)						
<25 years	28 (34)	12 (21)	21 (23)	29 (44)	26 (31)	43 (34)
25+ years	54 (64)	46 (79)	70 (77)	37 (56)	59 (69)	83 (66)
Not reported	--	--	--	--	--	--
Median age 1 st IDU (years)	17	--	17	--	17	--
Age range	11 – 38	--	11 – 34	--	8 – 35	--
Not reported	--	--	5	--	4	--
Median years IDU	9	--	10	--	13	--
Range	<1 – 28	--	<1 – 33	--	<1 – 34	--
Duration of drug injection (%)						
<3 years	9 (11)	--	6 (7)	--	5 (6)	--
3+ years	73 (89)	--	80 (88)	--	76 (89)	--
Not reported	--	--	5 (5)	--	4 (5)	--
Aboriginal and Torres Strait Islander origin (%)						
No	74 (90)	52 (90)	77 (85)	57 (86)	63 (74)	76 (60)
Yes	8 (10)	6 (10)	14 (15)	9 (14)	22 (26)	50 (40)
Not reported	--	--	--	--	--	--
Living situation prior to prison (%)*						
Not homeless	n/a	n/a	n/a	n/a	50 (59)	72 (57)
Primary homelessness	n/a	n/a	n/a	n/a	5 (6)	4 (3)
Secondary homelessness	n/a	n/a	n/a	n/a	18 (21)	31 (25)
Tertiary homelessness	n/a	n/a	n/a	n/a	7 (8)	3 (2)
Not reported	n/a	n/a	n/a	n/a	5 (6)	16 (13)
Residential remoteness in 12 months before prison (%)						
Highly accessible/accessible	80 (98)	52 (90)	82 (90)	60 (91)	72 (85)	89 (71)
Moderately accessible	--	1 (2)	1 (1)	2 (3)	4 (5)	9 (7)
Remote/very remote	2 (2)	2 (3)	2 (2)	1 (2)	3 (4)	22 (17)
Not reported	--	3 (5)	6 (7)	3 (5)	6 (7)	6 (5)
Region/Country of birth (%)						
Australia	71 (87)	40 (69)	83 (91)	61 (92)	76 (89)	106 (84)
Other Oceania	8 (10)	8 (14)	1 (1)	1 (2)	4 (5)	11 (9)
Asia	2 (2)	2 (3)	6 (7)	1 (2)	1 (1)	--
UK & Ireland	1 (1)	3 (5)	--	--	3 (4)	2 (2)
Other	--	5 (9)	--	3 (5)	1 (1)	7 (6)
Not reported	--	--	1 (1)	--	--	--
Main language spoke at home by parents (%)						
English	79 (96)	52 (90)	86 (95)	63 (95)	82 (96)	118 (94)
Non-English	3 (4)	6 (10)	5 (5)	3 (5)	2 (2)	7 (6)
Not reported	--	--	--	--	1 (1)	1 (1)

* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers' accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010.

Table 169 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)						
No	81 (99)	53 (91)	80 (88)	33 (50)	73 (86)	68 (54)
Yes	1 (1)	5 (9)	11 (12)	32 (48)	12 (14)	56 (44)
Not reported	--	--	--	1 (2)	--	2 (2)
Lifetime imprisonments (%)						
One	1 (1)	5 (9)	11 (12)	32 (48)	25 (29)	78 (62)
Two to four	57 (70)	47 (81)	48 (53)	25 (38)	28 (33)	30 (24)
Five to nine	19 (23)	4 (7)	20 (22)	3 (5)	21 (25)	8 (6)
Ten or more	5 (6)	1 (2)	10 (11)	4 (6)	11 (13)	8 (6)
Not reported	--	1 (2)	2 (2)	2 (3)	--	2 (2)
Imprisonment in last year (%)						
No	2 (2)	5 (9)	32 (40)	11 (32)	27 (32)	80 (63)
Yes	80 (98)	53 (91)	46 (58)	22 (65)	55 (65)	41 (33)
Not reported	--	--	2 (3)	1 (3)	3 (4)	5 (4)
Frequency of injection last month (%)						
Not last month	32 (39)	--	44 (48)	--	38 (45)	--
Less than weekly	6 (7)	--	10 (11)	--	8 (9)	--
Weekly not daily	7 (9)	--	6 (7)	--	5 (6)	--
Daily or more	37 (45)	--	28 (31)	--	33 (39)	--
Not reported	--	--	3 (3)	--	1 (1)	--
Ever smoked a full cigarette (%)*						
No	n/a	n/a	5 (5)	14 (21)	2 (2)	11 (9)
Yes	n/a	n/a	86 (95)	52 (79)	83 (98)	115 (91)
Not reported	n/a	n/a	--	--	--	--
<i>Median age first smoked (years)</i>	n/a	n/a	14	14	14	14
<i>Age range</i>	n/a	n/a	6 – 25	6 – 22	7 – 37	6 – 50
Current smoker (%)*						
No	n/a	n/a	5 (6)	14 (21)	8 (9)	30 (24)
Yes	n/a	n/a	86 (95)	52 (79)	77 (91)	96 (76)
Not reported	--	--	--	--	--	--
Smoking frequency (%)*						
Occasional – weekly or less	n/a	n/a	5 (6)	4 (8)	1 (1)	6 (6)
5 to 10 cigarettes a day	n/a	n/a	19 (22)	11 (21)	18 (23)	46 (48)
11 to 20 cigarettes a day	n/a	n/a	28 (33)	15 (29)	40 (52)	24 (25)
Over 20 cigarettes a day	n/a	n/a	34 (40)	21 (40)	17 (22)	19 (20)
Not reported	n/a	n/a	--	1 (2)	1 (1)	1 (1)
Other drugs used last month (%)**						
No drugs in past 4 weeks	n/a	n/a	n/a	n/a	17 (21)	53 (47)
Cannabis	n/a	n/a	n/a	n/a	45 (69)	48 (81)
Heroin	n/a	n/a	n/a	n/a	23 (35)	1 (2)
Cocaine	n/a	n/a	n/a	n/a	1 (2)	1 (2)
Amphetamine	n/a	n/a	n/a	n/a	33 (51)	7 (12)
Other's methadone	n/a	n/a	n/a	n/a	4 (6)	--
Other opiates	n/a	n/a	n/a	n/a	6 (9)	1 (2)
Other's buprenorphine	n/a	n/a	n/a	n/a	10 (15)	1 (2)
Steroids	n/a	n/a	n/a	n/a	--	1 (2)
Hallucinogens	n/a	n/a	n/a	n/a	1 (2)	--
Benzodiazepines	n/a	n/a	n/a	n/a	15 (23)	4 (7)
Ecstasy/MDA	n/a	n/a	n/a	n/a	2 (3)	2 (3)
Inhalants (e.g. petrol)	n/a	n/a	n/a	n/a	--	--
Other drug	n/a	n/a	n/a	n/a	--	1 (2)
Not reported	n/a	n/a	n/a	n/a	3 (4)	14 (11)

* Smoking questions not asked in 2004.

** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 170 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010
Last drug injected (%)	N = 82	N = 91	N = 85
Amphetamine (Speed, Ice)	59 (72)	57 (63)	49 (58)
Anabolic steroids	--	--	--
Cocaine	--	1 (1)	1 (1)
Heroin	20 (24)	20 (22)	21 (25)
Heroin + amphetamine	--	2 (2)	--
Heroin + cocaine	--	--	--
Methadone	1 (1)	2 (2)	--
Morphine	2 (2)	4 (4)	5 (6)
Other	--	4 (4)	7 (8)
Not reported	--	1 (1)	2 (2)
N° Injected last month	N = 50	N = 44	N = 46
Places injected last month (%)*			
Prison	3 (6)	1 (2)	2 (4)
Own home	45 (90)	39 (89)	28 (61)
Friend's home	37 (74)	27 (61)	20 (43)
Dealer's home	23 (46)	19 (43)	8 (17)
Street, park, beach	25 (50)	20 (45)	8 (17)
Car	31 (62)	21 (48)	12 (26)
Public toilet	21 (42)	16 (36)	11 (24)
Commercial injecting room	2 (4)	--	1 (2)
Medically Supervised Injecting Centre, Sydney	4 (8)	--	1 (2)
Squat	9 (18)	1 (2)	1 (2)
Other place	--	1 (2)	1 (2)
Use of sterile needles & syringes last month (%)			
All injections	37 (74)	28 (64)	38 (83)
Most of the time	8 (16)	9 (20)	4 (9)
Half of the time	4 (8)	4 (9)	2 (4)
Some of the time	1 (2)	3 (7)	--
Not last month	--	--	1 (2)
Not reported	--	--	1 (2)
Re-used someone else's used needle & syringe last month (%)			
None	39 (78)	33 (75)	36 (78)
Once	1 (2)	2 (5)	2 (4)
Twice	4 (8)	3 (7)	3 (7)
3-5 times	2 (4)	3 (7)	2 (4)
>5 times	4 (8)	3 (7)	2 (4)
Not reported	--	--	1 (2)
Number of people needle & syringe was re-used after last month (%)			
None	39 (78)	33 (75)	37 (80)
One	8 (16)	5 (11)	2 (4)
Two	2 (4)	1 (2)	2 (4)
Three to five	1 (2)	2 (5)	1 (2)
More than five	--	--	2 (4)
Don't know how many	--	3 (7)	1 (2)
Not reported	--	--	1 (2)
Relationship to people needle & syringe was re-used after last month (%)*			
Regular sex partner	8 (16)	6 (14)	3 (7)
Casual sex partner	1 (2)	1 (2)	2 (4)
Close friend	2 (4)	5 (11)	2 (4)
Acquaintance	1 (2)	1 (2)	3 (7)
Other	1 (2)	--	1 (2)
Equipment used after someone else last month (%)*			
Spoon	11 (22)	20 (46)	15 (33)
Water	42 (84)	18 (41)	12 (26)
Filter	42 (84)	19 (43)	12 (26)
Tourniquet	2 (4)	10 (23)	9 (20)
Drug mix	7 (14)	18 (41)	10 (22)

* More than one option could be selected.

Table 171 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment for drug use	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126
Any treatment/therapy for drug use (%)						
No	50 (61)	55 (95)	48 (53)	9 (14)	48 (56)	115 (91)
Yes	32 (38)	2 (3)	24 (26)	--	37 (44)	8 (6)
Not reported	--	1 (2)	19 (21)	57 (86)	--	3 (2)
History of methadone maintenance treatment (%)						
Currently	3 (4)	2 (3)	2 (2)	--	4 (5)	--
Previously	17 (21)	--	9 (10)	--	12 (14)	--
Never	62 (76)	56 (97)	62 (68)	--	69 (81)	123 (98)
Not reported	--	--	18 (20)	--	--	3 (2)
History of other pharmacotherapy treatment (%)						
Currently	66 (80)	56 (97)	7 (8)	--	5 (6)	1 (1)
Previously	4 (5)	2 (3)	9 (10)	--	11 (13)	--
Never	12 (15)	--	64 (70)	--	69 (81)	123 (98)
Not reported	--	--	11 (12)	--	--	2 (2)

Table 172 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010
N ^o surveyed	N = 50	N = 44	N = 85
Daily or almost daily	11 (22)	4 (9)	6 (7)
A couple of times each week	10 (20)	7 (16)	17 (20)
Weekly	n/a	n/a	6 (7)
Less than weekly	8 (16)	8 (18)	12 (14)
Once last month	10 (20)	3 (7)	--
Not in the last month	11 (22)	6 (14)	37 (44)
Not reported	--	16 (36)	6 (7)
From a chemist last month (%)			
Daily or almost daily	4 (8)	5 (11)	1 (1)
A couple of times each week	12 (24)	2 (5)	10 (12)
Less than weekly	12 (24)	12 (27)	7 (8)
Weekly	n/a	n/a	7 (8)
Once last month	7 (14)	5 (11)	--
Not in the last month	15 (30)	4 (9)	54 (64)
Not reported	--	16 (36)	4 (5)

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 173 Number (%) of respondents by body piercing and tattoos

Body piercing and tattoos	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126
Body or ear piercings (%)						
No	50 (61)	40 (69)	55 (60)	44 (67)	46 (54)	76 (60)
Yes	31 (38)	18 (31)	35 (38)	22 (33)	39 (46)	50 (40)
Not reported	1 (1)	--	1 (1)	--	--	--
Pierced in past 12 mths (%)						
No	10 (32)	5 (28)	14 (40)	9 (40)	26 (65)	26 (50)
Yes	5 (16)	--	4 (11)	1 (5)	4 (10)	3 (6)
Not reported	16 (52)	13 (72)	17 (49)	12 (55)	10 (25)	23 (44)
Who did piercing (%)*						
Chemist/hairdresser/beauty salon	--	--	--	--	--	--
Professional piercer / studio	1 (20)	--	3 (75)	1 (100)	--	2 (67)
Tattooist / parlour	--	--	--	--	1 (25)	1 (33)
Friend	1 (20)	--	--	--	1 (25)	--
Prison inmate	1 (20)	--	--	--	--	--
Self	3 (60)	--	1 (25)	--	2 (50)	--
Family member	--	--	--	--	--	--
Other	--	--	--	--	--	--
Needle used by other (%)						
No	5 (100)	--	1 (25)	--	3 (75)	--
Yes	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
Not reported	--	--	3 (75)	1 (100)	1 (25)	3 (100)
Tattoos (%)						
No	23 (28)	30 (52)	25 (27)	36 (55)	9 (11)	53 (42)
Yes	59 (72)	28 (48)	66 (73)	30 (45)	71 (84)	64 (51)
Not reported	--	--	--	--	5 (6)	9 (7)
Tattoos in past 12 mths (%)						
No	42 (71)	24 (86)	51 (77)	13 (43)	49 (69)	44 (69)
Yes	15 (25)	4 (14)	15 (23)	17 (57)	21 (30)	17 (27)
Not reported	2 (3)	--	--	--	1 (1)	3 (5)
Who did tattooing (%)*						
Professional tattooist	9 (60)	2 (50)	3 (20)	12 (71)	10 (48)	6 (35)
Friend	2 (13)	--	7 (47)	4 (24)	7 (33)	9 (53)
Prison inmate	3 (20)	--	3 (20)	1 (6)	3 (14)	1 (6)
Self	2 (13)	1 (25)	1 (7)	--	1 (5)	2 (12)
Family member	--	1 (25)	--	--	3 (14)	--
Other	--	--	--	--	--	--

* More than one option could be selected.

Table 174 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sexual behaviour	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126
Sex last month / last 3 months (%)**						
No	13 (16)	15 (26)	26 (29)	20 (30)	9 (11)	26 (21)
Yes	69 (84)	43 (74)	64 (70)	46 (70)	73 (86)	97 (77)
Not reported	--	--	1 (1)	--	3 (4)	3 (2)
Male sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	1	1
Range	n/a	n/a	n/a	n/a	0 – 300	0 – 2
Female sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	1	1
Range	n/a	n/a	n/a	n/a	0 – 12	0 – 26
Condom use at last sex (%)						
No	66 (80)	44 (76)	69 (76)	45 (68)	n/a	n/a
Yes	16 (20)	14 (24)	21 (23)	21 (32)	n/a	n/a
Not reported	--	--	1 (1)	--	n/a	n/a
Condom use with regular sex partner(s) last month (%)*						
No	47 (94)	29 (81)	33 (75)	29 (85)	n/a	n/a
Sometimes	3 (6)	2 (6)	4 (9)	4 (12)	n/a	n/a
Always	--	5 (14)	7 (16)	1 (3)	n/a	n/a
Condom use with new sex partner(s) last month (%)*						
No	8 (100)	2 (100)	1 (100)	--	n/a	n/a
Sometimes	--	--	--	1 (50)	n/a	n/a
Always	--	--	--	1 (50)	n/a	n/a
Condom use with casual sex partner(s) last month (%)*						
No	10 (50)	3 (33)	17 (85)	5 (42)	n/a	n/a
Sometimes	2 (10)	--	1 (5)	4 (33)	n/a	n/a
Always	8 (40)	6 (67)	2 (10)	3 (25)	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	8 (73)	9 (64)
Sometimes	n/a	n/a	n/a	n/a	1 (9)	2 (14)
Always	n/a	n/a	n/a	n/a	2 (18)	3 (21)
Condom use last sex - casual male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	3 (60)	1 (100)
Sometimes	n/a	n/a	n/a	n/a	--	--
Always	n/a	n/a	n/a	n/a	2 (40)	--
Condom use last sex - regular female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	37 (84)	40 (62)
Sometimes	n/a	n/a	n/a	n/a	4 (9)	12 (18)
Always	n/a	n/a	n/a	n/a	3 (7)	13 (20)
Condom use last sex - casual female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	16 (70)	8 (24)
Sometimes	n/a	n/a	n/a	n/a	4 (17)	9 (27)
Always	n/a	n/a	n/a	n/a	3 (13)	16 (48)
Sex work last month (%)						
No	81 (99)	57 (98)	90 (99)	66 (100)	82 (96)	122 (97)
Yes	--	1 (2)	--	--	3 (4)	--
Not reported	1 (1)	--	1 (1)	--	--	4 (3)
Condom used at last sex work last month (%)						
No	--	--	--	--	--	--
Yes	--	1 (100)	--	--	2 (67)	--
Not reported	--	--	--	--	1 (33)	--
Ever had cervical cancer vaccine (women only)*** (%)						
No	n/a	n/a	n/a	n/a	6 (75)	2 (50)
Yes	n/a	n/a	n/a	n/a	2 (25)	1 (25)
Unsure	n/a	n/a	n/a	n/a	--	1 (25)

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

*** Proportion of eligible women i.e. those under 27 years of age in 2007.

Table 175 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126
Previous HIV test (%)						
Yes, last year	33 (40)	10 (17)	59 (65)	26 (39)	52 (61)	53 (42)
>1 year ago	33 (40)	26 (45)	24 (26)	25 (38)	23 (27)	33 (26)
Never tested	16 (20)	22 (38)	7 (8)	15 (23)	9 (11)	40 (32)
Not reported	--	--	1 (1)	--	1 (1)	--
HBV infection (%)						
No	76 (93)	56 (97)	88 (97)	61 (92)	75 (88)	113 (90)
Yes	6 (7)	1 (2)	2 (2)	--	1 (1)	3 (2)
Don't know	--	1 (2)	1 (1)	1 (2)	9 (11)	10 (8)
Not reported	--	--	--	4 (6)	--	--
HBV vaccination (%)*						
No	13 (16)	27 (47)	14 (15)	17 (26)	11 (13)	34 (27)
Yes	69 (84)	31 (53)	72 (79)	42 (64)	68 (80)	68 (54)
Don't know	--	--	5 (5)	7 (11)	6 (7)	24 (19)
Not reported	--	--	--	--	--	--
Previous HCV test (%)						
Yes, last year	30 (37)	9 (16)	6 (7)	15 (23)	54 (64)	51 (40)
>1 year ago	43 (52)	21 (36)	60 (66)	28 (42)	24 (28)	34 (27)
Never tested	9 (11)	28 (48)	25 (27)	23 (35)	6 (7)	41 (33)
Unsure	--	--	--	--	1 (1)	--
Not reported	--	--	--	--	--	--
Any HCV treatment (%)**	N = 36	N = 2	N = 41	N = 2	N = 41	N = 0
Interferon	--	--	1 (2)	--	1 (2)	--
Interferon & Ribavirin	--	--	--	--	--	--
Pegasys & Ribavirin	--	--	--	--	--	--
Other	--	--	--	--	--	--
No treatment	36 (100)	2 (100)	40 (98)	2 (100)	40 (98)	--
Not reported	--	--	--	--	--	--
Current HCV treatment						
Interferon	--	--	--	--	1 (2)	--
Interferon & Ribavirin	--	--	--	--	--	--
Pegasys & Ribavirin	--	--	--	--	--	--
Other	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Number (%) of those testing positive for hepatitis C antibodies.

HIV antibody prevalence

Table 176 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	77	0 (0)	--	--	77	0 (0)
Non-IDU	53	1 (2)	--	--	53	1 (2)
p value		0.2		--		0.2
2007						
IDU	77	1 (1)	--	--	77	1 (1)
Non-IDU	59	0 (0)	--	--	59	0 (0)
p value		0.4		--		0.4
2010						
IDU	59	0 (0)	14	0 (0)	73	0 (0)
Non-IDU	103	0 (0)	15	0 (0)	118	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 177 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	75	36 (48)	--	--	75	36 (48)
Non-IDU	54	2 (4)	--	--	54	2 (4)
p value		<0.001		--		<0.001
2007						
IDU	77	41 (53)	--	--	77	41 (53)
Non-IDU	58	2 (3)	--	--	58	2 (3)
p value		<0.001		--		<0.001
2010						
IDU	58	29 (50)	14	12 (86)	72	41 (57)
Non-IDU	102	0 (0)	14	0 (0)	116	0 (0)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

Table 178 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	127	38 (30)	--	--	127	38 (30)
Bisexual	2	0 (0)	--	--	2	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.4				0.4
2007						
Heterosexual	134	42 (31)	--	--	134	42 (31)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2010						
Heterosexual	154	28 (18)	23	8 (35)	177	36 (20)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
Unsure	--	--	--	--	--	--
p value		0.1		0.2		<0.01

† Excludes equivocal test results and missing values.

Table 179 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	11	0 (0)	--	--	11	0 (0)
20 – 24	27	6 (22)	--	--	27	6 (22)
25 – 29	24	11 (46)	--	--	24	11 (46)
30 + years	67	21 (31)	--	--	67	21 (31)
p value		0.04		--		0.04
2007						
< 20 years	13	1 (8)	--	--	13	1 (8)
20 – 24	32	10 (31)	--	--	32	10 (31)
25 – 29	36	13 (36)	--	--	36	13 (36)
30 + years	54	19 (35)	--	--	54	19 (35)
p value		0.3		--		0.3
2010						
< 20 years	23	0 (0)	3	1 (33)	26	1 (4)
20 – 24	36	8 (22)	3	1 (33)	39	9 (23)
25 – 29	28	5 (18)	6	4 (67)	34	9 (27)
30 + years	73	16 (22)	16	6 (38)	89	22 (25)
p value		0.1		0.6		0.1

† Excludes equivocal test results and missing values.

Table 180 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	8	0 (0)	--	--	8	0 (0)
3 to 5 years	9	1 (11)	--	--	9	1 (11)
6 to 10 years	22	10 (45)	--	--	22	10 (45)
10 + years	36	25 (69)	--	--	36	25 (69)
p value		<0.001		--		<0.001
2007						
<3 years	5	1 (20)	--	--	5	1 (20)
3 to 5 years	10	5 (50)	--	--	10	5 (50)
6 to 10 years	23	9 (39)	--	--	23	9 (39)
10 + years	34	22 (65)	--	--	34	22 (65)
p value		0.1		--		0.1
2010						
<3 years	4	1 (25)	--	--	4	1 (25)
3 to 5 years	5	1 (20)	2	1 (50)	7	2 (29)
6 to 10 years	13	6 (46)	3	3 (100)	16	9 (56)
10 + years	33	20 (61)	8	7 (88)	41	27 (66)
p value		0.2		0.3		0.2

† Excludes equivocal test results and missing values.

Table 181 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	8	0 (0)	46	20 (43)	54	20 (37)
Heroin	--	--	19	15 (79)	19	15 (79)
More than one	--	--	2	1 (50)	2	1 (50)
Other/not reported	--	--	--	--	--	--
p value		--		0.03		0.007
2007						
Amphetamine (Speed, Ice)	4	0 (0)	46	19 (41)	50	19 (38)
Heroin	1	1 (100)	13	10 (77)	14	1 (79)
More than one	--	--	2	2 (100)	2	2 (100)
Other/not reported	--	--	6	5 (83)	6	5 (83)
p value		0.03		0.02		0.002
2010						
Amphetamine (Speed, Ice)	4	1 (25)	36	17 (47)	40	18 (45)
Heroin	--	--	18	15 (83)	18	15 (83)
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	--	--	9	6 (67)	9	6 (67)
p value		--		0.04		0.03

† Excludes equivocal test results and missing values.

Table 182 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	2	0 (0)	9	7 (78)	11	7 (64)
Daily or more	3	0 (0)	30	18 (60)	33	18 (55)
p value		--		0.09		0.6
2007						
Less than daily	1	0 (0)	13	6 (46)	14	6 (43)
Daily or more	1	1 (100)	21	15 (71)	22	16 (73)
p value		0.2		0.1		0.07
2010						
Less than daily	2	1 (50)	9	4 (44)	11	5 (45)
Daily or more	--	--	24	19 (79)	24	19 (79)
p value		--		0.05		0.05

† Excludes equivocal test results and missing values.

Table 183 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	5	0 (0)	28	16 (57)	33	16 (48)
Yes	0	0 (0)	11	9 (82)	11	9 (82)
p value		--		0.1		0.05
2007						
No	2	1 (50)	25	12 (48)	27	13 (48)
Yes	--	--	7	7 (100)	7	7 (100)
p value		--		0.01		0.005
2010						
No	1	0 (0)	27	19 (70)	28	19 (68)
Yes	1	1 (100)	5	3 (60)	6	4 (67)
p value		0.2		0.7		1.0

† Excludes equivocal test results and missing values.

Table 184 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	1	1(100)	1	1(100)
Yes	8	0 (0)	66	35 (53)	74	35 (47)
p value		--		0.4		0.3
2007						
No	2	0 (0)	24	9 (38)	26	9 (35)
Yes	2	1 (50)	33	26 (79)	35	27 (77)
p value		0.2		0.002		0.001
2010						
No	1	0 (0)	20	9 (45)	21	9 (43)
Yes	3	1 (33)	42	27 (64)	45	28 (62)
p value		0.5		0.2		0.1

† Excludes equivocal test results and missing values.

Table 185 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	5	1 (20)	--	--	5	1 (20)
2 to 4	97	24 (25)	--	--	97	24 (25)
5 to 9	20	10 (50)	--	--	20	10 (50)
10 +	6	3 (50)	--	--	6	3 (50)
p value		0.09		--		0.09
2007						
1	40	0 (0)	--	--	40	0 (0)
2 to 4	64	22 (34)	--	--	64	22 (34)
5 to 9	17	11 (65)	--	--	17	11 (65)
10 +	12	9 (75)	--	--	12	9 (75)
p value		<0.001		--		<0.001
2010						
1	78	4 (5)	17	5 (29)	95	9 (10)
2 to 4	50	11 (22)	6	5 (83)	56	16 (29)
5 to 9	17	9 (53)	3	1 (33)	20	10 (50)
10 +	14	5 (36)	2	1 (50)	16	6 (38)
p value		<0.001		0.1		<0.001

† Excludes equivocal test results and missing values.

Table 186 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	115	34 (30)	--	--	115	34 (30)
Indigenous	14	4 (29)	--	--	14	4 (29)
p value		0.9		--		0.9
2007						
Non-Indigenous	116	36 (31)	--	--	116	36 (31)
Indigenous	19	7 (37)	--	--	19	7 (37)
p value		0.6		--		0.6
2010						
Non-Indigenous	99	19 (19)	21	8 (38)	120	27 (23)
Indigenous	61	10 (16)	7	4 (57)	68	14 (21)
p value		0.7		0.4		0.8

† Excludes equivocal test results and missing values.

Table 187 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	48	2 (4)	67	32 (48)	115	34 (30)
Indigenous	6	0 (0)	8	4 (50)	14	4 (29)
p value		0.6		0.9		0.9
2007						
Non-Indigenous	50	1 (2)	66	35 (53)	116	36 (31)
Indigenous	8	1 (13)	11	6 (55)	19	7 (37)
p value		0.1		0.9		0.6
2010						
Non-Indigenous	68	0 (0)	52	27 (52)	120	27 (23)
Indigenous	48	0 (0)	20	14 (70)	68	14 (21)
p value		--		0.2		0.8

† Excludes equivocal test results and missing values.

Table 188 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	123	37 (30)	--	--	123	37 (30)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	3	1 (33)	--	--	3	1 (33)
p value		0.8		--		0.8
2007						
Highly accessible/accessible	123	40 (33)	--	--	123	40 (33)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	3	0 (0)	--	--	3	0 (0)
p value		0.6		--		0.6
2010						
Highly accessible/accessible	118	26 (22)	24	11 (46)	142	37 (26)
Moderately accessible	8	0 (0)	3	1 (33)	11	1 (9)
Remote/very remote	23	0 (0)	1	0 (0)	24	0 (0)
p value		0.02		0.6		0.01

† Excludes equivocal test results and missing values.

Table 189 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	104	34 (33)	--	--	104	34 (33)
Other Oceania	15	2 (13)	--	--	15	2 (13)
Asia	3	2 (67)	--	--	3	2 (67)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	4	0 (0)	--	--	4	0 (0)
p value		0.1		--		0.1
2007						
Australia	124	38 (31)	--	--	124	38 (31)
Other Oceania	2	1 (50)	--	--	2	1 (50)
Asia	6	4 (67)	--	--	6	4 (67)
UK & Ireland	--	--	--	--	--	--
Other	3	0 (0)	--	--	3	0 (0)
p value		0.2		--		0.2
2010						
Australia	143	26 (18)	23	10 (43)	166	36 (22)
Other Oceania	11	2 (18)	2	0 (0)	13	2 (15)
Asia	1	1 (100)	--	--	1	1 (100)
UK & Ireland	1	0 (0)	1	1 (100)	2	1 (50)
Other	4	0 (0)	2	1 (50)	6	1 (17)
p value		0.2		0.4		0.3

† Excludes equivocal test results and missing values.

Table 190 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	121	36 (30)	--	--	121	36 (30)
Non-English	8	2 (25)	--	--	8	2 (25)
p value		0.8		--		0.8
2007						
English	128	40 (31)	--	--	128	40 (31)
Non-English	7	3 (43)	--	--	7	3 (43)
p value		0.5		--		0.5
2010						
English	153	28 (18)	26	11 (42)	179	39 (22)
Non-English	5	1 (20)	2	1 (50)	7	2 (29)
p value		0.8		0.8		0.7

† Excludes equivocal test results and missing values.

Table 191 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	29	29 (100)	--	--	29	29 (100)
Negative	61	5 (8)	--	--	61	5 (8)
Not sure	4	2 (50)	--	--	4	2 (50)
p value		<0.001		--		<0.001
2007						
Positive	30	27 (90)	--	--	30	27 (90)
Negative	80	11 (14)	--	--	80	11 (14)
Not sure	7	4 (57)	--	--	7	4 (57)
p value		<0.001		--		<0.001
2010						
Positive	16	16 (100)	12	12 (100)	28	28 (100)
Negative	87	6 (7)	9	0 (0)	96	6 (6)
Not sure	18	6 (33)	--	--	18	6 (33)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 192 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	77	3 (4)	--	--	77	3 (4)
Non-IDU	54	0 (0)	--	--	54	0 (0)
p value		0.1		--		0.1
2007						
IDU	78	1 (1)	--	--	78	1 (1)
Non-IDU	59	0 (0)	--	--	59	0 (0)
p value		0.4		--		0.4
2010						
IDU	58	0 (0)	14	0 (0)	72	0 (0)
Non-IDU	93	2 (2)	14	0 (0)	107	2 (2)
p value		0.3		--		0.2

† Excludes equivocal test results and missing values.

Table 193 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	74	12 (16)	--	--	74	12 (16)
Non-IDU	54	5 (9)	--	--	54	5 (9)
p value		0.3		--		0.3
2007						
IDU	78	8 (10)	--	--	78	8 (10)
Non-IDU	59	4 (7)	--	--	59	4 (7)
p value		0.5		--		0.5
2010						
IDU	32	6 (19)	1	0 (0)	33	6 (18)
Non-IDU	48	8 (17)	1	0 (0)	49	8 (16)
p value		0.8		--		0.8

† Excludes equivocal test results and missing values.

Table 194 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	126	17 (13)	--	--	126	17 (13)
Bisexual	2	0 (0)	--	--	2	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.6		--		0.6
2007						
Heterosexual	136	12 (9)	--	--	136	12 (9)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2010						
Heterosexual	78	14 (18)	2	0 (0)	80	14 (18)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.6		--		0.7

† Excludes equivocal test results and missing values.

Table 195 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	12	1 (8)	--	--	12	1 (8)
20 – 24	26	1 (4)	--	--	26	1 (4)
25 – 29	24	3 (13)	--	--	24	3 (13)
30 + years	66	12 (18)	--	--	66	12 (18)
p value		0.3		--		0.3
2007						
< 20 years	13	2 (15)	--	--	13	2 (15)
20 – 24	33	1 (3)	--	--	33	1 (3)
25 – 29	36	4 (11)	--	--	36	4 (11)
30 + years	55	5 (9)	--	--	55	5 (9)
p value		0.5		--		0.5
2010						
< 20 years	13	0 (0)	--	--	13	0 (0)
20 – 24	19	1 (5)	--	--	19	1 (5)
25 – 29	12	2 (17)	--	--	12	2 (17)
30 + years	36	11 (31)	2	0 (0)	38	11 (29)
p value		0.03		--		0.04

† Excludes equivocal test results and missing values.

Table 196 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	9	1 (11)	--	--	9	1 (11)
3 to 5 years	9	0 (0)	--	--	9	0 (0)
6 to 10 years	22	2 (9)	--	--	22	2 (9)
10 + years	34	9 (26)	--	--	34	9 (26)
p value		0.1		--		0.1
2007						
<3 years	5	1 (20)	--	--	5	1 (20)
3 to 5 years	10	0 (0)	--	--	10	0 (0)
6 to 10 years	23	2 (9)	--	--	23	2 (9)
10 + years	35	3 (9)	--	--	35	3 (9)
p value		0.6		--		0.6
2010						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	4	0 (0)	--	--	4	0 (0)
6 to 10 years	7	1 (14)	--	--	7	1 (14)
10 + years	19	5 (26)	1	0 (0)	20	5 (25)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 197 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	9	1 (11)	46	7 (15)	55	8 (15)
Heroin	--	--	17	4 (24)	17	4 (24)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	--	--	--	--
p value		--		0.6		0.6
2007						
Amphetamine (Speed, Ice)	4	1 (25)	47	4 (9)	51	5 (10)
Heroin	1	0 (0)	13	0 (0)	14	0 (0)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	6	1 (17)	6	1 (17)
p value		0.6		0.6		0.5
2010						
Amphetamine (Speed, Ice)	1	0 (0)	19	2 (11)	20	2 (10)
Heroin	--	--	8	4 (50)	8	4 (50)
More than one	--	--	--	--	--	--
Other/not reported	--	--	4	0 (0)	4	0 (0)
p value		--		0.04		0.03

† Excludes equivocal test results and missing values.

Table 198 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	2	0 (0)	9	5 (56)	11	5 (45)
Daily or more	4	0 (0)	29	4 (14)	33	4 (12)
p value		--		0.01		0.01
2007						
Less than daily	1	0 (0)	13	2 (15)	14	2 (14)
Daily or more	1	0 (0)	21	1 (5)	22	1 (5)
p value		--		0.3		0.3
2010						
Less than daily	--	--	6	0 (0)	6	0 (0)
Daily or more	--	--	12	4 (33)	12	4 (33)
p value		--		0.1		0.1

† Excludes equivocal test results and missing values.

Table 199 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	27	6 (22)	33	6 (18)
Yes	0	0 (0)	11	3 (27)	11	3 (27)
p value		--		0.7		0.5
2007						
No	2	0 (0)	25	3 (12)	27	3 (11)
Yes	--	--	7	0 (0)	7	0 (0)
p value		--		0.3		0.4
2010						
No	--	--	15	3 (20)	15	3 (20)
Yes	--	--	2	0 (0)	2	0 (0)
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 200 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	1	1(100)	1	1(100)
Yes	9	1 (11)	64	11 (17)	73	12 (16)
p value		--		0.7		0.4
2007						
No	2	1 (50)	25	3 (12)	27	4 (15)
Yes	2	0 (0)	33	2 (6)	35	2 (6)
p value		0.3		0.4		0.2
2010						
No	--	--	11	4 (36)	11	4 (36)
Yes	1	0 (0)	19	2 (11)	20	2 (10)
p value		--		0.1		0.1

† Excludes equivocal test results and missing values.

Table 201 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	5	0 (0)	--	--	5	0 (0)
2 to 4	96	12 (13)	--	--	96	12 (13)
5 to 9	20	4 (20)	--	--	20	4 (20)
10 +	6	1 (17)	--	--	6	1 (17)
p value		0.7		--		0.7
2007						
1	40	2 (5)	--	--	40	2 (5)
2 to 4	66	10 (15)	--	--	66	10 (15)
5 to 9	17	0 (0)	--	--	17	0 (0)
10 +	12	0 (0)	--	--	12	0 (0)
p value		0.08		--		0.08
2010						
1	32	2 (6)	1	0 (0)	33	2 (6)
2 to 4	31	6 (19)	1	0 (0)	32	6 (19)
5 to 9	8	4 (50)	--	--	8	4 (50)
10 +	8	2 (25)	--	--	8	2 (25)
p value		0.03		--		0.03

† Excludes equivocal test results and missing values.

Table 202 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	114	15 (13)	--	--	114	15 (13)
Indigenous	14	2 (14)	--	--	14	2 (14)
p value		0.9		--		0.9
2007						
Non-Indigenous	117	7 (6)	--	--	117	7 (6)
Indigenous	20	5 (25)	--	--	20	5 (25)
p value		0.005		--		0.005
2010						
Non-Indigenous	47	4 (9)	1	0 (0)	48	4 (8)
Indigenous	33	10 (30)	1	0 (0)	34	10 (29)
p value		0.01		--		0.01

† Excludes equivocal test results and missing values.

Table 203 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	48	5 (10)	66	10 (15)	114	15 (13)
Indigenous	6	0 (0)	8	2 (25)	14	2 (14)
p value		0.7		0.5		0.9
2007						
Non-Indigenous	50	1 (2)	67	6 (9)	117	7 (6)
Indigenous	9	3 (33)	11	2 (18)	20	5 (25)
p value		0.001		0.4		0.005
2010						
Non-Indigenous	24	0 (0)	24	4 (17)	48	4 (8)
Indigenous	25	8 (32)	9	2 (22)	34	10 (29)
p value		0.002		0.7		0.01

† Excludes equivocal test results and missing values.

Table 204 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	122	15 (12)	--	--	122	15 (12)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	3	2 (67)	--	--	3	2 (67)
p value		0.02		--		0.02
2007						
Highly accessible/accessible	125	9 (7)	--	--	125	9 (7)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	3	1 (33)	--	--	3	1 (33)
p value		0.2		--		0.2
2010						
Highly accessible/accessible	60	7 (12)	2	0 (0)	62	7 (11)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	11	5 (45)	--	--	11	5 (46)
p value		0.02		--		0.01

† Excludes equivocal test results and missing values.

Table 205 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	103	12 (12)	--	--	103	12 (12)
Other Oceania	15	2 (13)	--	--	15	2 (13)
Asia	3	2 (67)	--	--	3	2 (67)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	4	1 (25)	--	--	4	1 (25)
p value		0.07		--		0.07
2007						
Australia	126	11 (9)	--	--	126	11 (9)
Other Oceania	2	1 (50)	--	--	2	1 (50)
Asia	6	0 (0)	--	--	6	0 (0)
UK & Ireland	--	--	--	--	--	--
Other	3	0 (0)	--	--	3	0 (0)
p value		0.2		--		0.2
2010						
Australia	72	13 (18)	2	0 (0)	74	13 (18)
Other Oceania	4	0 (0)	--	--	4	0 (0)
Asia	1	1(100)	--	--	1	1(100)
UK & Ireland	--	--	--	--	--	--
Other	3	0 (0)	--	--	3	0 (0)
p value		0.1		--		0.1

† Excludes equivocal test results and missing values.

Table 206 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	120	14 (12)	--	--	120	14 (12)
Non-English	8	3 (38)	--	--	8	3 (38)
p value		0.04		--		0.04
2007						
English	130	11 (8)	--	--	130	11 (8)
Non-English	7	1 (14)	--	--	7	1 (14)
p value		0.6		--		0.6
2010						
English	77	14 (18)	2	0 (0)	79	14 (18)
Non-English	3	0 (0)	--	--	3	0 (0)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 207 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	77	29 (38)	10 (13)	3 (4)	35 (45)
Non-IDU	54	35 (65)	5 (9)	0 (0)	14 (26)
p value					0.02
2007					
IDU	78	30 (38)	8 (10)	1 (1)	39 (50)
Non-IDU	59	38 (64)	4 (7)	0 (0)	17 (29)
p value					0.02
2010					
IDU	43	6 (14)	6 (14)	0 (0)	31 (72)
Non-IDU	64	10 (16)	8 (13)	2 (3)	44 (69)
p value					0.7

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 208 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	129	62 (48)	15 (12)	3 (2)	49 (38)
Bisexual	2	2 (100)	0 (0)	0 (0)	0 (0)
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2007					
Heterosexual	136	68 (50)	12 (9)	0 (0)	56 (41)
Homosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2010					
Heterosexual	102	13 (13)	14 (14)	2 (2)	73 (72)
Homosexual	--	--	--	--	--
Bisexual	3	1 (33)	0 (0)	0 (0)	2 (67)
Unsure	--	--	--	--	--
p value					0.7

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 209 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	12	5 (42)	0 (0)	1 (8)	6 (50)
20 – 24	28	12 (43)	2 (7)	0 (0)	14 (50)
25 – 29	24	9 (38)	2 (8)	1 (4)	12 (50)
30 + years	67	38 (57)	11 (16)	1 (1)	17 (25)
p value					0.1
2007					
< 20 years	13	8 (62)	2 (15)	0 (0)	3 (23)
20 – 24	33	11 (33)	1 (3)	0 (0)	21 (64)
25 – 29	36	18 (50)	4 (11)	0 (0)	14 (39)
30 + years	55	31 (53)	5 (9)	1 (2)	18 (33)
p value					0.2
2010					
< 20 years	17	5 (29)	0 (0)	0 (0)	12 (71)
20 – 24	19	2 (11)	1 (5)	0 (0)	16 (84)
25 – 29	21	3 (14)	2 (10)	1 (5)	15 (71)
30 + years	50	6 (12)	11 (22)	1 (2)	32 (64)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 210 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	5	4 (80)	0 (0)	0 (0)	1 (20)
2 to 4	98	50 (51)	12 (12)	2 (2)	34 (35)
5 to 9	21	6 (29)	3 (14)	0 (0)	12 (57)
10 +	6	3 (50)	0 (0)	1 (17)	2 (33)
p value					0.2
2007					
1	40	31 (78)	2 (5)	0 (0)	7 (18)
2 to 4	66	26 (39)	10 (15)	1 (2)	29 (44)
5 to 9	17	7 (41)	0 (0)	0 (0)	10 (59)
10 +	12	3 (25)	0 (0)	0 (0)	9 (75)
p value					<0.01
2010					
1	46	10 (22)	2 (4)	0 (0)	34 (74)
2 to 4	35	4 (11)	6 (17)	1 (3)	24 (69)
5 to 9	12	2 (17)	4 (33)	0 (0)	6 (50)
10 +	13	0 (0)	2 (15)	1 (8)	10 (77)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 211 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	117	60 (51)	13 (11)	3 (3)	41 (35)
Indigenous	14	4 (29)	2 (14)	0 (0)	8 (57)
p value					0.3
2007					
Non-Indigenous	117	61 (52)	7 (6)	0 (0)	49 (42)
Indigenous	20	7 (35)	5 (25)	1 (5)	7 (35)
p value					<0.01
2010					
Non-Indigenous	59	11 (19)	4 (7)	0 (0)	44 (75)
Indigenous	48	5 (10)	10 (21)	2 (4)	31 (65)
p value					<0.01

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 212 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	125	62 (50)	13 (10)	3 (2)	47 (38)
Moderately accessible	1	1(100)	0 (0)	0 (0)	0 (0)
Remote/very remote	3	0 (0)	2 (67)	0 (0)	1 (33)
p value					0.1
2007					
Highly accessible/accessible	125	61 (49)	9 (7)	1 (1)	54 (43)
Moderately accessible	2	2(100)	0 (0)	0 (0)	0 (0)
Remote/very remote	3	1 (33)	1 (33)	0 (0)	1 (33)
p value					0.6
2010					
Highly accessible/accessible	78	12 (15)	7 (9)	0 (0)	59 (76)
Moderately accessible	7	2 (29)	0 (0)	1(14)	4 (57)
Remote/very remote	22	8 (36)	1 (5)	1 (5)	12 (55)
p value					<0.01

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 213 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	123	62 (50)	13 (11)	2 (2)	46 (37)
Non-English	8	2 (25)	2 (25)	1 (13)	3 (38)
p value					0.1
2007					
English	130	65 (50)	11 (8)	1 (1)	53 (42)
Non-English	7	3 (43)	1 (14)	0 (0)	3 (43)
p value					0.4
2010					
English	102	16 (16)	14 (14)	2 (2)	70 (69)
Non-English	4	0 (0)	0 (0)	0 (0)	4(100)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 214 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	32	4 (13)	--	--	32	4 (13)
Yes	81	45 (56)	--	--	81	45 (56)
Not sure	--	--	--	--	--	--
p value		<0.001		--		<0.001
2007						
No	26	3 (12)	--	--	26	3 (12)
Yes	88	52 (59)	--	--	88	52 (59)
Not sure	10	1 (10)	--	--	10	1 (10)
p value		<0.001		--		<0.001
2010						
No	6	1 (17)	1	0 (0)	7	1 (14)
Yes	69	65 (94)	11	6 (55)	80	71 (89)
Not sure	4	3 (75)	--	--	4	3 (75)
p value		<0.001		0.3		<0.001

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 215 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	158	10 (6)
Female	31	0 (0)
p value		0.2

† Excludes missing values.

Gonorrhoea

Table 216 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	158	2 (1)
Female	31	0 (0)
p value		0.5

† Excludes missing values.

Syphilis

Table 217 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	161	15 (9)	7 (4)	15 (9)
Female	29	2 (7)	1 (3)	2 (7)
p value		0.7	0.9	0.7

† Excludes missing values.

South Australia 2010

Table 218 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographic characteristics	2010	
	IDU	Non-IDU
Number of sites surveyed	N = 4	
N ^o surveyed	N = 27	N = 29
Sex (%)		
Male	19 (70)	24 (83)
Female	8 (30)	5 (17)
Transgender	--	--
Sexual identity (%)		
Heterosexual	24 (89)	27 (93)
Bisexual	2 (7)	1 (3)
Homosexual	1 (4)	--
Unsure	--	--
Not reported	--	1 (3)
Age and duration of injection (years)		
Median age (years)	32	37
Age range	20 – 45	19 – 80
Age group (%)		
<25 years	5 (19)	10 (34)
25+ years	22 (81)	19 (66)
Not reported	--	--
Median age 1 st IDU (years)	16	--
Age range	10 – 35	--
Not reported	2	--
Median years IDU	13	--
Range	<1 – 30	--
Duration of drug injection (%)		
<3 years	1 (4)	--
3+ years	24 (89)	--
Not reported	2 (7)	--
Aboriginal and Torres Strait Islander origin (%)		
No	19 (70)	17 (59)
Yes	8 (30)	12 (41)
Not reported	--	--
Living situation prior to prison (%)*		
Not homeless	21 (78)	20 (69)
Primary homelessness	--	2 (7)
Secondary homelessness	2 (7)	5 (17)
Tertiary homelessness	4 (15)	2 (7)
Not reported	--	--
Residential remoteness in 12 months before prison (%)		
Highly accessible/accessible	24 (89)	22 (76)
Moderately accessible	--	2 (7)
Remote/very remote	1 (4)	4 (14)
Not reported	2 (7)	1 (3)
Region/Country of birth (%)		
Australia	25 (93)	28 (97)
Other Oceania	--	1 (3)
Asia	2 (7)	--
UK & Ireland	--	--
Other	--	--
Not reported	--	--
Main language spoke at home by parents (%)		
English	26 (96)	25 (86)
Non-English	1 (4)	2 (7)
Not reported	--	2 (7)

* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers' accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010.

Table 218 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographic characteristics	2010	
	IDU	Non-IDU
First time in prison (%)		
No	24 (89)	21 (72)
Yes	3 (11)	8 (28)
Not reported	--	--
Lifetime imprisonments (%)		
One	7 (26)	19 (66)
Two to four	11 (41)	5 (17)
Five to nine	5 (19)	4 (14)
Ten or more	4 (15)	1 (3)
Not reported	--	--
Imprisonment in last year (%)		
No	13 (48)	12 (41)
Yes	12 (44)	11 (38)
Not reported	2 (7)	6 (21)
Frequency of injection last month (%)		
Not last month	16 (59)	--
Less than weekly	4 (15)	--
Weekly not daily	2 (7)	--
Daily or more	5 (19)	--
Not reported	--	--
Ever smoked a full cigarette (%)*		
No	1 (4)	1 (3)
Yes	26 (96)	28 (97)
Not reported	--	--
<i>Median age first smoked (years)</i>		
Age range	8 – 20	6 – 20
Current smoker (%)*		
No	1 (4)	4 (14)
Yes	26 (96)	24 (83)
Not reported	--	1 (3)
Smoking frequency (%)*		
Occasional – weekly or less	1 (4)	2 (8)
5 to 10 cigarettes a day	7 (27)	8 (33)
11 to 20 cigarettes a day	10 (38)	11 (46)
Over 20 cigarettes a day	8 (31)	3 (13)
Not reported	--	--
Other drugs used last month (%)**		
No drugs in past 4 weeks	5 (19)	7 (29)
Cannabis	18 (82)	14 (78)
Heroin	4 (18)	1 (6)
Cocaine	3 (14)	--
Amphetamine	14 (64)	5 (28)
Other's methadone	--	--
Other opiates	2 (9)	--
Other's buprenorphine	4 (18)	--
Steroids	1 (5)	--
Hallucinogens	1 (5)	2 (11)
Benzodiazepines	4 (18)	3 (17)
Ecstasy/MDA	3 (14)	2 (11)
Inhalants (e.g. petrol)	1 (5)	--
Other drug	--	--
Not reported	--	5 (17)

* Smoking questions not asked in 2004.

** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 219 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2010
Last drug injected (%)	N = 27
Amphetamine (Speed, Ice)	19 (70)
Anabolic steroids	1 (4)
Cocaine	--
Heroin	6 (22)
Heroin + amphetamine	--
Heroin + cocaine	--
Methadone	1 (4)
Morphine	--
Other	--
Not reported	--
N° Injected last month	N = 11
Places injected last month (%)*	
Prison	--
Own home	7 (64)
Friend's home	3 (27)
Dealer's home	1 (9)
Street, park, beach	1 (9)
Car	3 (27)
Public toilet	1 (9)
Commercial injecting room	--
Medically Supervised Injecting Centre, Sydney	--
Squat	--
Other place	--
Use of sterile needles & syringes last month (%)	
All injections	10 (91)
Most of the time	1 (9)
Half of the time	--
Some of the time	--
Not last month	--
Not reported	--
Re-used someone else's used needle & syringe last month (%)	
None	10 (91)
Once	1 (9)
Twice	--
3-5 times	--
>5 times	--
Not reported	--
Number of people needle & syringe was re-used after last month (%)	
None	10 (91)
One	--
Two	1 (9)
Three to five	--
More than five	--
Don't know how many	--
Not reported	--
Relationship to people needle & syringe was re-used after last month (%)*	
Regular sex partner	--
Casual sex partner	--
Close friend	1 (9)
Acquaintance	--
Other	--
Equipment used after someone else last month (%)*	
Spoon	1 (9)
Water	--
Filter	--
Tourniquet	1 (9)
Drug mix	--

* More than one option could be selected.

Table 220 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment for drug use	2010	
	IDU	Non-IDU
N° surveyed	N = 27	N = 29
Any treatment/therapy for drug use (%)		
No	14 (52)	24 (83)
Yes	13 (48)	4 (14)
Not reported	--	1 (3)
History of methadone maintenance treatment (%)		
Currently	4 (15)	--
Previously	7 (26)	1 (3)
Never	16 (59)	27 (93)
Not reported	--	1 (3)
History of other pharmacotherapy treatment (%)		
Currently	2 (7)	--
Previously	5 (19)	--
Never	20 (74)	28 (97)
Not reported	--	1 (3)

Table 221 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2010
N° surveyed	N = 27
From an NSP last month (%)	
Daily or almost daily	2 (7)
A couple of times each week	1 (4)
Less than weekly	2 (7)
Weekly	3 (11)
Once last month	--
Not in the last month	18 (67)
Not reported	1 (4)
From a chemist last month (%)	
Daily or almost daily	1 (4)
A couple of times each week	1 (4)
Less than weekly	3 (11)
Weekly	1 (4)
Once last month	--
Not in the last month	20 (74)
Not reported	1 (4)

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 222 Number (%) of respondents by body piercing and tattoos

Body piercing and tattoos	2010	
	IDU	Non-IDU
N ^o surveyed	N = 27	N = 29
Body or ear piercings (%)		
No	13 (48)	18 (62)
Yes	13 (48)	11 (38)
Not reported	1 (4)	--
Pierced in past 12 mths (%)		
No	8 (57)	10 (91)
Yes	2 (14)	--
Not reported	4 (29)	1 (9)
Who did piercing (%)*		
Chemist/hairdresser/beauty salon	1 (50)	--
Professional piercer / studio	1 (50)	--
Tattooist / parlour	--	--
Friend	--	--
Prison inmate	--	--
Self	--	--
Family member	--	--
Other	--	--
Needle used by other (%)		
No	--	--
Yes	--	--
Unsure	--	--
Not reported	--	2 (100)
Tattoos (%)		
No	8 (30)	17 (59)
Yes	18 (67)	12 (41)
Not reported	1 (4)	--
Tattoos in past 12 mths (%)		
No	14 (78)	10 (83)
Yes	3 (17)	2 (17)
Not reported	1 (5)	--
Who did tattooing (%)*		
Professional tattooist	3 (100)	2 (100)
Friend	--	--
Prison inmate	--	--
Self	--	--
Family member	--	--
Other	--	--

* More than one option could be selected.

Table 223 Number (%) of respondents by sexual behaviour, injector status and survey year

Sexual behaviour	2010	
	IDU	Non-IDU
N ^o surveyed	N = 27	N = 29
Sex last 3 months (%)		
No	3 (11)	3 (10)
Yes	24 (89)	24 (83)
Not reported	--	2 (7)
Male sex partners in last 3 months		
Median	1	1
Range	0 – 2	0 – 1
Female sex partners in last 3 months		
Median	1	1
Range	0 – 11	0 – 6
Condom use last sex - regular male partners - last 3 months (%)		
No	5 (83)	2 (67)
Yes	--	--
Not reported	1 (17)	1 (33)
Condom use last sex - casual male partners - last 3 months (%)		
No	2 (100)	--
Sometimes	--	--
Always	--	--
Condom use last sex - regular female partners - last 3 months (%)		
No	12 (75)	16 (84)
Sometimes	4 (25)	3 (16)
Always	--	--
Condom use last sex - casual female partners - last 3 months (%)		
No	2 (67)	6 (100)
Sometimes	--	--
Always	1 (33)	--
Sex work last month (%)		
No	26 (96)	26 (90)
Yes	1 (4)	--
Not reported	--	3 (10)
Condom used at last sex work last month (%)		
No	--	--
Yes	1 (100)	--
Not reported	--	--
Ever had cervical cancer vaccine (women only)*** (%)		
No	2 (40)	1 (33)
Yes	3 (60)	2 (67)
Unsure	--	--

***Proportion of eligible women i.e. those under 27 years of age in 2007.

Table 224 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and survey year

Testing & treatment	2010	
	IDU	Non-IDU
N° surveyed	N = 27	N = 29
Previous HIV test (%)		
Yes, last year	14 (52)	6 (21)
>1 year ago	5 (19)	7 (24)
Never tested	8 (30)	14 (48)
Not reported	--	--
HBV infection (%)		
No	25 (93)	23 (79)
Yes	2 (7)	--
Don't know	--	5 (17)
Not reported	--	1 (3)
HBV vaccination (%)*		
No	8 (30)	11 (38)
Yes	17 (63)	11 (38)
Don't know	2 (7)	6 (21)
Not reported	--	1 (3)
Previous HCV test (%)		
Yes, last year	13 (48)	7 (24)
>1 year ago	7 (26)	4 (14)
Never tested	6 (22)	16 (55)
Unsure	--	--
Not reported	1 (4)	2 (7)
Any HCV treatment (%)**	N = 6	N = 1
Interferon	--	--
Interferon & Ribavirin	--	--
Pegasys & Ribavirin	--	--
Other	--	--
No treatment	6 (100)	1 (100)
Not reported	--	--
Current HCV treatment		
Interferon	--	--
Interferon & Ribavirin	--	--
Pegasys & Ribavirin	--	--
Other	--	--

* Number (%) among participants with no history of HBV infection.

** Number (%) of those testing positive for hepatitis C antibodies.

HIV antibody prevalence

Table 225 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2010						
IDU	11	0 (0)	4	0 (0)	15	0 (0)
Non-IDU	18	0 (0)	3	0 (0)	21	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 226 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	No with HCV (%)	No tested	No with HCV (%)	No tested	No with HCV (%)
2010						
IDU	10	4 (40)	4	2 (50)	14	6 (43)
Non-IDU	16	1 (6)	3	0 (0)	19	1 (5)
p value		0.03		0.2		<0.01

† Excludes equivocal test results and missing values.

Table 227 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Heterosexual	25	5 (20)	3	0 (0)	28	5 (18)
Bisexual	--	--	3	1 (33)	3	1 (33)
Homosexual	--	--	1	1 (100)	1	1 (100)
Unsure	--	--	--	--	--	--
p value		--		0.2		0.1

† Excludes equivocal test results and missing values.

Table 228 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	6	0 (0)	1	0 (0)	7	0 (0)
25 – 29	5	1 (20)	2	0 (0)	7	1 (14)
30 + years	14	4 (29)	4	2 (50)	18	6 (33)
p value		0.5		0.4		0.3

† Excludes equivocal test results and missing values.

Table 229 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	1	0 (0)	1	0 (0)	2	0 (0)
6 to 10 years	1	0 (0)	1	0 (0)	2	0 (0)
10 + years	6	3 (50)	2	2 (100)	8	5 (63)
p value		0.5		0.1		0.2

† Excludes equivocal test results and missing values.

Table 230 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Amphetamine (Speed, Ice)	--	--	8	4 (50)	8	4 (50)
Heroin	--	--	3	0 (0)	3	0 (0)
More than one	--	--	--	--	--	--
Other/not reported	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.2		0.3

† Excludes equivocal test results and missing values.

Table 231 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Less than daily	--	--	3	1 (33)	3	1 (33)
Daily or more	--	--	2	0 (0)	2	0 (0)
p value		--		0.4		0.4

† Excludes equivocal test results and missing values.

Table 232 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	--	--	4	1 (25)	4	1 (25)
Yes	--	--	1	0 (0)	1	0 (0)
p value		--		0.6		0.6

† Excludes equivocal test results and missing values.

Table 233 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	--	--	5	2 (40)	5	2 (40)
Yes	1	0 (0)	5	2 (40)	6	2 (33)
p value		--		1.0		0.8

† Excludes equivocal test results and missing values.

Table 234 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
1	16	2 (13)	3	1 (33)	19	3 (16)
2 to 4	4	1 (25)	2	1 (50)	6	2 (33)
5 to 9	4	1 (25)	2	0 (0)	6	1 (17)
10 +	2	1 (50)	--	--	2	1 (50)
p value		0.6		0.5		0.6

† Excludes equivocal test results and missing values.

Table 235 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	18	3 (17)	7	2 (29)	25	5 (20)
Indigenous	8	2 (25)	--	--	8	2 (25)
p value		0.6		--		0.8

† Excludes equivocal test results and missing values.

Table 236 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	14	0 (0)	11	5 (45)	25	5 (20)
Indigenous	5	1 (20)	3	1 (33)	8	2 (25)
p value		0.1		0.7		0.8

† Excludes equivocal test results and missing values.

Table 237 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Highly accessible/accessible	23	4 (17)	6	2 (33)	29	6 (21)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	1	1 (100)	--	--	1	1 (100)
p value		0.1		--		0.2

† Excludes equivocal test results and missing values.

Table 238 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Australia	25	5 (20)	7	2 (29)	32	7 (22)
Other Oceania	1	0 (0)	--	--	1	0 (0)
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 239 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
English	25	5 (20)	7	2 (29)	32	7 (22)
Non-English	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 240 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Positive	3	3 (100)	2	2 (100)	5	5 (100)
Negative	7	1 (14)	3	0 (0)	10	1 (10)
Not sure	1	0 (0)	--	--	1	0 (0)
p value		0.03		0.03		0.002

† Excludes equivocal test results and missing values.

HBV prevalence

Table 241 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	2	1 (50)	1	0 (0)	3	1 (33)
Non-IDU	3	0 (0)	3	0 (0)	6	0 (0)
p value		0.2				0.1

† Excludes equivocal test results and missing values.

Table 242 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	11	2 (18)	4	0 (0)	15	2 (13)
Non-IDU	16	1 (6)	3	0 (0)	19	1 (5)
p value		0.3		--		0.4

† Excludes equivocal test results and missing values.

Table 243 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Heterosexual	26	3 (12)	3	0 (0)	29	3 (10)
Bisexual	--	--	3	0 (0)	3	0 (0)
Homosexual	--	--	1	0 (0)	1	0 (0)
Unsure	--	--	--	--	--	--
p value		--		--		0.8

† Excludes equivocal test results and missing values.

Table 244 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	6	0 (0)	1	0 (0)	7	0 (0)
25 – 29	5	0 (0)	2	0 (0)	7	0 (0)
30 + years	15	3 (20)	4	0 (0)	19	3 (16)
p value		0.4		--		0.5

† Excludes equivocal test results and missing values.

Table 245 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	1	0 (0)	1	0 (0)	2	0 (0)
6 to 10 years	1	0 (0)	1	0 (0)	2	0 (0)
10 + years	7	2 (29)	2	0 (0)	9	2 (22)
p value		0.8		--		0.7

† Excludes equivocal test results and missing values.

Table 246 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Amphetamine (Speed, Ice)	--	--	9	2 (22)	9	2 (22)
Heroin	--	--	3	0 (0)	3	0 (0)
More than one	--	--	--	--	--	--
Other/not reported	1	0 (0)	1	0 (0)	2	0 (0)
p value		--		0.6		0.5

† Excludes equivocal test results and missing values.

Table 247 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Less than daily	--	--	3	1 (33)	3	1 (33)
Daily or more	--	--	2	0 (0)	2	0 (0)
p value		--		0.4		0.4

† Excludes equivocal test results and missing values.

Table 248 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	--	--	4	1 (25)	4	1 (25)
Yes	--	--	1	0 (0)	1	0 (0)
p value		--		0.6		0.6

† Excludes equivocal test results and missing values.

Table 249 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	--	--	6	0 (0)	6	0 (0)
Yes	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		0.3		0.3

† Excludes equivocal test results and missing values.

Table 250 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
1	16	1 (6)	3	0 (0)	19	1 (5)
2 to 4	5	0 (0)	2	0 (0)	7	0 (0)
5 to 9	4	1 (25)	2	0 (0)	6	1 (17)
10 +	2	1 (50)	--	--	2	1 (50)
p value		0.2		--		0.1

† Excludes equivocal test results and missing values.

Table 251 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	19	1 (5)	7	0 (0)	26	1 (4)
Indigenous	8	2 (25)	--	--	8	2 (25)
p value		0.1		--		0.07

† Excludes equivocal test results and missing values.

Table 252 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	14	0 (0)	12	1 (8)	26	1 (4)
Indigenous	5	1 (20)	3	1 (33)	8	2 (25)
p value		0.09		0.3		0.07

† Excludes equivocal test results and missing values.

Table 253 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Highly accessible/accessible	24	2 (8)	6	0 (0)	30	2 (7)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	1	1 (100)	--	--	1	1 (100)
p value		0.02		--		0.01

† Excludes equivocal test results and missing values.

Table 254 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Australia	26	3 (12)	7	0 (0)	33	3 (9)
Other Oceania	1	0 (0)	--	--	1	0 (0)
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		0.7		--		0.8

† Excludes equivocal test results and missing values.

Table 255 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
English	26	3 (12)	7	0 (0)	33	3 (9)
Non-English	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 256 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
IDU	15	1 (7)	1 (7)	1 (7)	12 (80)
Non-IDU	18	7 (39)	1 (6)	0 (0)	10 (56)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 257 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Heterosexual	28	7 (25)	2 (7)	1 (4)	18 (64)
Homosexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Bisexual	3	0 (0)	0 (0)	0 (0)	3 (100)
Unsure	--	--	--	--	--
p value					0.9

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 258 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
< 20 years	1	1 (100)	0 (0)	0 (0)	0 (0)
20 – 24	7	0 (0)	0 (0)	0 (0)	7 (100)
25 – 29	7	1 (14)	0 (0)	0 (0)	6 (86)
30 + years	18	6 (33)	2 (11)	1 (6)	9 (50)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 259 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
1	18	6 (33)	1 (6)	0 (0)	11 (61)
2 to 4	7	1 (14)	0 (0)	0 (0)	6 (86)
5 to 9	6	1 (17)	0 (0)	1 (17)	4 (67)
10 +	2	0 (0)	1 (50)	0 (0)	1 (50)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 260 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Non-Indigenous	25	5 (20)	0 (0)	1 (4)	19 (76)
Indigenous	8	3 (38)	2 (25)	0 (0)	3 (38)
p value					0.03

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 261 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Highly accessible/accessible	29	7 (24)	2 (7)	0 (0)	20 (69)
Moderately accessible	1	0 (0)	0 (0)	0 (0)	1 (100)
Remote/very remote	1	0 (0)	0 (0)	1 (100)	0 (0)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 262 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
English	32	8 (25)	2 (6)	1 (3)	21 (66)
Non-English	--	--	--	--	--
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 263 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2010						
No	8	4 (50)	1	0 (0)	9	4 (44)
Yes	11	10 (91)	5	5 (100)	16	15 (94)
Not sure	4	3 (75)	--	--	4	3 (75)
p value		0.1		0.01		0.02

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 264 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	29	0 (0)
Female	8	0 (0)
p value		--

† Excludes missing values.

Gonorrhoea

Table 265 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	29	0 (0)
Female	8	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 266 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	25	2 (8)	0 (0)	2 (8)
Female	--	--	--	--
p value		--	--	--

† Excludes missing values.

Tasmania
2004, 2007, 2010

Table 267 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 2		N = 3		N = 4	
N ^o surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13
Sex (%)						
Male	22 (85)	14 (93)	19 (86)	21 (88)	18 (95)	13 (100)
Female	4 (15)	1 (7)	3 (14)	3 (13)	1 (5)	--
Transgender	--	--	--	--	--	--
Sexual identity (%)						
Heterosexual	25 (96)	15 (100)	21 (95)	23 (96)	19 (100)	12 (92)
Bisexual	1 (4)	--	--	1 (4)	--	1 (8)
Homosexual	--	--	1 (5)	--	--	--
Unsure	--	--	--	--	--	--
Not reported	--	--	--	--	--	--
Age and duration of injection (years)						
Median age (years)	25	42	32	26	27	26
Age range	21 – 48	17 – 64	21 – 45	19 – 58	19 – 50	19 – 59
Age group (%)						
<25 years	2 (8)	3 (20)	1 (5)	11 (46)	6 (32)	5 (38)
25+ years	24 (92)	12 (80)	21 (95)	13 (54)	13 (68)	8 (62)
Not reported	--	--	--	--	--	--
Median age 1 st IDU (years)	20	--	19	--	18	--
Age range	14 – 30	--	12 – 40	--	12 – 35	--
Not reported	--	--	--	--	--	--
Median years IDU	10	--	10	--	9	--
Range	1 – 32	--	<1 – 27	--	<1 – 25	--
Duration of drug injection (%)						
<3 years	1 (4)	--	1 (5)	--	4 (21)	--
3+ years	23 (88)	--	21 (95)	--	15 (79)	--
Not reported	2 (8)	--	--	--	--	--
Aboriginal and Torres Strait Islander origin (%)						
No	16 (62)	9 (60)	18 (82)	20 (83)	17 (89)	10 (77)
Yes	2 (8)	4 (27)	4 (18)	4 (17)	2 (11)	3 (23)
Not reported	8 (31)	2 (13)	--	--	--	--
Living situation prior to prison (%)*						
Not homeless	n/a	n/a	n/a	n/a	10 (53)	7 (54)
Primary homelessness	n/a	n/a	n/a	n/a	2 (11)	1 (8)
Secondary homelessness	n/a	n/a	n/a	n/a	6 (32)	5 (38)
Tertiary homelessness	n/a	n/a	n/a	n/a	1 (5)	--
Not reported	n/a	n/a	n/a	n/a	--	--
Residential remoteness in 12 months before prison (%)						
Highly accessible/accessible	20 (77)	11 (73)	13 (59)	18 (75)	16 (84)	8 (62)
Moderately accessible	2 (8)	1 (7)	6 (27)	4 (17)	1 (5)	4 (31)
Remote/very remote	--	2 (13)	3 (14)	2 (8)	1 (5)	--
Not reported	4 (15)	1 (7)	--	--	1 (5)	1 (8)
Region/Country of birth (%)						
Australia	26 (100)	13 (87)	22 (100)	23 (96)	19 (100)	13 (100)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	1 (4)	--	--
Not reported	--	2 (13)	--	--	--	--
Main language spoke at home by parents (%)						
English	26 (100)	13 (87)	22 (100)	23 (96)	19 (100)	12 (92)
Non-English	--	--	--	1 (4)	--	1 (8)
Not reported	--	2 (13)	--	--	--	--

* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers' accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010.

Table 267 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)						
No	17 (65)	10 (67)	19 (86)	12 (50)	15 (79)	10 (77)
Yes	9 (35)	5 (33)	3 (14)	12 (50)	4 (21)	3 (23)
Not reported	--	--	--	--	--	--
Lifetime imprisonments (%)						
One	9 (35)	5 (33)	3 (14)	12 (50)	5 (26)	6 (46)
Two to four	8 (31)	5 (33)	10 (45)	9 (38)	8 (42)	6 (46)
Five to nine	6 (23)	1 (7)	6 (27)	3 (13)	4 (21)	--
Ten or more	2 (8)	--	2 (9)	--	2 (11)	1 (8)
Not reported	1 (4)	4 (27)	1 (5)	--	--	--
Imprisonment in last year (%)						
No	12 (46)	7 (47)	5 (26)	5 (42)	11 (58)	8 (62)
Yes	11 (42)	4 (27)	13 (68)	7 (58)	8 (42)	5 (38)
Not reported	3 (12)	4 (27)	1 (5)	--	--	--
Frequency of injection last month (%)						
Not last month	12 (46)	--	6 (27)	--	10 (53)	--
Less than weekly	2 (8)	--	4 (18)	--	5 (26)	--
Weekly not daily	6 (23)	--	4 (18)	--	2 (11)	--
Daily or more	5 (19)	--	8 (36)	--	2 (11)	--
Not reported	1 (4)	--	--	--	--	--
Ever smoked a full cigarette (%)*						
No	n/a	n/a	--	1 (4)	--	1 (8)
Yes	n/a	n/a	22 (100)	23 (96)	19 (100)	12 (92)
Not reported	n/a	n/a	--	--	--	--
Median age first smoked (years)						
Age range	n/a	n/a	14	14	13	13
	n/a	n/a	7 – 36	6 – 17	8 – 15	10 – 20
Current smoker (%)*						
No	n/a	n/a	1 (5)	4 (17)	1 (5)	4 (31)
Yes	n/a	n/a	21 (95)	20 (83)	18 (85)	9 (69)
Not reported	n/a	n/a	--	--	--	--
Smoking frequency (%)*						
Occasional – weekly or less	n/a	n/a	--	1 (5)	--	--
5 to 10 cigarettes a day	n/a	n/a	4 (19)	3 (15)	12 (67)	6 (67)
11 to 20 cigarettes a day	n/a	n/a	8 (38)	9 (45)	3 (17)	3 (33)
Over 20 cigarettes a day	n/a	n/a	9 (43)	7 (35)	3 (17)	--
Not reported	n/a	n/a	--	--	--	--
Other drugs used last month (%)**						
No drugs in past 4 weeks	n/a	n/a	n/a	n/a	5 (26)	4 (31)
Cannabis	n/a	n/a	n/a	n/a	10 (71)	8 (89)
Heroin	n/a	n/a	n/a	n/a	1 (7)	--
Cocaine	n/a	n/a	n/a	n/a	2 (14)	--
Amphetamine	n/a	n/a	n/a	n/a	7 (50)	--
Other's methadone	n/a	n/a	n/a	n/a	--	--
Other opiates	n/a	n/a	n/a	n/a	2 (14)	--
Other's buprenorphine	n/a	n/a	n/a	n/a	2 (14)	1 (11)
Steroids	n/a	n/a	n/a	n/a	--	--
Hallucinogens	n/a	n/a	n/a	n/a	--	--
Benzodiazepines	n/a	n/a	n/a	n/a	6 (43)	--
Ecstasy/MDA	n/a	n/a	n/a	n/a	1 (7)	--
Inhalants (e.g. petrol)	n/a	n/a	n/a	n/a	--	--
Other drug	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	--	--

* Smoking questions not asked in 2004.

** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 268 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010
Last drug injected (%)	N = 26	N = 22	N = 19
Amphetamine (Speed, Ice)	20 (77)	16 (73)	12 (63)
Anabolic steroids	--	--	--
Cocaine	--	--	--
Heroin	2 (8)	1 (5)	--
Heroin + amphetamine	--	--	--
Heroin + cocaine	--	--	--
Methadone	--	--	--
Morphine	3 (12)	4 (18)	5 (26)
Other	1 (4)	1 (5)	2 (11)
Not reported	--	--	--
N° Injected last month	N = 14	N = 16	N = 9
Places injected last month (%)*			
Prison	1 (8)	1 (6)	--
Own home	11 (79)	15 (94)	4 (44)
Friend's home	7 (50)	13 (81)	4 (44)
Dealer's home	2 (14)	4 (25)	1 (11)
Street, park, beach	2 (14)	3 (19)	2 (22)
Car	7 (50)	10 (63)	5 (56)
Public toilet	4 (29)	4 (25)	2 (22)
Commercial injecting room	--	--	--
Medically Supervised Injecting Centre, Sydney	--	--	--
Squat	--	--	--
Other place	--	--	--
Use of sterile needles & syringes last month (%)			
All injections	12 (86)	13 (81)	7 (28)
Most of the time	1 (7)	2 (13)	2 (22)
Half of the time	1 (7)	--	--
Some of the time	--	--	--
Not last month	--	--	--
Not reported	--	1 (6)	--
Re-used someone else's used needle & syringe last month (%)			
None	12 (86)	14 (88)	8 (89)
Once	1 (7)	1 (6)	--
Twice	1 (7)	--	--
3-5 times	--	1 (6)	1 (11)
>5 times	--	--	--
Not reported	--	--	--
Number of people needle & syringe was re-used after last month (%)			
None	12 (86)	14 (88)	8 (89)
One	1 (7)	1 (6)	--
Two	--	--	--
Three to five	--	--	--
More than five	--	--	--
Don't know how many	--	1 (6)	1 (11)
Not reported	1 (7)	--	--
Relationship to people needle & syringe was re-used after last month (%)*			
Regular sex partner	1 (7)	2 (13)	1 (11)
Casual sex partner	--	--	--
Close friend	--	--	1 (11)
Acquaintance	1 (7)	--	--
Other	--	--	--
Equipment used after someone else last month (%)*			
Spoon	1 (7)	3 (19)	1 (11)
Water	4 (29)	2 (13)	1 (11)
Filter	2 (14)	1 (6)	1 (11)
Tourniquet	1 (7)	--	1 (11)
Drug mix	1 (7)	2 (13)	1 (11)

* More than one option could be selected.

Table 269 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment for drug use	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13
Any treatment/therapy for drug use (%)						
No	10 (38)	14 (93)	9 (41)	16 (67)	7 (37)	12 (92)
Yes	16 (62)	--	13 (59)	4 (17)	12 (63)	1 (8)
Not reported	--	1 (7)	--	4 (17)	--	--
History of methadone maintenance treatment (%)						
Currently	3 (12)	--	3 (14)	--	1 (5)	--
Previously	6 (23)	--	2 (9)	--	2 (11)	--
Never	16 (62)	14 (93)	17 (77)	--	16 (84)	13 (100)
Not reported	1 (4)	1 (7)	--	--	--	--
History of other pharmacotherapy treatment (%)						
Currently	2 (8)	--	--	--	2 (11)	1 (8)
Previously	2 (8)	--	5 (23)	--	3 (16)	--
Never	21 (81)	14 (93)	17 (77)	--	14 (74)	12 (92)
Not reported	1 (4)	1 (7)	--	--	--	--

Table 270 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010
N° surveyed	N = 14	N = 16	N = 19
From an NSP last month (%)			
Daily or almost daily	--	1 (6)	--
A couple of times each week	2 (14)	5 (31)	3 (16)
Less than weekly	4 (29)	1 (6)	1 (5)
Weekly	n/a	n/a	4 (21)
Once last month	--	1 (6)	--
Not in the last month	--	1 (6)	11 (58)
Not reported	8 (57)	7 (44)	--
From a chemist last month (%)			
Daily or almost daily	2 (14)	--	--
A couple of times each week	1 (7)	3 (19)	--
Less than weekly	1 (7)	3 (19)	1 (5)
Weekly	n/a	n/a	3 (16)
Once last month	6 (43)	--	--
Not in the last month	4 (29)	2 (13)	15 (79)
Not reported	--	8 (50)	--

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 271 Number (%) of respondents by body piercing and tattoos

Body piercing and tattoos	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13
Body or ear piercings (%)						
No	11 (42)	8 (53)	8 (36)	15 (63)	12 (63)	10 (77)
Yes	15 (58)	7 (47)	14 (64)	9 (38)	7 (37)	3 (23)
Not reported	--	--	--	--	--	--
Pierced in past 12 mths (%)						
No	12 (80)	5 (71)	13 (93)	9 (100)	3 (43)	2 (67)
Yes	1 (7)	1 (14)	--	--	4 (57)	1 (33)
Not reported	2 (13)	1 (14)	1 (7)	--	--	--
Who did piercing (%)*						
Chemist/hairdresser/beauty salon	--	--	--	--	--	1 (100)
Professional piercer / studio	--	1 (100)	--	--	--	--
Tattooist / parlour	--	--	--	--	--	--
Friend	--	--	--	--	1 (25)	--
Prison inmate	--	--	--	--	1 (25)	--
Self	--	--	--	--	2 (50)	--
Family member	--	--	--	--	--	--
Other	--	--	--	--	--	--
Needle used by other (%)						
No	--	--	--	--	4 (100)	--
Yes	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
Not reported	3 (100)	1 (100)	--	--	--	1 (100)
Tattoos (%)						
No	2 (8)	9 (60)	6 (27)	11 (46)	1 (5)	7 (54)
Yes	24 (92)	6 (40)	16 (73)	13 (54)	18 (95)	5 (38)
Not reported	--	--	--	--	--	1 (8)
Tattoos in past 12 mths (%)						
No	16 (67)	5 (83)	13 (81)	10 (77)	9 (50)	2 (40)
Yes	7 (29)	1 (17)	3 (19)	3 (23)	9 (50)	3 (60)
Not reported	1 (4)	--	--	--	--	--
Who did tattooing (%)*						
Professional tattooist	3 (43)	1 (100)	1 (33)	2 (67)	6 (67)	3 (100)
Friend	1 (14)	--	2 (67)	1 (33)	3 (33)	--
Prison inmate	1 (14)	--	2 (67)	--	--	--
Self	1 (14)	--	--	--	--	--
Family member	--	--	--	--	--	--
Other	--	--	--	--	--	--

* More than one option could be selected.

Table 272 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sexual behaviour	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13
Sex last month / last 3 months (%)**						
No	9 (35)	8 (53)	6 (27)	3 (13)	4 (13)	2 (15)
Yes	17 (65)	7 (47)	16 (73)	21 (88)	28 (88)	11 (85)
Not reported	--	--	--	--	--	--
Male sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	0.5	--
Range	n/a	n/a	n/a	n/a	0 – 1	--
Female sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	1	1
Range	n/a	n/a	n/a	n/a	0 – 4	0 – 2
Condom use at last sex (%)						
No	22 (85)	10 (67)	19 (86)	23 (96)		
Yes	4 (15)	5 (33)	3 (14)	1 (4)		
Not reported	--	--	--	--		
Condom use with regular sex partner(s) last month (%)*						
No	9 (90)	4 (57)	10 (91)	13 (76)	n/a	n/a
Sometimes	1 (10)	1 (14)	1 (9)	4 (24)	n/a	n/a
Always	--	2 (29)	--	--	n/a	n/a
Condom use with new sex partner(s) last month (%)*						
No	1 (50)	--	2 (100)	1 (100)	n/a	n/a
Sometimes	1 (50)	--	--	--	n/a	n/a
Always	--	--	--	--	n/a	n/a
Condom use with casual sex partner(s) last month (%)*						
No	5 (71)	--	4 (100)	3 (60)	n/a	n/a
Sometimes	2 (29)	--	--	--	n/a	n/a
Always	--	--	--	2 (40)	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	--	--
Sometimes	n/a	n/a	n/a	n/a	1 (100)	--
Always	n/a	n/a	n/a	n/a	--	--
Condom use last sex - casual male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	--	--
Sometimes	n/a	n/a	n/a	n/a	1 (100)	--
Always	n/a	n/a	n/a	n/a	--	--
Condom use last sex - regular female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	7 (70)	7 (70)
Sometimes	n/a	n/a	n/a	n/a	2 (20)	2 (20)
Always	n/a	n/a	n/a	n/a	1 (10)	1 (10)
Condom use last sex - casual female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	5 (71)	--
Sometimes	n/a	n/a	n/a	n/a	2 (29)	--
Always	n/a	n/a	n/a	n/a	--	1 (100)
Sex work last month (%)						
No	25 (96)	15 (100)	21 (95)	24 (100)	19 (100)	13 (100)
Yes	1 (4)	--	1 (5)	--	--	--
Not reported	--	--	--	--	--	--
Condom used at last sex work last month (%)						
No	--	--	1 (100)	--	--	--
Yes	1 (100)	--	--	--	--	--
Not reported	--	--	--	--	--	--
Ever had cervical cancer vaccine (women only)*** (%)						
No	n/a	n/a	n/a	n/a	1 (100)	--
Yes	n/a	n/a	n/a	n/a	--	--
Unsure	n/a	n/a	n/a	n/a	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

*** Proportion of eligible women i.e. those under 27 years of age in 2007.

Table 273 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13
Previous HIV test (%)						
Yes, last year	13 (50)	5 (22)	3 (14)	11 (46)	7 (37)	5 (38)
>1 year ago	8 (31)	4 (27)	7 (32)	5 (21)	6 (32)	1 (8)
Never tested	5 (19)	5 (33)	12 (55)	8 (33)	6 (32)	7 (54)
Not reported	--	1 (7)	--	--	--	--
HBV infection (%)						
No	19 (73)	14 (93)	20 (91)	23 (96)	17 (89)	12 (92)
Yes	6 (23)	--	--	1 (4)	2 (11)	1 (8)
Don't know	1 (4)	1 (7)	2 (9)	--	--	--
Not reported	--	--	--	--	--	--
HBV vaccination (%)*						
No	12 (46)	11 (73)	9 (41)	10 (42)	5 (26)	5 (38)
Yes	11 (42)	4 (27)	12 (55)	10 (42)	10 (53)	5 (38)
Don't know	6 (23)	--	1 (5)	4 (17)	3 (16)	3 (23)
Not reported	--	--	--	--	1 (5)	--
Previous HCV test (%)						
Yes, last year	9 (35)	4 (27)	5 (23)	11 (46)	5 (26)	5 (38)
>1 year ago	11 (42)	3 (20)	7 (32)	7 (29)	7 (37)	1 (8)
Never tested	6 (23)	8 (53)	10 (45)	6 (25)	6 (32)	7 (54)
Unsure	--	--	--	--	--	--
Not reported	--	--	--	--	1 (5)	--
Any HCV treatment (%)**	N = 12	N = 1	N = 7	N = 1	N = 8	N = 0
Interferon	--	--	--	--	--	--
Interferon & Ribavirin	--	1 (100)	--	--	1 (13)	--
Pegasys & Ribavirin	--	--	--	--	--	--
Other	--	--	--	--	--	--
No treatment	12 (100)	--	7 (100)	1 (100)	7 (88)	--
Not reported	--	--	--	--	--	--
Current HCV treatment						
Interferon	--	--	--	--	--	--
Interferon & Ribavirin	--	--	--	--	1 (13)	--
Pegasys & Ribavirin	--	--	--	--	--	--
Other	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Number (%) of those testing positive for hepatitis C antibodies.

HIV antibody prevalence

Table 274 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	15	0 (0)	2	0 (0)	17	0 (0)
Non-IDU	8	0 (0)	--	--	8	0 (0)
p value		--		--		--
2007						
IDU	16	0 (0)	--	--	16	0 (0)
Non-IDU	17	0 (0)	--	--	17	0 (0)
p value		--		--		--
2010						
IDU	18	0 (0)	1	0 (0)	19	0 (0)
Non-IDU	12	0 (0)	--	--	12	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 275 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	16	10 (63)	2	2 (100)	18	12 (67)
Non-IDU	9	1 (11)	--	--	9	1 (11)
p value		0.01		--		<0.01
2007						
IDU	15	7 (47)	--	--	15	7 (47)
Non-IDU	17	1 (6)	--	--	17	1 (6)
p value		0.008		--		0.008
2010						
IDU	17	8 (47)	1	0 (0)	18	8 (44)
Non-IDU	12	0 (0)	--	--	12	0 (0)
p value		<0.01		--		<0.01

† Excludes equivocal test results and missing values.

Table 276 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	25	11 (44)	1	1 (100)	26	12 (46)
Bisexual	--	--	1	1 (100)	1	1 (100)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		0.3
2007						
Heterosexual	32	8 (25)	--	--	32	8 (25)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2010						
Heterosexual	28	8 (29)	1	0 (0)	29	8 (28)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 277 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	2	1 (50)	--	--	2	1 (50)
25 – 29	8	2 (25)	3	2 (67)	11	4 (36)
30 + years	16	9 (56)	--	--	16	9 (56)
p value		0.4		--		0.6
2007						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	8	1 (13)	--	--	8	1 (13)
25 – 29	6	1 (17)	--	--	6	1 (17)
30 + years	17	6 (35)	--	--	17	6 (35)
p value		0.5		--		0.5
2010						
< 20 years	3	1 (33)	--	--	3	1 (33)
20 – 24	7	1 (14)	1	0 (0)	8	1 (13)
25 – 29	6	2 (33)	--	--	6	2 (33)
30 + years	13	4 (31)	--	--	13	4 (31)
p value		0.8		--		0.8

† Excludes equivocal test results and missing values.

Table 278 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	6	2 (33)	1	1 (100)	7	3 (43)
10 + years	9	8 (89)	1	1 (100)	10	9 (90)
p value		0.03		--		0.04
2007						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	--	--	--	--	--	--
6 to 10 years	4	1 (25)	--	--	4	1 (25)
10 + years	10	6 (60)	--	--	10	6 (60)
p value		0.3		--		0.3
2010						
<3 years	4	0 (0)	--	--	4	0 (0)
3 to 5 years	3	1 (33)	--	--	3	1 (33)
6 to 10 years	2	2 (100)	1	0 (0)	3	2 (67)
10 + years	8	5 (63)	--	--	8	5 (63)
p value		0.08		--		0.2

† Excludes equivocal test results and missing values.

Table 279 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	--	--	9	6 (67)	9	6 (67)
Heroin	--	--	1	1 (100)	1	1 (100)
More than one	--	--	7	5 (71)	7	5 (71)
Other/not reported	--	--	--	--	--	--
p value		--		0.7		0.7
2007						
Amphetamine (Speed, Ice)	1	0 (0)	10	3 (30)	11	3 (27)
Heroin	--	--	1	1 (100)	1	1 (100)
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	3 (100)	3	3 (100)
p value		--		0.06		0.04
2010						
Amphetamine (Speed, Ice)	3	0 (0)	8	3 (38)	11	3 (27)
Heroin	--	--	--	--	--	--
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	1	0 (0)	5	5 (100)	6	5 (83)
p value		--		0.04		0.06

† Excludes equivocal test results and missing values.

Table 280 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	--	--	5	3 (60)	5	3 (60)
Daily or more	--	--	4	4 (100)	4	4 (100)
p value		--		0.3		0.3
2007						
Less than daily	--	--	5	1 (20)	5	1 (20)
Daily or more	1	0 (0)	5	3 (60)	6	3 (50)
p value		--		0.2		0.3
2010						
Less than daily	2	0 (0)	5	3 (60)	7	3 (43)
Daily or more	--	--	2	2 (100)	2	2 (100)
p value		--		0.3		0.2

† Excludes equivocal test results and missing values.

Table 281 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	8	6 (75)	8	6 (75)
Yes	--	--	2	2 (100)	2	2 (100)
p value		--		0.4		0.4
2007						
No	1	0 (0)	10	4 (40)	11	4 (36)
Yes	--	--	--	--	--	--
p value		--		--		--
2010						
No	2	0 (0)	6	4 (67)	8	4 (50)
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 282 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	8	6 (75)	8	6 (75)
Yes	--	--	2	2 (100)	6	2 (100)
p value		--		0.7		0.7
2007						
No	--	--	4	3 (75)	4	3 (75)
Yes	--	--	10	4 (40)	10	4 (40)
p value		--		0.2		0.2
2010						
No	3	0 (0)	7	3 (43)	10	3 (30)
Yes	1	0 (0)	7	5 (71)	8	5 (63)
p value		--		0.3		0.2

† Excludes equivocal test results and missing values.

Table 283 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	10	4 (40)	--	--	10	4 (40)
2 to 4	9	4 (44)	--	--	9	4 (44)
5 to 9	4	3 (75)	1	1 (100)	5	4 (80)
10 +	--	--	1	1 (100)	1	1 (100)
p value		0.5		--		0.4
2007						
1	7	0 (0)	--	--	7	0 (0)
2 to 4	15	3 (20)	--	--	15	3 (20)
5 to 9	9	4 (44)	--	--	9	4 (44)
10 +	1	1 (100)	--	--	1	1 (100)
p value		0.06		--		0.06
2010						
1	9	0 (0)	--	--	9	0 (0)
2 to 4	13	2 (15)	1	0 (0)	14	2 (14)
5 to 9	4	4 (100)	--	--	4	4 (100)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 284 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	16	9 (56)	1	1 (100)	17	10 (59)
Indigenous	3	1 (33)	--	--	3	1 (33)
p value		0.5		--		0.4
2007						
Non-Indigenous	28	6 (21)	--	--	28	6 (21)
Indigenous	4	2 (50)	--	--	4	2 (50)
p value		0.2		--		0.2
2010						
Non-Indigenous	24	6 (25)	1	0 (0)	25	6 (24)
Indigenous	5	2 (40)	--	--	5	2 (40)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 285 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	5	0 (0)	11	9 (82)	16	9 (56)
Indigenous	2	0 (0)	1	1 (100)	3	1 (33)
p value		--		0.6		0.6
2007						
Non-Indigenous	16	1 (6)	12	5 (42)	28	6 (21)
Indigenous	1	0 (0)	3	2 (67)	4	2 (50)
p value		0.8		0.4		0.2
2010						
Non-Indigenous	9	0 (0)	16	6 (38)	25	6 (24)
Indigenous	3	0 (0)	2	2 (100)	5	2 (40)
p value		--		0.1		0.5

† Excludes equivocal test results and missing values.

Table 286 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	19	8 (42)	2	2 (100)	21	10 (48)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.6
2007						
Highly accessible/accessible	24	7 (29)	--	--	24	7 (29)
Moderately accessible	4	1 (25)	--	--	4	1 (25)
Remote/very remote	4	0 (0)	--	--	4	0 (0)
p value		0.5		--		0.5
2010						
Highly accessible/accessible	21	7 (33)	1	0 (0)	22	7 (32)
Moderately accessible	5	0 (0)	--	--	5	0 (0)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 287 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	25	11 (44)	2	2 (100)	27	13 (48)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	31	8 (26)	--	--	31	8 (26)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
p value		0.6		--		0.6
2010						
Australia	29	8 (28)	1	0 (0)	30	8 (27)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 288 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	25	11 (44)	2	2 (100)	27	13 (48)
Non-English	--	--	--	--	--	--
p value		--		--		--
2007						
English	31	8 (26)	--	--	31	8 (26)
Non-English	1	0 (0)	--	--	1	0 (0)
p value		0.6		--		0.6
2010						
English	28	8 (29)	1	0 (0)	29	8 (28)
Non-English	1	0 (0)	--	--	1	0 (0)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 289 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	8	8 (100)	2	2 (100)	10	10 (100)
Negative	7	2 (29)	--	--	7	2 (29)
Not sure	2	1 (50)	--	--	2	1 (50)
p value		0.01		--		0.006
2007						
Positive	4	4 (100)	--	--	4	4 (100)
Negative	11	1 (9)	--	--	11	1 (9)
Not sure	4	1 (25)	--	--	4	1 (25)
p value		0.003		--		0.003
2010						
Positive	7	6 (86)	--	--	7	6 (86)
Negative	11	1 (9)	1	0 (0)	12	1 (8)
Not sure	--	--	--	--	--	--
p value		0.001		--		0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 290 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	15	0 (0)	3	1 (33)	18	1 (6)
Non-IDU	8	0 (0)	--	--	8	0 (0)
p value		--		--		0.5
2007						
IDU	14	1 (7)	--	--	14	1 (7)
Non-IDU	16	0 (0)	--	--	16	0 (0)
p value		0.3		--		0.3
2010						
IDU	17	0 (0)	1	0 (0)	18	0 (0)
Non-IDU	12	0 (0)	--	--	12	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 291 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	16	6 (38)	3	2 (67)	19	8 (42)
Non-IDU	9	0 (0)	--	--	9	0 (0)
p value		0.04		--		0.02
2007						
IDU	15	3 (20)	--	--	15	3 (20)
Non-IDU	17	0 (0)	--	--	17	0 (0)
p value		0.05		--		0.05
2010						
IDU	17	2 (12)	1	0 (0)	18	2 (11)
Non-IDU	12	3 (25)	--	--	12	3 (25)
p value		0.4		--		0.3

† Excludes equivocal test results and missing values.

Table 292 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	25	6 (24)	2	2 (100)	27	8 (30)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		0.08		0.5
2007						
Heterosexual	32	3 (9)	--	--	32	3 (9)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2010						
Heterosexual	28	4 (14)	1	0 (0)	29	4 (14)
Bisexual	1	1 (100)	--	--	1	1 (100)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.03		--		0.02

† Excludes equivocal test results and missing values.

Table 293 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	2	0 (0)	1	1 (100)	3	1 (33)
25 – 29	8	3 (38)	3	1 (33)	11	4 (36)
30 + years	16	3 (19)	--	-	16	3 (19)
p value		0.6		0.3		0.7
2007						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	8	0 (0)	--	--	8	0 (0)
25 – 29	6	0 (0)	--	--	6	0 (0)
30 + years	17	3 (18)	--	--	17	3 (18)
p value		0.4		--		0.4
2010						
< 20 years	3	0 (0)	--	--	3	0 (0)
20 – 24	7	0 (0)	1	0 (0)	8	0 (0)
25 – 29	6	1 (17)	--	--	6	1 (17)
30 + years	13	4 (31)	--	--	13	4 (31)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 294 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	1	1 (100)	1	1 (100)
6 to 10 years	6	1 (17)	1	1 (100)	7	2 (29)
10 + years	9	4 (44)	1	0 (0)	10	4 (40)
p value		0.3		0.2		0.4
2007						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	--	--	--	--	--	--
6 to 10 years	4	0 (0)	--	--	4	0 (0)
10 + years	10	3 (30)	--	--	10	3 (30)
p value		0.4		--		0.4
2010						
<3 years	4	0 (0)	--	--	4	0 (0)
3 to 5 years	3	0 (0)	--	--	3	0 (0)
6 to 10 years	2	0 (0)	1	0 (0)	3	0 (0)
10 + years	8	2 (25)	--	--	8	2 (25)
p value		0.5		--		0.4

† Excludes equivocal test results and missing values.

Table 295 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	--	--	10	5 (50)	10	5 (50)
Heroin	--	--	1	0 (0)	1	0 (0)
More than one	--	--	7	2 (29)	7	2 (29)
Other/not reported	--	--	--	--	--	--
p value		--		0.4		0.4
2007						
Amphetamine (Speed, Ice)	1	0 (0)	10	1 (10)	11	1 (9)
Heroin	--	--	1	1 (100)	1	1 (100)
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	1 (33)	3	1 (33)
p value		--		0.1		0.08
2010						
Amphetamine (Speed, Ice)	3	0 (0)	8	1 (13)	11	1 (9)
Heroin	--	--	--	--	--	--
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		0.9		0.8

† Excludes equivocal test results and missing values.

Table 296 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	--	--	6	1 (17)	6	1 (17)
Daily or more	--	--	4	3 (75)	4	3 (75)
p value		--		0.07		0.07
2007						
Less than daily	--	--	5	1 (20)	5	1 (20)
Daily or more	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		1.0		0.9
2010						
Less than daily	2	0 (0)	5	1 (20)	7	1 (14)
Daily or more	--	--	2	0 (0)	2	0 (0)
p value		--		0.5		0.6

† Excludes equivocal test results and missing values.

Table 297 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	8	3 (38)	8	3 (38)
Yes	--	--	3	1 (33)	3	1 (33)
p value		--		0.9		0.9
2007						
No	1	0 (0)	10	2 (20)	11	2 (18)
Yes	--	--	--	--	--	--
p value		--		--		--
2010						
No	2	0 (0)	6	1 (17)	8	1 (13)
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 298 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	8	3 (38)	8	3 (38)
Yes	--	--	7	2 (29)	7	2 (29)
p value		--		0.5		0.5
2007						
No	--	--	4	1 (25)	4	1 (25)
Yes	--	--	10	2 (20)	10	2 (20)
p value		--		0.8		0.8
2010						
No	3	0 (0)	7	0 (0)	10	0 (0)
Yes	1	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.1		0.1

† Excludes equivocal test results and missing values.

Table 299 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	10	3 (30)	--	--	10	3 (30)
2 to 4	9	1 (11)	1	1 (100)	10	2 (20)
5 to 9	4	1 (25)	1	0 (0)	5	1 (20)
10 +	--	--	1	1 (100)	1	1 (100)
p value		0.6		0.2		0.4
2007						
1	7	0 (0)	--	--	7	0 (0)
2 to 4	15	1 (7)	--	--	15	1 (7)
5 to 9	9	2 (22)	--	--	9	2 (22)
10 +	1	0 (0)	--	--	1	0 (0)
p value		0.4		--		0.4
2010						
1	9	2 (22)	--	--	9	2 (22)
2 to 4	13	1 (8)	1	0 (0)	14	1 (7)
5 to 9	4	2 (50)	--	--	4	2 (50)
10 +	3	0 (0)	--	--	3	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 300 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	16	4 (25)	2	1 (50)	18	5 (28)
Indigenous	3	1 (33)	--	--	3	1 (33)
p value		0.8		--		0.8
2007						
Non-Indigenous	28	1 (4)	--	--	28	1 (4)
Indigenous	4	2 (50)	--	--	4	2 (50)
p value		0.003		--		0.003
2010						
Non-Indigenous	24	5 (21)	1	0 (0)	25	5 (20)
Indigenous	5	0 (0)	--	--	5	0 (0)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 301 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	5	0 (0)	12	5 (42)	17	5 (29)
Indigenous	2	0 (0)	1	1 (100)	3	1 (33)
p value		--		0.3		0.9
2007						
Non-Indigenous	16	0 (0)	12	1 (8)	28	1 (4)
Indigenous	1	0 (0)	3	2 (67)	4	2 (50)
p value		--		0.02		0.003
2010						
Non-Indigenous	9	3 (33)	16	2 (13)	25	5 (20)
Indigenous	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.3		0.6		0.3

† Excludes equivocal test results and missing values.

Table 302 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	19	3 (16)	2	1 (50)	21	4 (19)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.4		--		0.5
2007						
Highly accessible/accessible	24	2 (8)	--	--	24	2 (8)
Moderately accessible	4	1 (25)	--	--	4	1 (25)
Remote/very remote	4	0 (0)	--	--	4	0 (0)
p value		0.5		--		0.5
2010						
Highly accessible/accessible	21	3 (14)	1	0 (0)	22	3 (14)
Moderately accessible	5	2 (40)	--	--	5	2 (40)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.4		--		0.3

† Excludes equivocal test results and missing values.

Table 303 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	25	6 (24)	3	2 (67)	28	8 (29)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	31	3 (10)	--	--	31	3 (10)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.7
2010						
Australia	29	5 (17)	1	0 (0)	30	5 (17)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 304 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	25	6 (24)	3	2 (67)	28	8 (29)
Non-English	--	--	--	--	--	--
p value		--		--		--
2007						
English	31	3 (10)	--	--	31	3 (10)
Non-English	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.7
2010						
English	28	5 (18)	1	0 (0)	29	5 (17)
Non-English	1	0 (0)	--	--	1	0 (0)
p value		0.6		--		0.7

† Excludes equivocal test results and missing values.

Table 305 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	20	7 (35)	7 (35)	1 (5)	5 (25)
Non-IDU	9	8 (89)	0 (0)	0 (0)	1 (11)
p value					0.05
2007					
IDU	7	2 (29)	3 (43)	0 (0)	2 (29)
Non-IDU	7	0 (0)	0 (0)	0 (0)	7 (100)
p value					0.02
2010					
IDU	17	10 (59)	2 (12)	0 (0)	5 (29)
Non-IDU	11	6 (55)	3 (27)	0 (0)	2 (18)
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 306 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	28	14 (50)	7 (25)	1 (4)	6 (21)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					0.8
2007					
Heterosexual	14	2 (14)	3 (21)	0 (0)	9 (64)
Homosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2010					
Heterosexual	27	16 (59)	4 (15)	0 (0)	7 (26)
Homosexual	--	--	--	--	--
Bisexual	1	0 (0)	1 (100)	0 (0)	0 (0)
Unsure	--	--	--	--	--
p value					0.09

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 307 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	1	1 (100)	0 (0)	0 (0)	0 (0)
20 – 24	3	1 (33)	0 (0)	1 (33)	1 (33)
25 – 29	12	7 (58)	4 (33)	0 (0)	1 (8)
30 + years	16	9 (56)	3 (19)	0 (0)	4 (25)
p value					0.1
2007					
< 20 years	1	0 (0)	0 (0)	0 (0)	1 (100)
20 – 24	4	0 (0)	0 (0)	0 (0)	4 (100)
25 – 29	1	0 (0)	0 (0)	0 (0)	1 (100)
30 + years	8	2 (25)	3 (38)	0 (0)	3 (38)
p value					0.4
2010					
< 20 years	2	1 (50)	0 (0)	0 (0)	1 (50)
20 – 24	7	4 (57)	0 (0)	0 (0)	3 (43)
25 – 29	6	5 (83)	1 (17)	0 (0)	0 (0)
30 + years	13	6 (46)	4 (31)	0 (0)	3 (23)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 308 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	10	5 (50)	3 (30)	0 (0)	2 (20)
2 to 4	10	8 (80)	1 (10)	1 (10)	0 (0)
5 to 9	6	1 (17)	1 (17)	0 (0)	4 (67)
10 +	1	0 (0)	1 (100)	0 (0)	0 (0)
p value					0.05
2007					
1	4	0 (0)	0 (0)	0 (0)	4 (100)
2 to 4	4	1 (25)	1 (25)	0 (0)	2 (50)
5 to 9	5	0 (0)	2 (40)	0 (0)	3 (60)
10 +	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.1
2010					
1	9	4 (44)	2 (22)	0 (0)	3 (33)
2 to 4	12	9 (75)	1 (8)	0 (0)	2 (17)
5 to 9	4	2 (50)	2 (50)	0 (0)	0 (0)
10 +	3	1 (33)	0 (0)	0 (0)	2 (67)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 309 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	18	9 (50)	4 (22)	1 (6)	4 (22)
Indigenous	3	2 (67)	1 (33)	0 (0)	0 (0)
p value					0.8
2007					
Non-Indigenous	12	2 (17)	1 (8)	0 (0)	9 (75)
Indigenous	2	0 (0)	2 (100)	0 (0)	0 (0)
p value					0.01
2010					
Non-Indigenous	24	12 (50)	5 (21)	0 (0)	7 (29)
Indigenous	4	4 (100)	0 (0)	0 (0)	0 (0)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 310 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	22	12 (55)	4 (18)	0 (0)	6 (27)
Moderately accessible	2	1 (50)	1 (50)	0 (0)	0 (0)
Remote/very remote	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.7
2007					
Highly accessible/accessible	13	2 (15)	2 (15)	0 (0)	9 (69)
Moderately accessible	1	0 (0)	1 (100)	0 (0)	0 (0)
Remote/very remote	--	--	--	--	--
p value					0.1
2010					
Highly accessible/accessible	21	12 (57)	3 (14)	0 (0)	6 (29)
Moderately accessible	5	3 (60)	2 (40)	0 (0)	0 (0)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 311 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	29	15 (52)	7 (24)	1 (3)	6 (21)
Non-English	--	--	--	--	--
p value					--
2007					
English	14	2 (14)	3 (21)	0 (0)	9 (64)
Non-English	--	--	--	--	--
p value					--
2010					
English	27	15 (56)	5 (19)	0 (0)	7 (26)
Non-English	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.7

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 312 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	9	0 (0)	--	--	9	0 (0)
Yes	10	6 (60)	1	0 (0)	11	6 (55)
Not sure	1	0 (0)	--	--	1	0 (0)
p value		0.01		--		0.02
2007						
No	1	0 (0)	--	--	1	0 (0)
Yes	9	8 (89)	--	--	9	8 (89)
Not sure	1	1 (100)	--	--	1	1 (100)
p value		0.08		--		0.08
2010						
No	5	0 (0)	1	1 (100)	6	1 (17)
Yes	14	6 (43)	--	--	14	6 (43)
Not sure	3	0 (0)	--	--	3	0 (0)
p value		0.1		--		0.2

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 313 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	10	0 (0)
Female	--	--
p value		--

† Excludes missing values.

Gonorrhoea

Table 314 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	--	--
Female	--	--
p value		--

† Excludes missing values.

Syphilis

Table 315 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	5	0 (0)	0 (0)	0 (0)
Female		--	--	--
p value		--	--	--

† Excludes missing values.

Victoria
2007, 2010

Table 316 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed			N = 2		N = 2	
N° surveyed	--	--	N = 87	N = 75	N = 31	N = 17
Sex (%)						
Male	--	--	78 (90)	71 (95)	27 (87)	15 (88)
Female	--	--	9 (10)	4 (5)	4 (13)	2 (12)
Transgender	--	--	--	--	--	--
Sexual identity (%)						
Heterosexual	--	--	84 (97)	73 (97)	29 (94)	15 (88)
Bisexual	--	--	1 (1)	1 (1)	1 (3)	--
Homosexual	--	--	--	1 (1)	1 (3)	1 (6)
Unsure	--	--	2 (2)	--	--	--
Not reported	--	--	--	--	--	1 (6)
Age and duration of injection (years)						
Median age (years)	--	--	32	32	30	32
Age range	--	--	18 – 54	18 – 77	21 – 55	20 – 75
Age group (%)						
<25 years	--	--	12 (14)	22 (29)	6 (19)	3 (18)
25+ years	--	--	75 (86)	53 (71)	25 (81)	14 (82)
Not reported	--	--	--	--	--	--
Median age 1 st IDU (years)	--	--	18	--	17	--
Age range	--	--	10 – 35	--	13 – 39	--
Not reported	--	--	--	--	--	--
Median years IDU	--	--	12	--	11	--
Range	--	--	<1 – 29	--	2 – 35	--
Duration of drug injection (%)						
<3 years	--	--	4 (5)	--	2 (6)	--
3+ years	--	--	83 (95)	--	29 (94)	--
Not reported	--	--	--	--	--	--
Aboriginal and Torres Strait Islander origin (%)						
No	--	--	80 (92)	73 (97)	27 (87)	16 (94)
Yes	--	--	7 (8)	2 (3)	4 (13)	1 (6)
Not reported	--	--	--	--	--	--
Living situation prior to prison (%)*						
Not homeless	--	--	n/a	n/a	--	--
Primary homelessness	--	--	n/a	n/a	--	--
Secondary homelessness	--	--	n/a	n/a	--	--
Tertiary homelessness	--	--	n/a	n/a	--	--
Not reported	--	--	n/a	n/a	31 (100)	17 (100)
Residential remoteness in 12 months before prison (%)						
Highly accessible/accessible	--	--	83 (95)	66 (88)	31 (100)	12 (71)
Moderately accessible	--	--	2 (2)	5 (7)	--	--
Remote/very remote	--	--	1 (1)	--	--	3 (18)
Not reported	--	--	1 (1)	4 (5)	--	2 (12)
Region/Country of birth (%)						
Australia	--	--	67 (77)	62 (83)	28 (90)	12 (71)
Other Oceania	--	--	3 (3)	2 (3)	--	1 (6)
Asia	--	--	6 (7)	4 (5)	--	3 (18)
UK & Ireland	--	--	4 (5)	1 (1)	1 (3)	--
Other	--	--	7 (8)	5 (7)	1 (3)	1 (6)
Not reported	--	--	--	1 (1)	1 (3)	--
Main language spoke at home by parents (%)						
English	--	--	72 (83)	59 (79)	30 (97)	12 (71)
Non-English	--	--	14 (16)	14 (19)	1 (3)	5 (29)
Not reported	--	--	1 (1)	2 (3)	--	--

* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers' accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010.

Table 316 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)						
No	--	--	69 (79)	25 (33)	25 (81)	8 (47)
Yes	--	--	18 (21)	50 (67)	6 (19)	9 (53)
Not reported	--	--	--	--	--	--
Lifetime imprisonments (%)						
One	--	--	18 (21)	50 (67)	11 (35)	13 (76)
Two to four	--	--	33 (38)	17 (23)	11 (35)	3 (18)
Five to nine	--	--	24 (28)	6 (8)	5 (16)	1 (6)
Ten or more	--	--	12 (14)	2 (3)	4 (13)	--
Not reported	--	--	--	--	--	--
Imprisonment in last year (%)						
No	--	--	22 (32)	6 (24)	16 (52)	13 (76)
Yes	--	--	47 (68)	19 (76)	13 (42)	2 (12)
Not reported	--	--	--	--	2 (6)	2 (12)
Frequency of injection last month (%)						
Not last month	--	--	27 (31)	--	8 (26)	--
Less than weekly	--	--	7 (8)	--	9 (29)	--
Weekly not daily	--	--	17 (20)	--	1 (3)	--
Daily or more	--	--	36 (41)	--	13 (42)	--
Not reported	--	--	--	--	--	--
Ever smoked a full cigarette (%)*						
No	--	--	1 (1)	12 (16)	--	2 (12)
Yes	--	--	86 (99)	63 (84)	31 (100)	14 (82)
Not reported	--	--	--	--	--	1 (6)
<i>Median age first smoked (years)</i>	--	--	13	15	13	14
<i>Age range</i>	--	--	5 – 25	9 – 30	7 – 35	10 – 21
Current smoker (%)*						
No	--	--	4 (5)	24 (32)	1 (3)	4 (24)
Yes	--	--	83 (95)	51 (68)	30 (97)	12 (71)
Not reported	--	--	--	--	--	1 (6)
Smoking frequency (%)*						
Occasional – weekly or less	--	--	1 (1)	2 (4)	--	--
5 to 10 cigarettes a day	--	--	30 (36)	19 (37)	9 (30)	6 (50)
11 to 20 cigarettes a day	--	--	32 (39)	16 (31)	14 (47)	3 (25)
Over 20 cigarettes a day	--	--	20 (24)	14 (27)	7 (23)	3 (25)
Not reported	--	--	--	--	--	--
Other drugs used last month (%)**						
No drugs in past 4 weeks	--	--	n/a	n/a	3 (14)	5 (42)
Cannabis	--	--	n/a	n/a	14 (74)	6 (86)
Heroin	--	--	n/a	n/a	9 (47)	1 (14)
Cocaine	--	--	n/a	n/a	1 (5)	1 (14)
Amphetamine	--	--	n/a	n/a	11 (58)	3 (43)
Other's methadone	--	--	n/a	n/a	3 (16)	--
Other opiates	--	--	n/a	n/a	6 (32)	1 (14)
Other's buprenorphine	--	--	n/a	n/a	5 (26)	--
Steroids	--	--	n/a	n/a	2 (11)	--
Hallucinogens	--	--	n/a	n/a	3 (16)	--
Benzodiazepines	--	--	n/a	n/a	10 (53)	--
Ecstasy/MDA	--	--	n/a	n/a	2 (11)	--
Inhalants (e.g. petrol)	--	--	n/a	n/a	--	--
Other drug	--	--	n/a	n/a	--	--
Not reported	--	--	n/a	n/a	9 (29)	5 (29)

* Smoking questions not asked in 2004.

** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 317 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010
Last drug injected (%)		N = 87	N = 31
Amphetamine (Speed, Ice)	--	37 (43)	12 (39)
Anabolic steroids	--	--	--
Cocaine	--	1 (1)	--
Heroin	--	43 (49)	14 (45)
Heroin + amphetamine	--	4 (5)	--
Heroin + cocaine	--	--	2 (6)
Methadone	--	--	--
Morphine	--	2 (2)	2 (6)
Other	--	--	1 (3)
Not reported	--	--	--
N° Injected last month	--	N = 60	N = 23
Places injected last month (%)*			
Prison	--	1 (2)	1 (4)
Own home	--	47 (78)	15 (65)
Friend's home	--	32 (53)	8 (35)
Dealer's home	--	15 (25)	3 (13)
Street, park, beach	--	21 (35)	7 (30)
Car	--	34 (57)	9 (39)
Public toilet	--	16 (27)	6 (26)
Commercial injecting room	--	--	--
Medically Supervised Injecting Centre, Sydney	--	--	--
Squat	--	3 (5)	2 (9)
Other place	--	6 (10)	--
Use of sterile needles & syringes last month (%)			
All injections	--	44 (73)	11 (48)
Most of the time	--	13 (22)	9 (39)
Half of the time	--	--	2 (9)
Some of the time	--	2 (3)	1 (4)
Not last month	--	--	--
Not reported	--	1 (2)	--
Re-used someone else's used needle & syringe last month (%)			
None	--	50 (83)	18 (78)
Once	--	3 (5)	3 (13)
Twice	--	2 (3)	--
3-5 times	--	1 (2)	--
>5 times	--	1 (2)	2 (9)
Not reported	--	3 (5)	--
Number of people needle & syringe was re-used after last month (%)			
None	--	50 (83)	18 (78)
One	--	3 (5)	2 (9)
Two	--	2 (3)	--
Three to five	--	1 (2)	1 (4)
More than five	--	1 (2)	--
Don't know how many	--	--	2 (9)
Not reported	--	3 (5)	--
Relationship to people needle & syringe was re-used after last month (%)*			
Regular sex partner	--	6 (10)	4 (17)
Casual sex partner	--	--	--
Close friend	--	3 (5)	--
Acquaintance	--	--	2 (9)
Other	--	1 (2)	1 (4)
Equipment used after someone else last month (%)*			
Spoon	--	22 (37)	10 (43)
Water	--	10 (17)	7 (30)
Filter	--	11 (18)	6 (26)
Tourniquet	--	4 (7)	3 (13)
Drug mix	--	6 (10)	5 (22)

* More than one option could be selected.

Table 318 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment for drug use	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75	N = 31	N = 17
Any treatment/therapy for drug use (%)						
No	--	--	14 (16)	42 (56)	6 (19)	14 (82)
Yes	--	--	71 (82)	13 (17)	24 (77)	3 (18)
Not reported			2 (2)	20 (27)	1 (3)	--
History of methadone maintenance treatment (%)						
Currently	--	--	37 (43)	--	9 (29)	--
Previously	--	--	16 (18)	--	4 (13)	--
Never	--	--	32 (37)	--	17 (55)	17 (100)
Not reported			2 (2)	--	1 (3)	--
History of other pharmacotherapy treatment (%)						
Currently	--	--	40 (46)	--	4 (13)	--
Previously	--	--	12 (14)	--	7 (23)	--
Never	--	--	35 (40)	--	19 (61)	17 (100)
Not reported			--	--	1 (3)	--

Table 319 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010
N° surveyed	--	N = 60	N = 31
From an NSP last month (%)			
Daily or almost daily	--	13 (22)	7 (23)
A couple of times each week	--	23 (38)	2 (6)
Less than weekly	--	8 (13)	6 (19)
Weekly	--	n/a	2 (6)
Once last month	--	7 (12)	1 (3)
Not in the last month	--	9 (15)	12 (39)
Not reported	--	--	1 (3)
From a chemist last month (%)			
Daily or almost daily	--	1 (2)	2 (6)
A couple of times each week	--	11 (18)	4 (13)
Less than weekly	--	5 (8)	2 (6)
Weekly	--	n/a	5 (16)
Once last month	--	10 (17)	--
Not in the last month	--	33 (55)	17 (55)
Not reported	--	--	1 (3)

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 320 Number (%) of respondents by body piercing and tattoos

Body piercing and tattoos	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75	N = 31	N = 17
Body or ear piercings (%)						
No	--	--	35 (40)	53 (71)	14 (45)	12 (71)
Yes	--	--	52 (60)	22 (29)	17 (55)	5 (59)
Not reported	--	--	--	--	--	--
Pierced in past 12 mths (%)						
No	--	--	42 (81)	16 (73)	8 (47)	1 (20)
Yes	--	--	6 (12)	4 (18)	2 (12)	--
Not reported	--	--	4 (8)	2 (9)	7 (41)	4 (80)
Who did piercing (%)*						
Chemist/hairdresser/beauty salon	--	--	1 (17)	2 (50)	--	--
Professional piercer / studio	--	--	2 (33)	--	--	--
Tattooist / parlour	--	--	--	2 (50)	1 (50)	--
Friend	--	--	1 (17)	--	1 (50)	--
Prison inmate	--	--	--	--	--	--
Self	--	--	1 (17)	--	1 (50)	--
Family member	--	--	--	--	--	--
Other	--	--	--	--	--	--
Needle used by other (%)						
No	--	--	1 (20)	--	2 (100)	--
Yes	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
Not reported	--	--	4 (80)	4 (100)	--	--
Tattoos (%)						
No	--	--	26 (30)	45 (60)	8 (26)	10 (59)
Yes	--	--	61 (70)	30 (40)	23 (74)	7 (41)
Not reported	--	--	--	--	--	--
Tattoos in past 12 mths (%)						
No	--	--	41 (67)	17 (57)	16 (65)	3 (43)
Yes	--	--	20 (33)	13 (43)	7 (30)	4 (57)
Not reported	--	--	--	--	1 (4)	--
Who did tattooing (%)*						
Professional tattooist	--	--	15 (75)	10 (77)	4 (57)	3 (75)
Friend	--	--	4 (20)	1 (8)	1 (14)	3 (75)
Prison inmate	--	--	4 (20)	1 (8)	--	--
Self	--	--	1 (5)	2 (15)	--	--
Family member	--	--	--	--	--	--
Other	--	--	--	--	--	--

* More than one option could be selected.

Table 321 Number (%) of respondents by sexual behaviour **in the month** (3 months) prior to survey by injector status and survey year

Sexual behaviour	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75	N = 31	N = 17
Sex last month / last 3 months (%)**						
No	--	--	19 (22)	20 (27)	1 (11)	8 (12)
Yes	--	--	68 (78)	55 (73)	8 (89)	57 (86)
Not reported	--	--	--	--	--	1 (2)
Male sex partners in last 3 months**						
Median	--	--	n/a	n/a	1	0.5
Range	--	--	n/a	n/a	1 – 4	0 – 2
Female sex partners in last 3 months**						
Median	--	--	n/a	n/a	1	1
Range	--	--	n/a	n/a	0 - 20	0 – 5
Condom use at last sex (%)						
No	--	--	69 (79)	48 (64)	n/a	n/a
Yes	--	--	18 (21)	27 (36)	n/a	n/a
Not reported	--	--	--	--	n/a	n/a
Condom use with regular sex partner(s) last month (%)*						
No	--	--	41 (85)	33 (70)	n/a	n/a
Sometimes	--	--	7 (15)	7 (15)	n/a	n/a
Always	--	--	--	7 (15)	n/a	n/a
Condom use with new sex partner(s) last month (%)*						
No	--	--	10 (56)	1 (13)	n/a	n/a
Sometimes	--	--	3 (17)	3 (38)	n/a	n/a
Always	--	--	5 (28)	4 (50)	n/a	n/a
Condom use with casual sex partner(s) last month (%)*						
No	--	--	15 (58)	3 (33)	n/a	n/a
Sometimes	--	--	4 (15)	3 (33)	n/a	n/a
Always	--	--	7 (27)	3 (33)	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**						
Never	--	--	n/a	n/a	5 (83)	--
Sometimes	--	--	n/a	n/a	1 (17)	1 (100)
Always	--	--	n/a	n/a	--	--
Condom use last sex - casual male partners - last 3 months (%)**						
Never	--	--	n/a	n/a	2 (50)	--
Sometimes	--	--	n/a	n/a	1 (25)	1 (100)
Always	--	--	n/a	n/a	1 (25)	--
Condom use last sex - regular female partners - last 3 months (%)**						
Never	--	--	n/a	n/a	14 (78)	6 (46)
Sometimes	--	--	n/a	n/a	4 (22)	4 (31)
Always	--	--	n/a	n/a	--	3 (23)
Condom use last sex - casual female partners - last 3 months (%)**						
Never	--	--	n/a	n/a	5 (42)	1 (100)
Sometimes	--	--	n/a	n/a	4 (33)	--
Always	--	--	n/a	n/a	3 (25)	--
Sex work last month (%)						
No	--	--	85 (98)	74 (99)	27 (87)	15 (88)
Yes	--	--	2 (2)	--	2 (6)	1 (6)
Not reported	--	--	--	1 (1)	2 (6)	1 (6)
Condom used at last sex work last month (%)						
No	--	--	--	--	1 (50)	--
Yes	--	--	2 (100)	--	1 (50)	1 (100)
Not reported	--	--	--	--	--	--
Ever had cervical cancer vaccine (women only)*** (%)						
No	--	--	n/a	n/a	2 (100)	1 (50)
Yes	--	--	n/a	n/a	--	1 (50)
Unsure	--	--	n/a	n/a	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

*** Proportion of eligible women i.e. those under 27 years of age in 2007.

Table 322 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75	N = 31	N = 17
Previous HIV test (%)						
Yes, last year	--	--	43 (49)	13 (17)	13 (42)	5 (29)
>1 year ago	--	--	28 (32)	19 (25)	13 (42)	5 (29)
Never tested	--	--	16 (18)	43 (57)	4 (13)	6 (35)
Not reported			--	--	1 (3)	1 (6)
HBV infection (%)						
No	--	--	67 (77)	72 (96)	25 (81)	13 (76)
Yes	--	--	9 (10)	--	4 (13)	2 (12)
Don't know	--	--	11 (13)	2 (3)	2 (6)	2 (12)
Not reported			--	1 (1)	--	--
HBV vaccination (%)*						
No	--	--	25 (29)	43 (57)	5 (16)	6 (35)
Yes	--	--	51 (59)	20 (27)	15 (48)	6 (35)
Don't know	--	--	10 (11)	11 (15)	11 (35)	5 (29)
Not reported			1 (1)	1 (1)	--	--
Previous HCV test (%)						
Yes, last year	--	--	11 (13)	53 (71)	18 (58)	5 (29)
>1 year ago	--	--	41 (47)	10 (13)	12 (39)	6 (35)
Never tested	--	--	35 (40)	12 (16)	1 (3)	6 (35)
Unsure	--	--	--	--	--	--
Not reported	--	--	--	--	--	--
Any HCV treatment (%)**			N = 46	N = 3	N = 9	N = 1
Interferon	--	--	--	--	--	--
Interferon & Ribavirin	--	--	--	--	--	--
Pegasys & Ribavirin	--	--	1 (2)	--	--	--
Other	--	--	--	--	--	--
No treatment	--	--	45 (98)	3 (100)	9 (100)	1 (100)
Not reported	--	--	--	--	--	--
Current HCV treatment						
Interferon	--	--	--	--	--	--
Interferon & Ribavirin	--	--	--	--	--	--
Pegasys & Ribavirin	--	--	1 (2)	--	--	--
Other	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Number (%) of those testing positive for hepatitis C antibodies.

HIV antibody prevalence

Table 323 HIV antibody prevalence by sex, injector status and survey year

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	59	0 (0)	5	0 (0)	64	0 (0)
Non-IDU	49	0 (0)	4	0 (0)	53	0 (0)
p value		--		--		--
2010						
IDU	17	0 (0)	3	0 (0)	20	0 (0)
Non-IDU	9	0 (0)	2	0 (0)	11	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 324 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	49	2 (4)	4	1 (25)	53	3 (6)
Non-IDU	59	40 (68)	7	6 (86)	66	46 (70)
p value		<0.001		0.04		<0.001
2010						
IDU	15	6 (40)	3	3 (100)	18	9 (50)
Non-IDU	10	1 (10)	2	0 (0)	12	1 (8)
p value		0.1		0.03		0.02

† Excludes equivocal test results and missing values.

Table 325 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	--	--	--	--	--	--
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	106	42 (40)	9	6 (67)	115	48 (42)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.5		0.3		0.5
2010						
Heterosexual	23	6 (26)	4	2 (50)	27	8 (30)
Bisexual	--	--	1	1 (100)	1	1 (100)
Homosexual	1	1 (100)	--	--	1	1 (100)
Unsure	--	--	--	--	--	--
p value		0.1		0.4		0.1

† Excludes equivocal test results and missing values.

Table 326 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	--	--	--	--	--	--
20 – 24	--	--	--	--	--	--
25 – 29	--	--	--	--	--	--
30 + years	--	--	--	--	--	--
p value		--		--		--
2007						
< 20 years	6	0 (0)	--	--	6	0 (0)
20 – 24	21	4 (19)	--	--	21	4 (19)
25 – 29	25	17 (68)	3	2 (67)	28	19 (68)
30 + years	56	21 (38)	8	5 (63)	64	26 (41)
p value		0.001		0.9		0.001
2010						
< 20 years	--	--	--	--	--	--
20 – 24	8	3 (38)	--	--	8	3 (38)
25 – 29	5	1 (20)	3	1 (33)	8	2 (25)
30 + years	12	3 (25)	2	2 (100)	14	5 (36)
p value		0.8		0.1		0.8

† Excludes equivocal test results and missing values.

Table 327 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	--	--	--	--	--	--
10 + years	--	--	--	--	--	--
p value		--		--		--
2007						
<3 years	3	0 (0)	--	--	3	0 (0)
3 to 5 years	7	4 (57)	1	1 (100)	8	5 (63)
6 to 10 years	17	9 (53)	2	1 (50)	19	10 (53)
10 + years	32	27 (84)	4	4 (100)	36	31 (86)
p value		0.006		0.2		0.003
2010						
<3 years	2	0 (0)	--	--	2	0 (0)
3 to 5 years	4	2 (50)	--	--	4	2 (50)
6 to 10 years	3	1 (33)	1	1 (100)	4	2 (50)
10 + years	6	3 (50)	2	2 (100)	8	5 (63)
p value		0.6		--		0.5

† Excludes equivocal test results and missing values.

Table 328 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	--	--	--	--	--	--
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	--	--	--	--
p value		--		--		--
2007						
Amphetamine (Speed, Ice)	3	0 (0)	27	15 (56)	30	15 (50)
Heroin	--	--	30	26 (87)	30	26 (87)
More than one	--	--	4	3 (75)	4	3 (75)
Other/not reported	--	--	2	2 (100)	2	2 (100)
p value		--		0.05		0.02
2010						
Amphetamine (Speed, Ice)	1	0 (0)	5	3 (60)	6	3 (50)
Heroin	1	0 (0)	7	5 (71)	8	5 (63)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	2	1 (50)	2	1 (50)
p value		--		0.4		0.5

† Excludes equivocal test results and missing values.

Table 329 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	--	--	--	--	--	--
Daily or more	--	--	--	--	--	--
p value		--		--		--
2007						
Less than daily	--	--	20	16 (80)	20	16 (80)
Daily or more	--	--	26	23 (88)	26	23 (88)
p value		--		0.4		0.4
2010						
Less than daily	--	--	5	2 (40)	5	2 (40)
Daily or more	2	0 (0)	8	6 (75)	10	6 (60)
p value		--		0.2		0.5

† Excludes equivocal test results and missing values.

Table 330 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	--	--	36	30 (83)	36	30 (83)
Yes	--	--	9	8 (89)	9	8 (89)
p value		--		0.7		0.7
2010						
No	2	0 (0)	9	5 (56)	11	5 (45)
Yes	--	--	2	2 (100)	2	2 (100)
p value		--		0.2		0.2

† Excludes equivocal test results and missing values.

Table 331 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	--	--	13	10 (77)	13	10 (77)
Yes	1	0 (0)	35	32 (91)	36	32 (89)
p value		--		0.2		0.3
2010						
No	1	0 (0)	8	5 (63)	9	5 (56)
Yes	--	--	8	4 (50)	8	4 (50)
p value		--		0.6		0.8

† Excludes equivocal test results and missing values.

Table 332 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	--	--	--	--	--	--
2 to 4	--	--	--	--	--	--
5 to 9	--	--	--	--	--	--
10 +	--	--	--	--	--	--
p value		--		--		--
2007						
1	48	2 (4)	6	3 (50)	54	5 (9)
2 to 4	33	17 (52)	3	2 (67)	36	19 (53)
5 to 9	17	15 (88)	2	2 (100)	19	17 (89)
10 +	10	8 (80)	--	--	10	8 (80)
p value		<0.001		0.4		<0.001
2010						
1	13	4 (31)	2	0 (0)	15	4 (27)
2 to 4	8	2 (25)	2	2 (100)	10	4 (40)
5 to 9	3	1 (33)	--	--	3	1 (33)
10 +	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.9		0.08		0.9

† Excludes equivocal test results and missing values.

Table 333 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	100	37 (37)	10	6 (60)	110	43 (39)
Indigenous	8	5 (63)	1	1 (100)	9	6 (67)
p value		0.2		0.4		0.1
2010						
Non-Indigenous	22	6 (27)	5	3 (60)	27	9 (33)
Indigenous	3	1 (33)	--	--	3	1 (33)
p value		0.8		--		1.0

† Excludes equivocal test results and missing values.

Table 334 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	51	3 (6)	59	40 (68)	110	43 (39)
Indigenous	2	0 (0)	7	6 (86)	9	6 (67)
p value		0.7		0.3		0.1
2010						
Non-Indigenous	11	1 (9)	16	8 (50)	27	9 (33)
Indigenous	1	0 (0)	2	1 (50)	3	1 (33)
p value		0.8		1.0		1.0

† Excludes equivocal test results and missing values.

Table 335 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	--	--	--	--	--	--
Moderately accessible	--	--	--	--	--	--
Remote/very remote	--	--	--	--	--	--
p value		--		--		--
2007						
Highly accessible/accessible	98	42 (43)	11	7 (64)	109	49 (45)
Moderately accessible	6	0 (0)	--	--	6	0 (0)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.08		--		0.07
2010						
Highly accessible/accessible	21	7 (33)	5	3 (60)	26	10 (39)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	2	0 (0)	--	--	2	0 (0)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 336 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	--	--	--	--	--	--
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	88	31 (35)	8	5 (63)	96	36 (38)
Other Oceania	3	1 (33)	1	0 (0)	4	1 (25)
Asia	8	5 (63)	1	1 (100)	9	6 (67)
UK & Ireland	3	3 (100)	1	1 (100)	4	4 (100)
Other	6	2 (33)	--	--	6	2 (33)
p value		0.1		0.4		0.6
2010						
Australia	22	6 (27)	3	3 (100)	25	9 (36)
Other Oceania	--	--	--	--	--	--
Asia	1	0 (0)	2	0 (0)	3	0 (0)
UK & Ireland	--	--	--	--	--	--
Other	2	1 (50)	--	--	2	1 (50)
p value		0.7		0.03		0.4

† Excludes equivocal test results and missing values.

Table 337 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	--	--	--	--	--	--
Non-English	--	--	--	--	--	--
p value		--		--		--
2007						
English	93	34 (37)	10	6 (60)	103	40 (39)
Non-English	14	7 (50)	1	1 (100)	15	8 (53)
p value		0.3		0.4		0.3
2010						
English	23	7 (30)	4	3 (75)	27	10 (37)
Non-English	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.4		0.2		0.2

† Excludes equivocal test results and missing values.

Table 338 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	--	--	--	--	--	--
Negative	--	--	--	--	--	--
Not sure	--	--	--	--	--	--
p value		--		--		--
2007						
Positive	35	35 (100)	7	7 (100)	42	42 (100)
Negative	24	4 (17)	2	0 (0)	26	4 (15)
Not sure	2	0 (0)	--	--	2	0 (0)
p value		<0.001		0.003		<0.001
2010						
Positive	4	4 (100)	3	3 (100)	7	7 (100)
Negative	14	1 (7)	1	0 (0)	15	1 (7)
Not sure	3	1 (33)	--	--	3	1 (33)
p value		0.001		0.05		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 339 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	59	4 (7)	6	0 (0)	65	4 (6)
Non-IDU	49	0 (0)	2	0 (0)	51	0 (0)
p value		0.06		--		0.07
2010						
IDU	15	0 (0)	3	0 (0)	18	0 (0)
Non-IDU	12	0 (0)	2	1 (50)	14	1 (7)
p value		--		0.2		0.3

† Excludes equivocal test results and missing values.

Table 340 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	56	23 (41)	6	2 (33)	62	25 (40)
Non-IDU	49	2 (4)	4	0 (0)	53	2 (4)
p value		<0.001		0.2		<0.001
2010						
IDU	15	2 (13)	--	--	15	2 (13)
Non-IDU	12	1 (8)	1	1 (100)	13	2 (15)
p value		0.7		--		0.9

† Excludes equivocal test results and missing values.

Table 341 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	--	--	--	--	--	--
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	103	25 (24)	8	1 (13)	111	26 (23)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.7		0.1		0.7
2010						
Heterosexual	25	2 (8)	1	1 (100)	26	3 (12)
Bisexual	--	--	--	--	--	--
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	--	--	--	--	--	--
p value		0.8		--		0.7

† Excludes equivocal test results and missing values.--

Table 342 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	--	--	--	--	--	--
20 – 24	--	--	--	--	--	--
25 – 29	--	--	--	--	--	--
30 + years	--	--	--	--	--	--
p value		--		--		--
2007						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	21	3 (14)	--	--	21	3 (14)
25 – 29	25	9 (36)	2	0 (0)	27	9 (33)
30 + years	54	13 (24)	8	2 (25)	62	15 (24)
p value		0.2		0.4		0.3
2010						
< 20 years	--	--	--	--	--	--
20 – 24	9	0 (0)	--	--	9	0 (0)
25 – 29	4	0 (0)	1	1 (100)	5	1 (20)
30 + years	14	3 (21)	--	--	14	3 (21)
p value		0.2		--		0.3

† Excludes equivocal test results and missing values.

Table 343 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	--	--	--	--	--	--
10 + years	--	--	--	--	--	--
p value		--		--		--
2007						
<3 years	4	0 (0)	--	--	4	0 (0)
3 to 5 years	7	3 (43)	1	0 (0)	8	3 (38)
6 to 10 years	16	7 (44)	2	1 (50)	18	8 (44)
10 + years	29	13 (45)	3	1 (33)	32	14 (44)
p value		0.4		0.7		0.4
2010						
<3 years	2	0 (0)	--	--	2	0 (0)
3 to 5 years	2	0 (0)	--	--	2	0 (0)
6 to 10 years	3	0 (0)	--	--	3	0 (0)
10 + years	8	2 (25)	--	--	8	2 (25)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 344 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	--	--	--	--	--	--
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	--	--	--	--
p value		--		--		--
2007						
Amphetamine (Speed, Ice)	4	0 (0)	24	6 (25)	28	6 (21)
Heroin	--	--	28	15 (54)	28	15 (54)
More than one	--	--	4	2 (50)	4	2 (50)
Other/not reported	--	--	2	2 (100)	2	2 (100)
p value		--		0.07		0.03
2010						
Amphetamine (Speed, Ice)	1	0 (0)	4	1 (25)	5	1 (20)
Heroin	1	0 (0)	5	1 (20)	6	1 (17)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	2	0 (0)	2	0 (0)
p value		--		0.8		0.8

† Excludes equivocal test results and missing values.

Table 345 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	--	--	--	--	--	--
Daily or more	--	--	--	--	--	--
p value		--		--		--
2007						
Less than daily	--	--	19	11 (58)	19	11 (58)
Daily or more	1	0 (0)	23	12 (52)	24	12 (50)
p value		--		0.7		0.6
2010						
Less than daily	--	--	4	0 (0)	4	0 (0)
Daily or more	2	0 (0)	7	1 (14)	9	1 (11)
p value		--		0.4		0.5

† Excludes equivocal test results and missing values.

Table 346 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	1	0 (0)	35	18 (51)	36	18 (50)
Yes	--	--	6	4 (67)	6	4 (67)
p value		--		0.5		0.5
2010						
No	2	0 (0)	7	1 (14)	9	1 (11)
Yes	--	--	2	0 (0)	2	0 (0)
p value		--		0.6		0.6

† Excludes equivocal test results and missing values.

Table 347 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	--	--	11	4 (36)	11	4 (36)
Yes	1	0 (0)	33	16 (48)	34	16 (47)
p value		--		0.5		0.5
2010						
No	1	0 (0)	5	2 (40)	6	2 (33)
Yes	--	--	8	0 (0)	8	0 (0)
p value		--		0.05		0.08

† Excludes equivocal test results and missing values.

Table 348 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	--	--	--	--	--	--
2 to 4	--	--	--	--	--	--
5 to 9	--	--	--	--	--	--
10 +	--	--	--	--	--	--
p value		--		--		--
2007						
1	48	5 (10)	6	1 (17)	54	6 (11)
2 to 4	33	9 (27)	3	0 (0)	36	9 (25)
5 to 9	14	7 (50)	1	1 (100)	15	8 (53)
10 +	10	4 (40)	--	--	10	4 (40)
p value		0.008		0.09		0.003
2010						
1	14	1 (7)	1	0 (0)	15	2 (13)
2 to 4	7	1 (14)	--	--	7	1 (14)
5 to 9	3	0 (0)	--	--	3	0 (0)
10 +	3	1 (33)	--	--	3	1 (33)
p value		0.5		--		0.7

† Excludes equivocal test results and missing values.

Table 349 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	97	20 (21)	9	2 (22)	106	22 (21)
Indigenous	8	5 (63)	1	0 (0)	9	5 (56)
p value		0.008		0.6		0.02
2010						
Non-Indigenous	23	2 (9)	1	1 (100)	24	3 (13)
Indigenous	4	1 (25)	--	--	4	1 (25)
p value		0.3		--		0.5

† Excludes equivocal test results and missing values.

Table 350 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	51	2 (4)	55	20 (36)	106	22 (21)
Indigenous	2	0 (0)	7	5 (71)	9	5 (56)
p value		0.8		0.08		0.02
2010						
Non-Indigenous	12	2 (17)	12	1 (8)	24	3 (13)
Indigenous	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.7		0.3		0.5

† Excludes equivocal test results and missing values.

Table 351 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	--	--	--	--	--	--
Moderately accessible	--	--	--	--	--	--
Remote/very remote	--	--	--	--	--	--
p value		--		--		--
2007						
Highly accessible/accessible	96	25 (26)	10	2 (20)	106	27 (25)
Moderately accessible	6	0 (0)	--	--	6	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.2		--		0.2
2010						
Highly accessible/accessible	23	2 (9)	1	1 (100)	24	3 (13)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	2	0 (0)	--	--	2	0 (0)
p value		0.7		--		0.6

† Excludes equivocal test results and missing values.

Table 352 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	--	--	--	--	--	--
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	85	17 (20)	7	2 (29)	92	19 (21)
Other Oceania	3	0 (0)	1	0 (0)	4	0 (0)
Asia	8	4 (50)	1	0 (0)	9	4 (44)
UK & Ireland	3	3 (100)	1	0 (0)	4	3 (75)
Other	6	1 (17)	--	--	6	1 (17)
p value		0.006		0.8		0.04
2010						
Australia	24	2 (8)	--	--	24	2 (8)
Other Oceania	--	--	--	--	--	--
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	--	--	--	--	--	--
Other	2	1 (50)	--	--	2	1 (50)
p value		0.2		--		0.09

† Excludes equivocal test results and missing values.

Table 353 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	--	--	--	--	--	--
Non-English	--	--	--	--	--	--
p value		--		--		--
2007						
English	90	19 (21)	9	2 (22)	99	21 (21)
Non-English	14	5 (36)	1	0 (0)	15	5 (33)
p value		0.3		0.6		0.3
2010						
English	24	2 (8)	--	--	24	2 (8)
Non-English	3	1 (33)	1	1 (100)	4	2 (50)
p value		0.2		--		0.03

† Excludes equivocal test results and missing values.

Table 354 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	--	--	--	--	--
Non-IDU	--	--	--	--	--
p value					--
2007					
IDU	67	26 (39)	24 (36)	4 (6)	13 (9)
Non-IDU	53	45 (85)	2 (4)	0 (0)	6 (11)
p value					<0.001
2010					
IDU	19	7 (37)	2 (11)	0 (0)	10 (53)
Non-IDU	14	8 (57)	1 (7)	1 (7)	4 (29)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 355 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2007					
Heterosexual	116	68 (59)	25 (22)	4 (3)	19 (16)
Homosexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Unsure	2	1 (50)	1 (50)	0 (0)	0 (0)
p value					1.0
2010					
Heterosexual	30	14 (47)	2 (7)	1 (3)	13 (43)
Homosexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	--	--	--	--	--
p value					0.8

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 356 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	--	--	--	--	--
20 – 24	--	--	--	--	--
25 – 29	--	--	--	--	--
30 + years	--	--	--	--	--
p value					--
2007					
< 20 years	6	3 (50)	1 (17)	0 (0)	2 (33)
20 – 24	21	11 (52)	2 (10)	1 (5)	7 (33)
25 – 29	29	14 (48)	9 (31)	1 (3)	5 (17)
30 + years	64	43 (67)	14 (22)	2 (3)	5 (8)
p value					0.2
2010					
< 20 years	--	--	--	--	--
20 – 24	9	4 (44)	0 (0)	0 (0)	5 (56)
25 – 29	7	3 (43)	0 (0)	1 (14)	3 (43)
30 + years	17	8 (47)	3 (18)	0 (0)	6 (35)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 357 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	--	--	--	--	--
2 to 4	--	--	--	--	--
5 to 9	--	--	--	--	--
10 +	--	--	--	--	--
p value					--
2007					
1	55	42 (76)	6 (11)	1 (2)	6 (11)
2 to 4	36	24 (67)	8 (22)	1 (3)	3 (8)
5 to 9	19	3 (16)	10 (53)	0 (0)	6 (32)
10 +	10	2 (20)	2 (20)	2 (20)	4 (40)
p value					<0.001
2010					
1	17	10 (59)	1 (6)	1 (6)	5 (29)
2 to 4	8	3 (38)	1 (13)	0 (0)	4 (50)
5 to 9	4	1 (25)	0 (0)	0 (0)	3 (75)
10 +	4	1 (25)	1 (25)	0 (0)	2 (50)
p value					0.7

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 358 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	--	--	--	--	--
Indigenous	--	--	--	--	--
p value					--
2007					
Non-Indigenous	111	69 (62)	21 (19)	4 (4)	17 (15)
Indigenous	9	2 (22)	5 (56)	0 (0)	2 (22)
p value					0.05
2010					
Non-Indigenous	28	15 (54)	2 (7)	1 (4)	10 (36)
Indigenous	5	0 (0)	1 (20)	0 (0)	4 (80)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 359 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	--	--	--	--	--
Moderately accessible	--	--	--	--	--
Remote/very remote	--	--	--	--	--
p value					--
2007					
Highly accessible/accessible	110	62 (56)	25 (23)	4 (4)	19 (17)
Moderately accessible	6	6 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	1	0 (0)	1 (100)	0 (0)	0 (0)
p value					0.2
2010					
Highly accessible/accessible	29	14 (48)	2 (7)	1 (3)	12 (41)
Moderately accessible	--	--	--	--	--
Remote/very remote	2	1 (50)	0 (0)	0 (0)	1 (50)
p value					0.9

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 360 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	--	--	--	--	--
Non-English	--	--	--	--	--
p value					--
2007					
English	104	62 (60)	22 (21)	2 (2)	18 (17)
Non-English	15	9 (60)	3 (20)	2 (13)	1 (7)
p value					0.1
2010					
English	28	13 (46)	2 (7)	0 (0)	13 (46)
Non-English	5	2 (40)	1 (20)	1 (20)	1 (20)
p value					0.07

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 361 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
Not sure	--	--	--	--	--	--
p value		--		--		--
2007						
No	38	3 (8)	4	0 (0)	42	3 (7)
Yes	26	12 (46)	5	2 (40)	31	14 (45)
Not sure	16	2 (13)	1	0 (0)	17	2 (12)
p value		0.001		0.3		<0.001
2010						
No	5	1 (20)	0	0 (0)	5	1 (20)
Yes	12	8 (67)	2	2 (100)	14	10 (71)
Not sure	10	3 (30)	--	--	10	3 (30)
p value		0.4		--		0.05

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 362 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	19	1 (5)
Female	6	0 (0)
p value		0.6

† Excludes missing values.

Gonorrhoea

Table 363 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	19	0 (0)
Female	6	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 364 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	27	1 (4)	0 (0)	1 (4)
Female	6	0 (0)	0 (0)	0 (0)
p value		0.6	--	0.6

† Excludes missing values.

**Western Australia
2004, 2007, 2010**

Table 365 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 3		N = 4		N = 2	
N° surveyed	N = 66	N = 47	N = 55	N = 43	N = 77	N = 45
Sex (%)						
Male	51 (77)	38 (81)	47 (85)	41 (95)	72 (94)	42 (93)
Female	15 (23)	9 (19)	8 (15)	2 (5)	5 (6)	3 (7)
Transgender	--	--	--	--	--	--
Sexual identity (%)						
Heterosexual	64 (97)	46 (98)	53 (96)	43 (100)	75 (97)	43 (96)
Bisexual	2 (3)	--	--	--	--	1 (2)
Homosexual	--	1 (2)	2 (4)	--	1 (1)	1 (2)
Unsure	--	--	--	--	1 (1)	--
Not reported	--	--	--	--	--	--
Age and duration of injection (years)						
Median age (years)	30	30	33	27	29	26
Age range	27 – 35	18 – 60	19 – 53	19 – 65	18 – 57	18 – 74
Age group (%)						
<25 years	18 (27)	15 (32)	14 (25)	14 (33)	18 (23)	20 (44)
25+ years	43 (65)	32 (68)	41 (75)	29 (67)	58 (75)	25 (56)
Not reported	5 (8)	--	--	--	1 (1)	--
Median age 1 st IDU (years)	19	--	19	--	18	--
Age range	10 – 39	--	14 – 44	--	8 – 36	--
Not reported	2	--	1	--	2	--
Median years IDU	8	--	12	--	10	--
Range	<1 – 26	--	<1 – 35	--	<1 – 28	--
Duration of drug injection (%)						
<3 years	10 (16)	--	6 (11)	--	11 (14)	--
3+ years	52 (84)	--	48 (87)	--	63 (82)	--
Not reported	--	--	1 (2)	--	3 (4)	--
Aboriginal and Torres Strait Islander origin (%)						
No	40 (61)	30 (64)	36 (65)	26 (60)	46 (60)	35 (78)
Yes	26 (39)	17 (36)	17 (31)	17 (40)	31 (40)	10 (22)
Not reported	--	--	2 (4)	--	--	--
Living situation prior to prison (%)*						
Not homeless	n/a	n/a	n/a	n/a	68 (88)	40 (89)
Primary homelessness	n/a	n/a	n/a	n/a	3 (4)	--
Secondary homelessness	n/a	n/a	n/a	n/a	4 (5)	2 (4)
Tertiary homelessness	n/a	n/a	n/a	n/a	2 (3)	3 (7)
Not reported	n/a	n/a	n/a	n/a	--	--
Residential remoteness in 12 months before prison (%)						
Highly accessible/accessible	51 (77)	35 (74)	47 (85)	29 (67)	69 (90)	40 (89)
Moderately accessible	4 (6)	2 (4)	1 (2)	1 (2)	4 (5)	1 (2)
Remote/very remote	8 (12)	10 (21)	4 (7)	6 (14)	3 (4)	4 (9)
Not reported	3 (5)	--	3 (5)	7 (16)	1 (1)	--
Region/Country of birth (%)						
Australia	57 (86)	42 (90)	47 (85)	34 (79)	71 (92)	32 (71)
Other Oceania	1 (2)	1 (2)	3 (5)	1 (2)	1 (1)	3 (7)
Asia	--	1 (2)	--	2 (5)	1 (1)	1 (2)
UK & Ireland	4 (5)	1 (2)	1 (2)	4 (9)	2 (3)	3 (7)
Other	3 (5)	2 (4)	4 (7)	2 (5)	2 (3)	6 (13)
Not reported	1 (2)	--	--	--	--	--
Main language spoke at home by parents (%)						
English	64 (98)	44 (94)	53 (96)	40 (93)	73 (95)	37 (82)
Non-English	1 (2)	3 (6)	2 (4)	3 (7)	3 (4)	8 (18)
Not reported	--	--	--	--	1 (1)	--

* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers' accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010.

Table 365 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographic characteristics	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)						
No	47 (71)	27 (57)	40 (73)	21 (49)	57 (74)	14 (31)
Yes	19 (29)	20 (43)	15 (27)	21 (49)	20 (26)	31 (69)
Not reported	--	--	--	1 (2)	--	--
Lifetime imprisonments (%)						
One	19 (29)	20 (43)	15 (27)	21 (49)	36 (47)	39 (87)
Two to four	29 (44)	21 (45)	17 (31)	14 (33)	22 (29)	4 (9)
Five to nine	12 (18)	3 (6)	9 (16)	2 (5)	11 (14)	2 (4)
Ten or more	5 (8)	--	2 (4)	1 (2)	8 (10)	--
Not reported	1 (2)	3 (6)	12 (22)	5 (12)	--	--
Imprisonment in last year (%)						
No	31 (47)	28 (60)	14 (35)	9 (41)	39 (51)	38 (84)
Yes	30 (45)	14 (30)	21 (53)	10 (45)	34 (44)	6 (13)
Not reported	5 (8)	5 (11)	5 (13)	3 (14)	4 (5)	1 (2)
Frequency of injection last month (%)						
Not last month	26 (39)	--	25 (45)	--	26 (34)	--
Less than weekly	10 (15)	--	9 (16)	--	22 (29)	--
Weekly not daily	1 (2)	--	6 (11)	--	6 (8)	--
Daily or more	29 (44)	--	15 (27)	--	22 (29)	--
Not reported	--	--	--	--	1 (1)	--
Ever smoked a full cigarette (%)*						
No	n/a	n/a	4 (7)	4 (9)	1 (1)	8 (18)
Yes	n/a	n/a	51 (93)	39 (91)	76 (99)	37 (82)
Not reported	n/a	n/a	--	--	--	--
Median age first smoked (years)	n/a	n/a	13	15	13	16
Age range	n/a	n/a	7 – 20	6 – 24	3 – 22	11 – 33
Current smoker (%)*						
No	n/a	n/a	7 (13)	11 (26)	3 (4)	13 (29)
Yes	n/a	n/a	47 (85)	32 (74)	74 (96)	32 (71)
Not reported	n/a	n/a	1 (2)	--	--	--
Smoking frequency (%)*						
Occasional – weekly or less	n/a	n/a	3 (6)	5 (16)	7 (9)	1 (3)
5 to 10 cigarettes a day	n/a	n/a	15 (31)	10 (31)	28 (38)	17 (53)
11 to 20 cigarettes a day	n/a	n/a	16 (33)	13 (41)	26 (35)	9 (28)
Over 20 cigarettes a day	n/a	n/a	13 (27)	4 (13)	12 (16)	5 (16)
Not reported	n/a	n/a	1 (2)	--	1 (1)	--
Other drugs used last month (%)**						
No drugs in past 4 weeks	n/a	n/a	n/a	n/a	9 (12)	16 (36)
Cannabis	n/a	n/a	n/a	n/a	57 (85)	22 (79)
Heroin	n/a	n/a	n/a	n/a	14 (21)	1 (4)
Cocaine	n/a	n/a	n/a	n/a	1 (1)	1 (4)
Amphetamine	n/a	n/a	n/a	n/a	47 (70)	8 (29)
Other's methadone	n/a	n/a	n/a	n/a	1 (1)	--
Other opiates	n/a	n/a	n/a	n/a	15 (22)	--
Other's buprenorphine	n/a	n/a	n/a	n/a	6 (9)	--
Steroids	n/a	n/a	n/a	n/a	--	--
Hallucinogens	n/a	n/a	n/a	n/a	1 (1)	1 (4)
Benzodiazepines	n/a	n/a	n/a	n/a	10 (15)	1 (4)
Ecstasy/MDA	n/a	n/a	n/a	n/a	8 (12)	4 (14)
Inhalants (e.g. petrol)	n/a	n/a	n/a	n/a	--	--
Other drug	n/a	n/a	n/a	n/a	1 (1)	--
Not reported	n/a	n/a	n/a	n/a	1 (1)	1 (2)

* Smoking questions not asked in 2004.

** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 366 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010
Last drug injected (%)	N = 66	N = 55	N = 77
Amphetamine (Speed, Ice)	54 (82)	47 (85)	58 (75)
Anabolic steroids	--	--	--
Cocaine	--	--	--
Heroin	7 (11)	7 (13)	10 (13)
Heroin + amphetamine	--	1 (2)	--
Heroin + cocaine	--	--	--
Methadone	3 (5)	--	--
Morphine	2 (3)	--	4 (5)
Other	--	--	4 (5)
Not reported	--	--	1 (1)
N° Injected last month	N = 40	N = 30	N = 50
Places injected last month (%)*			
Prison	1 (3)	1 (3)	1 (2)
Own home	26 (65)	23 (77)	27 (55)
Friend's home	19 (48)	11 (37)	23 (47)
Dealer's home	5 (13)	8 (27)	5 (10)
Street, park, beach	6 (15)	9 (30)	3 (6)
Car	7 (18)	5 (17)	5 (10)
Public toilet	2 (5)	4 (13)	3 (6)
Commercial injecting room	--	--	--
Medically Supervised Injecting Centre, Sydney	--	--	--
Squat	--	1 (3)	1 (2)
Other place	--	3 (10)	--
Use of sterile needles & syringes last month (%)			
All injections	26 (65)	16 (53)	30 (60)
Most of the time	9 (23)	11 (37)	15 (30)
Half of the time	1 (3)	--	2 (4)
Some of the time	4 (10)	3 (10)	1 (2)
Not last month	--	--	1 (2)
Not reported	1 (3)	--	1 (2)
Re-used someone else's used needle & syringe last month (%)			
None	29 (73)	21 (70)	41 (82)
Once	--	6 (20)	3 (6)
Twice	6 (15)	--	2 (4)
3-5 times	1 (3)	1 (3)	--
>5 times	2 (5)	2 (7)	3 (6)
Not reported	2 (5)	--	1 (2)
Number of people needle & syringe was re-used after last month (%)			
None	29 (73)	21 (70)	40 (80)
One	3 (8)	6 (20)	3 (6)
Two	3 (8)	--	2 (4)
Three to five	1 (3)	1 (3)	--
More than five	2 (5)	--	2 (4)
Don't know how many	--	1 (3)	2 (4)
Not reported	2 (5)	1 (3)	1 (2)
Relationship to people needle & syringe was re-used after last month (%)*			
Regular sex partner	5 (13)	3 (10)	6 (12)
Casual sex partner	--	1 (3)	--
Close friend	2 (5)	2 (7)	2 (4)
Acquaintance	--	2 (7)	--
Other	4 (10)	2 (7)	1 (2)
Equipment used after someone else last month (%)*			
Spoon	9 (23)	4 (13)	10 (20)
Water	8 (20)	8 (27)	8 (16)
Filter	7 (18)	4 (13)	11 (22)
Tourniquet	5 (13)	3 (10)	1 (2)
Drug mix	7 (18)	5 (17)	11 (22)

* More than one option could be selected.

Table 367 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment for drug use	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 66	N = 47	N = 55	N = 43	N = 77	N = 45
Any treatment/therapy for drug use (%)						
No	41 (62)	41 (87)	23 (42)	31 (72)	50 (65)	36 (80)
Yes	25 (38)	6 (13)	30 (55)	8 (19)	27 (35)	9 (20)
Not reported			2 (4)	4 (9)	--	--
History of methadone maintenance treatment (%)						
Currently	3 (5)	1 (2)	2 (4)	--	1 (1)	--
Previously	3 (5)	--	7 (13)	--	5 (6)	--
Never	60 (90)	45 (96)	38 (69)	--	71 (92)	45 (100)
Not reported	--	1 (2)	8 (15)	--	--	--
History of other pharmacotherapy treatment (%)						
Currently	4 (6)	1 (2)	5 (9)	--	--	--
Previously	4 (6)	--	7 (13)	--	3 (4)	1 (2)
Never	58 (88)	45 (96)	43 (78)	--	74 (96)	44 (98)
Not reported	--	1 (2)	--	--	--	--

Table 368 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010
N° surveyed	N = 40	N = 30	N = 76
From an NSP last month (%)			
Daily or almost daily	3 (8)	1 (3)	2 (3)
A couple of times each week	5 (13)	2 (7)	2 (3)
Less than weekly	7 (18)	3 (10)	7 (9)
Weekly	n/a	n/a	3 (4)
Once last month	5 (13)	3 (10)	--
Not in the last month	18 (45)	17 (57)	55 (72)
Not reported	2 (5)	4 (13)	7 (9)
From a chemist last month (%)			
Daily or almost daily	6 (15)	3 (10)	9 (12)
A couple of times each week	6 (15)	8 (27)	8 (10)
Less than weekly	8 (20)	5 (17)	18 (23)
Weekly	n/a	n/a	11 (14)
Once last month	6 (15)	5 (17)	--
Not in the last month	13 (33)	6 (20)	27 (35)
Not reported	1 (3)	3 (10)	3 (4)

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 369 Number (%) of respondents by body piercing and tattoos

Body piercing and tattoos	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 66	N = 47	N = 55	N = 43	N = 77	N = 45
Body or ear piercings (%)						
No	30 (45)	29 (62)	25 (45)	22 (51)	53 (69)	27 (60)
Yes	36 (55)	18 (38)	29 (53)	21 (49)	24 (31)	18 (40)
Not reported	--	--	1 (2)	--	--	--
Pierced in past 12 mths (%)						
No	25 (69)	9 (50)	23 (79)	17 (81)	15 (63)	13 (72)
Yes	5 (14)	3 (17)	1 (3)	1 (5)	5 (21)	3 (17)
Not reported	6 (17)	6 (33)	5 (17)	3 (14)	4 (17)	2 (11)
Who did piercing (%)*						
Chemist/hairdresser/beauty salon	3 (60)	--	1 (100)	--	1 (20)	2 (67)
Professional piercer / studio	1 (20)	2 (67)	1 (100)	--	4 (80)	1 (33)
Tattooist / parlour	1 (20)	2 (67)	--	--	--	--
Friend	1 (20)	--	--	--	--	--
Prison inmate	--	--	--	--	--	--
Self	1 (20)	--	--	1 (100)	--	--
Family member	--	--	--	--	--	--
Other	--	--	--	--	--	--
Needle used by other (%)						
No	--	1 (33)	--	1 (100)	--	1 (33)
Yes	1 (20)	--	--	--	--	--
Unsure	--	--	--	--	--	--
Not reported	4 (80)	2 (67)	1 (100)	--	5 (100)	2 (67)
Tattoos (%)						
No	23 (25)	31 (66)	21 (38)	27 (63)	22 (29)	26 (58)
Yes	43 (65)	16 (34)	34 (62)	16 (37)	55 (71)	19 (42)
Not reported	--	--	--	--	--	--
Tattoos in past 12 mths (%)						
No	33 (77)	14 (88)	27 (79)	14 (88)	39 (71)	11 (58)
Yes	10 (23)	2 (13)	7 (21)	2 (13)	16 (29)	8 (42)
Not reported	--	--	--	--	--	--
Who did tattooing (%)*						
Professional tattooist	8 (80)	1 (50)	5 (71)	2 (100)	7 (44)	2 (25)
Friend	3 (30)	1 (50)	--	--	4 (25)	5 (63)
Prison inmate	2 (20)	--	1 (14)	--	3 (19)	--
Self	1 (10)	--	1 (14)	--	1 (6)	1 (13)
Family member	--	--	--	--	2 (13)	--
Other	--	--	--	--	--	--

* More than one option could be selected.

Table 370 Number (%) of respondents by sexual behaviour **in the month** (3 months) prior to survey by injector status and survey year

Sexual behaviour	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 66	N = 47	N = 55	N = 43	N = 77	N = 45
Sex last month / last 3 months (%)**						
No	24 (36)	14 (30)	15 (27)	11 (26)	5 (6)	9 (20)
Yes	41 (62)	32 (68)	40 (73)	32 (74)	71 (92)	36 (80)
Not reported	1 (2)	1 (2)	--	--	1 (1)	--
Male sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	1	1
Range	n/a	n/a	n/a	n/a	1 – 8	0 – 2
Female sex partners in last 3 months**						
Median	n/a	n/a	n/a	n/a	1	1
Range	n/a	n/a	n/a	n/a	0 – 12	0 – 6
Condom use at last sex (%)						
No	46 (70)	36 (77)	42 (76)	26 (60)	n/a	n/a
Yes	20 (30)	11 (23)	13 (24)	17 (40)	n/a	n/a
Not reported			--	--	n/a	n/a
Condom use with regular sex partner(s) last month (%)*						
No	21 (75)	22 (88)	27 (84)	13 (54)	n/a	n/a
Sometimes	2 (7)	2 (8)	4 (13)	6 (25)	n/a	n/a
Always	5 (18)	1 (4)	1 (3)	5 (21)	n/a	n/a
Condom use with new sex partner(s) last month (%)*						
No	12 (71)	5 (63)	10 (50)	4 (33)	n/a	n/a
Sometimes	1 (6)	2 (25)	5 (25)	5 (42)	n/a	n/a
Always	4 (24)	1 (13)	5 (25)	3 (25)	n/a	n/a
Condom use with casual sex partner(s) last month (%)*						
No	9 (69)	7 (78)	10 (59)	2 (18)	n/a	n/a
Sometimes	1 (8)	2 (22)	5 (29)	5 (45)	n/a	n/a
Always	3 (23)	--	2 (12)	4 (36)	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	4 (80)	2 (67)
Sometimes	n/a	n/a	n/a	n/a	1 (20)	--
Always	n/a	n/a	n/a	n/a	--	1 (33)
Condom use last sex - casual male partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	1 (50)	1 (100)
Sometimes	n/a	n/a	n/a	n/a	--	--
Always	n/a	n/a	n/a	n/a	1 (50)	--
Condom use last sex - regular female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	34 (79)	17 (61)
Sometimes	n/a	n/a	n/a	n/a	4 (9)	8 (29)
Always	n/a	n/a	n/a	n/a	5 (12)	3 (11)
Condom use last sex - casual female partners - last 3 months (%)**						
Never	n/a	n/a	n/a	n/a	18 (60)	4 (50)
Sometimes	n/a	n/a	n/a	n/a	6 (20)	1 (13)
Always	n/a	n/a	n/a	n/a	6 (20)	3 (38)
Sex work last month (%)						
No	65 (100)	46 (98)	52 (95)	43 (100)	76 (99)	44 (98)
Yes	--	1 (2)	3 (5)	--	1 (1)	--
Not reported			--	--	--	1 (2)
Condom used at last sex work last month (%)						
No	--	--	--	--	--	--
Yes	--	1 (100)	3 (100)	--	1 (100)	--
Not reported	--	--	--	--	--	--
Ever had cervical cancer vaccine (women only)*** (%)						
No	n/a	n/a	n/a	n/a	--	3 (100)
Yes	n/a	n/a	n/a	n/a	1 (100)	--
Unsure	n/a	n/a	n/a	n/a	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

*** Proportion of eligible women i.e. those under 27 years of age in 2007.

Table 371 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 66	N = 47	N = 55	N = 43	N = 77	N = 45
Previous HIV test (%)						
Yes, last year	26 (39)	8 (7)	15 (27)	6 (14)	26 (34)	11 (24)
>1 year ago	17 (26)	11 (23)	25 (45)	11 (26)	21 (27)	9 (20)
Never tested	23 (35)	27 (57)	13 (24)	26 (60)	30 (39)	25 (56)
Not reported	--	1 (2)	2 (40)	--	--	--
HBV infection (%)						
No	52 (79)	41 (87)	38 (69)	37 (86)	71 (92)	44 (98)
Yes	5 (8)	1 (2)	10 (18)	1 (2)	4 (5)	--
Don't know	9 (14)	5 (11)	7 (13)	5 (12)	1 (1)	--
Not reported	--	--	--	--	1 (1)	1 (2)
HBV vaccination (%)*						
No	21 (32)	22 (47)	27 (49)	27 (63)	36 (47)	31 (69)
Yes	34 (52)	12 (26)	22 (40)	9 (21)	34 (44)	8 (18)
Don't know	11 (17)	12 (26)	6 (11)	7 (16)	7 (9)	6 (13)
Not reported	--	1 (2)	--	--	--	--
Previous HCV test (%)						
Yes, last year	31 (47)	6 (13)	20 (36)	5 (12)	26 (34)	10 (22)
>1 year ago	12 (18)	7 (15)	25 (45)	10 (23)	27 (35)	9 (20)
Never tested	23 (35)	33 (72)	10 (18)	28 (65)	24 (31)	26 (58)
Unsure	--	--	--	--	--	--
Not reported	--	1 (<1)	--	--	--	--
Any HCV treatment (%)**	N = 16	N = 2	N = 16	N = 1	N = 22	N = 0
Interferon	--	--	--	--	--	--
Interferon & Ribavirin	--	--	--	--	--	--
Pegasys & Ribavirin	--	--	--	--	--	--
Other	16 (100)	2 (100)	--	--	--	--
No treatment	--	--	16 (100)	1 (100)	22 (100)	--
Not reported	--	--	--	--	--	--
Current HCV treatment						
Interferon	--	--	--	--	--	--
Interferon & Ribavirin	--	--	--	--	--	--
Pegasys & Ribavirin	--	--	--	--	--	--
Other	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Number (%) of those testing positive for hepatitis C antibodies.

HIV antibody prevalence

Table 372 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	44	0 (0)	5	0 (0)	49	0 (0)
Non-IDU	36	0 (0)	7	0 (0)	43	0 (0)
p value		--		--		--
2007						
IDU	38	0 (0)	5	0 (0)	43	0 (0)
Non-IDU	36	0 (0)	2	0 (0)	38	0 (0)
p value		--		--		--
2010						
IDU	60	0 (0)	2	0 (0)	62	0 (0)
Non-IDU	33	0 (0)	2	0 (0)	35	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 373 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	43	12 (28)	5	4 (80)	48	16 (33)
Non-IDU	36	2 (6)	7	0 (0)	43	2 (5)
p value		0.01		0.004		0.001
2007						
IDU	38	14 (37)	5	2 (40)	43	16 (37)
Non-IDU	37	1 (3)	2	0 (0)	39	1 (3)
p value		<0.001		0.3		<0.001
2010						
IDU	59	22 (37)	2	0 (0)	61	22 (36)
Non-IDU	33	0 (0)	2	0 (0)	35	0 (0)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 374 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	79	14 (18)	12	4 (33)	91	18 (20)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	73	14 (19)	7	2 (29)	80	16 (20)
Bisexual	--	--	--	--	--	--
Homosexual	2	1 (50)	--	--	2	1 (50)
Unsure	--	--	--	--	--	--
p value		0.3		--		0.3
2010						
Heterosexual	90	22 (24)	2	0 (0)	92	22 (24)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
Unsure	--	--	--	--	--	--
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 375 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	11	1 (9)	--	--	11	1 (9)
20 – 24	18	2 (11)	1	0 (0)	19	2 (11)
25 – 29	17	1 (6)	2	1 (50)	19	2 (11)
30 + years	36	10 (28)	7	1 (14)	43	11 (26)
p value		0.2		0.5		0.3
2007						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	20	1 (5)	--	--	20	1 (5)
25 – 29	12	1 (8)	2	0 (0)	14	1 (7)
30 + years	38	13 (34)	5	2 (40)	43	15 (35)
p value		0.02		0.3		0.01
2010						
< 20 years	9	0 (0)	1	0 (0)	10	0 (0)
20 – 24	22	4 (18)	2	0 (0)	24	4 (17)
25 – 29	27	6 (22)	--	--	27	6 (22)
30 + years	34	12 (35)	1	0 (0)	35	12 (34)
p value		0.1		--		0.1

† Excludes equivocal test results and missing values.

Table 376 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	9	0 (0)	--	--	9	0 (0)
3 to 5 years	5	3 (60)	--	--	5	3 (60)
6 to 10 years	12	2 (17)	1	1 (100)	13	3 (23)
10 + years	16	7 (44)	3	2 (67)	19	9 (47)
p value		0.03		0.6		0.02
2007						
<3 years	5	--	--	--	5	0 (0)
3 to 5 years	7	--	--	--	7	0 (0)
6 to 10 years	6	1 (17)	1	0 (0)	7	1 (14)
10 + years	19	12 (63)	4	2 (50)	23	14 (61)
p value		0.003		0.4		0.002
2010						
<3 years	10	1 (10)	1	0 (0)	11	1 (9)
3 to 5 years	4	2 (50)	--	--	4	2 (50)
6 to 10 years	16	7 (44)	1	0 (0)	17	7 (41)
10 + years	27	11 (41)	--	--	27	11 (41)
p value		0.3		--		0.2

† Excludes equivocal test results and missing values.

Table 377 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	8	0 (0)	32	13 (41)	40	13 (33)
Heroin	--	--	--	--	--	--
More than one	1	0 (0)	5	3 (60)	6	3 (50)
Other/not reported	--	--	--	--	--	--
p value		--		0.5		0.5
2007						
Amphetamine (Speed, Ice)	5	0 (0)	34	12 (35)	39	12 (31)
Heroin	--	--	2	2 (100)	2	2 (100)
More than one	--	--	1	1 (100)	1	1 (100)
Other/not reported	--	--	--	--	--	--
p value		--		0.09		0.07
2010						
Amphetamine (Speed, Ice)	9	0 (0)	37	14 (38)	46	14 (30)
Heroin	--	--	7	6 (86)	7	6 (86)
More than one	--	--	--	--	--	--
Other/not reported	2	1 (50)	4	0 (0)	6	1 (17)
p value		0.03		0.01		0.01

† Excludes equivocal test results and missing values.

Table 378 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	3	0 (0)	5	3 (60)	8	3 (38)
Daily or more	4	0 (0)	15	9 (60)	19	9 (47)
p value		--		0.06		0.6
2007						
Less than daily	--	--	11	2 (18)	11	2 (18)
Daily or more	2	0 (0)	11	9 (82)	13	9 (69)
p value		--		0.003		0.008
2010						
Less than daily	6	0 (0)	16	7 (44)	22	7 (32)
Daily or more	4	1 (25)	13	6 (46)	17	7 (41)
p value		0.2		0.9		0.6

† Excludes equivocal test results and missing values.

Table 379 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	6	0 (0)	14	10 (71)	20	10 (50)
Yes	1	0 (0)	5	2 (40)	6	2 (33)
p value		--		0.2		0.5
2007						
No	2	0 (0)	14	7 (50)	16	7 (44)
Yes	--	--	7	4 (57)	7	4 (57)
p value		--		0.8		0.3
2010						
No	8	1 (13)	23	10 (43)	31	11 (35)
Yes	1	0 (0)	4	1 (25)	5	1 (20)
p value		0.7		0.5		0.5

† Excludes equivocal test results and missing values.

Table 380 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	6	0 (0)	18	5 (28)	24	5 (21)
Yes	3	0 (0)	18	10 (56)	21	10 (48)
p value		--		0.09		0.06
2007						
No	2	0 (0)	11	6 (55)	13	6 (46)
Yes	1	0 (0)	13	3 (23)	14	3 (21)
p value		--		0.1		0.2
2010						
No	6	1 (17)	24	11 (46)	30	12 (40)
Yes	5	0 (0)	22	8 (36)	27	8 (30)
p value		0.4		0.5		0.4

† Excludes equivocal test results and missing values.

Table 381 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	28	0 (0)	5	0 (0)	33	0 (0)
2 to 4	33	7 (21)	7	4 (57)	40	11 (28)
5 to 9	12	6 (50)	--	--	12	6 (50)
10 +	2	1 (50)	--	--	2	1 (50)
p value		0.001		0.04		0.001
2007						
1	28	2 (7)	2	1 (50)	30	3 (10)
2 to 4	22	3 (14)	3	1 (33)	25	4 (16)
5 to 9	10	3 (30)	1	0 (0)	11	3 (27)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.03		0.7		0.07
2010						
1	55	7 (13)	2	0 (0)	57	7 (12)
2 to 4	19	9 (47)	2	0 (0)	21	9 (43)
5 to 9	13	3 (23)	--	--	13	3 (23)
10 +	5	3 (60)	--	--	5	3 (60)
p value		0.004		--		0.007

† Excludes equivocal test results and missing values.

Table 382 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	51	6 (12)	6	2 (33)	57	8 (14)
Indigenous	31	8 (26)	6	2 (33)	37	10 (27)
p value		0.1		1.0		0.1
2007						
Non-Indigenous	49	12 (24)	2	1 (50)	51	13 (25)
Indigenous	25	3 (12)	5	1 (20)	30	4 (13)
p value		0.2		0.4		0.2
2010						
Non-Indigenous	60	13 (22)	1	0 (0)	61	13 (21)
Indigenous	32	9 (28)	3	0 (0)	35	9 (26)
p value		0.5		--		0.6

† Excludes equivocal test results and missing values.

Table 383 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	26	1 (4)	29	7 (24)	55	8 (15)
Indigenous	17	1 (6)	19	9 (47)	36	10 (28)
p value		0.8		0.1		0.1
2007						
Non-Indigenous	23	1 (4)	28	12 (43)	51	13 (25)
Indigenous	16	0 (0)	14	4 (29)	30	4 (13)
p value		0.4		0.4		0.2
2010						
Non-Indigenous	26	0 (0)	35	13 (37)	61	13 (21)
Indigenous	9	0 (0)	26	9 (35)	35	9 (26)
p value		--		0.8		0.6

† Excludes equivocal test results and missing values.

Table 384 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	62	13 (21)	8	3 (38)	70	16 (23)
Moderately accessible	4	0 (0)	1	0 (0)	5	0 (0)
Remote/very remote	13	1 (8)	2	0 (0)	15	1 (7)
p value		0.3		0.5		0.2
2007						
Highly accessible/accessible	57	11 (19)	6	2 (33)	63	13 (21)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	9	1 (11)	1	0 (0)	10	1 (10)
p value		0.5		0.5		0.4
2010						
Highly accessible/accessible	84	19 (23)	3	0 (0)	87	19 (22)
Moderately accessible	3	2 (67)	--	--	3	2 (67)
Remote/very remote	5	1 (20)	1	0 (0)	6	1 (17)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 385 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	71	13 (18)	12	4 (33)	83	17 (20)
Other Oceania	1	0 (0)	--	--	1	0 (0)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	1	0 (0)	--	--	1	0 (0)
Other	4	1 (25)	--	--	4	1 (25)
p value		0.9		--		0.9
2007						
Australia	60	14 (23)	7	2 (29)	67	16 (24)
Other Oceania	4	0 (0)	--	--	4	0 (0)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	5	0 (0)	--	--	5	0 (0)
Other	5	1 (20)	--	--	5	1 (20)
p value		0.6		--		0.6
2010						
Australia	78	22 (28)	4	0 (0)	82	22 (27)
Other Oceania	4	0 (0)	--	--	4	0 (0)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	6	0 (0)	--	--	6	0 (0)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 386 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	76	14 (18)	11	3 (27)	87	17 (20)
Non-English	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.5		0.1		0.6
2007						
English	71	14 (20)	7	2 (29)	78	16 (21)
Non-English	4	1 (25)	--	--	4	1 (25)
p value		0.8		--		0.8
2010						
English	86	22 (26)	4	0 (0)	90	22 (24)
Non-English	6	0 (0)	--	--	6	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 387 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	6	6 (100)	2	2 (100)	8	8 (100)
Negative	25	6 (24)	3	0 (0)	28	6 (21)
Not sure	2	1 (50)	1	1 (100)	3	2 (67)
p value		0.003		0.05		<0.001
2007						
Positive	8	8 (100)	2	2 (100)	10	10 (100)
Negative	31	5 (16)	2	0 (0)	33	5 (15)
Not sure	7	1 (14)	--	--	7	1 (14)
p value		<0.001		0.05		<0.001
2010						
Positive	9	9 (100)	--	--	9	9 (100)
Negative	31	2 (6)	3	0 (0)	34	2 (6)
Not sure	8	3 (38)	--	--	8	3 (38)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 388 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	44	3 (7)	5	0 (0)	49	3 (6)
Non-IDU	35	0 (0)	7	0 (0)	42	0 (0)
p value		0.1		--		0.1
2007						
IDU	38	2 (5)	5	0 (0)	43	2 (5)
Non-IDU	37	0 (0)	2	0 (0)	39	0 (0)
p value		0.2		--		0.2
2010						
IDU	60	0 (0)	2	0 (0)	62	0 (0)
Non-IDU	33	0 (0)	2	0 (0)	35	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 389 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	44	11 (25)	4	2 (50)	48	13 (27)
Non-IDU	35	3 (9)	5	0 (0)	40	3 (8)
p value		0.06		0.07		0.02
2007						
IDU	38	16 (42)	5	2 (40)	43	18 (42)
Non-IDU	37	4 (11)	2	1 (50)	39	5 (13)
p value		0.002		0.8		0.003
2010						
IDU	60	9 (15)	2	0 (0)	62	9 (15)
Non-IDU	33	7 (21)	2	0 (0)	35	7 (20)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 390 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	79	14 (18)	9	2 (22)	88	16 (18)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	73	19 (26)	7	3 (43)	80	22 (28)
Bisexual	--	--	--	--	--	--
Homosexual	2	1 (50)	--	--	2	1 (50)
Unsure	--	--	--	--	--	--
p value		0.5		--		0.5
2010						
Heterosexual	91	15 (16)	2	0 (0)	93	15 (16)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	1 (100)	1	0 (0)	2	1 (50)
Unsure	--	--	--	--	--	--
p value		0.03		--		0.4

† Excludes equivocal test results and missing values.

Table 391 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	11	0 (0)	--	--	11	0 (0)
20 – 24	18	1 (6)	1	0 (0)	19	1 (5)
25 – 29	17	3 (18)	1	1 (100)	18	4 (22)
30 + years	36	10 (28)	6	1 (17)	42	11 (26)
p value		0.08		0.2		0.08
2007						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	20	1 (5)	--	--	20	1 (5)
25 – 29	12	4 (33)	2	0 (0)	14	4 (29)
30 + years	38	15 (39)	5	3 (60)	43	18 (42)
p value		0.02		0.2		0.01
2010						
< 20 years	9	0 (0)	1	0 (0)	10	0 (0)
20 – 24	22	2 (9)	2	0 (0)	24	2 (8)
25 – 29	27	4 (15)	--	--	27	4 (15)
30 + years	35	10 (29)	1	0 (0)	36	10 (28)
p value		0.1		--		0.09

† Excludes equivocal test results and missing values.

Table 392 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	9	1 (11)	--	--	9	1 (11)
3 to 5 years	5	0 (0)	--	--	5	0 (0)
6 to 10 years	13	3 (23)	1	1 (100)	14	4 (29)
10 + years	16	7 (44)	3	1 (33)	19	8 (42)
p value		0.1		0.3		0.2
2007						
<3 years	5	1 (20)	--	--	5	1 (20)
3 to 5 years	7	1 (14)	--	--	7	1 (14)
6 to 10 years	6	2 (33)	1	0 (0)	7	2 (29)
10 + years	19	11 (58)	4	2 (50)	23	13 (57)
p value		0.2		0.4		0.1
2010						
<3 years	10	0 (0)	1	0 (0)	11	0 (0)
3 to 5 years	4	1 (25)	--	--	4	1 (25)
6 to 10 years	16	2 (13)	1	0 (0)	17	2 (12)
10 + years	28	5 (18)	--	--	28	5 (18)
p value		0.5		--		0.4

† Excludes equivocal test results and missing values.

Table 393 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	8	1 (13)	32	10 (31)	40	11 (28)
Heroin	--	--	--	--	--	--
More than one	1	0 (0)	5	2 (40)	6	2 (33)
Other/not reported	--	--	--	--	--	--
p value		0.7		0.7		0.7
2007						
Amphetamine (Speed, Ice)	5	1 (20)	34	14 (41)	39	15 (38)
Heroin	--	--	2	1 (50)	2	1 (50)
More than one	--	--	1	1 (100)	1	1 (100)
Other/not reported	--	--	--	--	--	--
p value		--		0.5		0.5
2010						
Amphetamine (Speed, Ice)	9	0 (0)	38	7 (18)	47	7 (15)
Heroin	--	--	7	1 (14)	7	1 (14)
More than one	--	--	--	--	--	--
Other/not reported	2	0 (0)	4	0 (0)	6	0 (0)
p value		--		0.6		0.6

† Excludes equivocal test results and missing values.

Table 394 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	3	1 (33)	5	4 (80)	8	5 (63)
Daily or more	4	0 (0)	16	5 (31)	20	5 (25)
p value		0.2		0.06		0.06
2007						
Less than daily	--	--	11	4 (36)	11	4 (36)
Daily or more	2	0 (0)	11	7 (64)	13	7 (54)
p value		--		0.2		0.4
2010						
Less than daily	6	0 (0)	16	4 (25)	22	4 (18)
Daily or more	4	0 (0)	14	0 (0)	18	0 (0)
p value		--		0.04		0.06

† Excludes equivocal test results and missing values.

Table 395 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	1 (17)	15	8 (53)	21	9 (43)
Yes	1	0 (0)	5	1 (20)	6	1 (17)
p value		0.7		0.2		0.3
2007						
No	2	0 (0)	14	6 (43)	16	6 (38)
Yes	--	--	7	4 (57)	7	4 (57)
p value		--		0.5		0.4
2010						
No	8	0 (0)	24	3 (13)	32	3 (9)
Yes	1	0 (0)	4	0 (0)	5	0 (0)
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 396 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	18	6 (33)	24	6 (25)
Yes	3	1 (33)	18	6 (33)	21	7 (33)
p value		0.1		0.6		0.9
2007						
No	2	1 (50)	11	6 (55)	13	7 (54)
Yes	1	0 (0)	13	3 (23)	14	3 (21)
p value		0.4		0.1		0.08
2010						
No	6	0 (0)	25	3 (12)	31	3 (10)
Yes	5	0 (0)	22	4 (18)	27	4 (15)
p value		--		0.6		0.6

† Excludes equivocal test results and missing values.

Table 397 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	28	2 (7)	3	0 (0)	31	2 (6)
2 to 4	34	8 (24)	6	2 (23)	40	10 (25)
5 to 9	12	4 (33)	--	--	12	4 (33)
10 +	2	0 (0)	--	--	2	0 (0)
p value		0.2		0.3		0.1
2007						
1	28	5 (18)	2	1 (50)	30	6 (20)
2 to 4	22	3 (14)	3	1 (33)	25	4 (16)
5 to 9	10	5 (50)	1	0 (0)	11	5 (45)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.04		0.7		0.08
2010						
1	55	7 (13)	2	0 (0)	57	7 (12)
2 to 4	19	6 (32)	2	0 (0)	21	6 (29)
5 to 9	13	3 (23)	--	--	13	3 (23)
10 +	6	0 (0)	--	--	6	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 398 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	52	5 (10)	4	1 (25)	56	6 (11)
Indigenous	30	9 (30)	5	1 (20)	35	10 (29)
p value		0.2		0.9		0.03
2007						
Non-Indigenous	49	10 (20)	2	0 (0)	51	10 (20)
Indigenous	25	9 (36)	5	3 (60)	30	12 (40)
p value		0.1		0.2		0.05
2010						
Non-Indigenous	60	10 (17)	1	0 (0)	61	10 (16)
Indigenous	33	6 (18)	3	0 (0)	36	6 (17)
p value		0.9		--		1.0

† Excludes equivocal test results and missing values.

Table 399 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	25	0 (0)	29	6 (21)	54	6 (11)
Indigenous	15	3 (20)	19	7 (37)	34	10 (29)
p value		0.02		0.2		0.03
2007						
Non-Indigenous	23	1 (4)	28	9 (32)	51	10 (20)
Indigenous	16	4 (25)	14	8 (57)	30	12 (40)
p value		0.06		0.1		0.05
2010						
Non-Indigenous	26	4 (15)	35	6 (17)	61	10 (16)
Indigenous	9	3 (33)	27	3 (11)	36	6 (17)
p value		0.3		0.5		1.0

† Excludes equivocal test results and missing values.

Table 400 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	62	9 (15)	5	1 (20)	67	10 (15)
Moderately accessible	4	0 (0)	1	0 (0)	5	0 (0)
Remote/very remote	13	5 (38)	2	0 (0)	15	5 (33)
p value		0.08		0.7		0.1
2007						
Highly accessible/accessible	57	13 (23)	6	2 (33)	63	15 (24)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	9	5 (56)	1	1 (100)	10	6 (60)
p value		0.08		0.2		0.04
2010						
Highly accessible/accessible	85	15 (18)	3	0 (0)	88	15 (17)
Moderately accessible	3	0 (0)	--	--	3	0 (0)
Remote/very remote	5	1 (20)	1	0 (0)	6	1 (17)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 401 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	71	13 (18)	9	2 (22)	80	15 (19)
Other Oceania	1	1 (100)	--	--	1	1 (100)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	1	0 (0)	--	--	1	0 (0)
Other	4	0 (0)	--	--	4	0 (0)
p value		0.2		--		0.2
2007						
Australia	60	19 (32)	7	3 (43)	67	22 (33)
Other Oceania	4	1 (25)	--	--	4	1 (25)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	5	0 (0)	--	--	5	0 (0)
Other	5	0 (0)	--	--	5	0 (0)
p value		0.3		--		0.3
2010						
Australia	79	11 (14)	4	0 (0)	83	11 (13)
Other Oceania	4	2 (50)	--	--	4	2 (50)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	6	3 (50)	--	--	6	3 (50)
p value		0.06		--		0.05

† Excludes equivocal test results and missing values.

Table 402 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	76	14 (18)	8	1 (13)	84	15 (18)
Non-English	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.5		0.05		0.5
2007						
English	71	19 (27)	7	3 (43)	78	22 (28)
Non-English	4	1 (25)	--	--	4	1 (25)
p value		0.9		--		0.9
2010						
English	87	15 (17)	4	0 (0)	91	15 (16)
Non-English	6	1 (17)	--	--	6	1 (17)
p value		1.0		--		1.0

† Excludes equivocal test results and missing values.

Table 403 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	No (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	49	21 (43)	10 (20)	3 (6)	15 (31)
Non-IDU	42	29 (69)	3 (7)	0 (0)	10 (24)
p value					0.04
2007					
IDU	43	16 (27)	16 (37)	2 (5)	9 (21)
Non-IDU	39	29 (74)	5 (13)	0 (0)	5 (13)
p value					<0.01
2010					
IDU	62	28 (45)	9 (15)	0 (0)	25 (40)
Non-IDU	35	22 (63)	7 (20)	0 (0)	6 (17)
p value					0.06

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 404 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	90	50 (56)	13 (14)	3 (3)	24 (27)
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					0.4
2007					
Heterosexual	80	44 (55)	20 (25)	2 (3)	14 (18)
Homosexual	--	--	--	--	--
Bisexual	2	1 (50)	1 (50)	0 (0)	0 (0)
Unsure	--	--	--	--	--
p value					0.8
2010					
Heterosexual	93	48 (52)	15 (16)	0 (0)	30 (32)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Homosexual	2	1 (50)	1 (50)	0 (0)	0 (0)
Unsure	--	--	--	--	--
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 405 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	11	6 (55)	0 (0)	0 (0)	5 (45)
20 – 24	19	13 (68)	0 (0)	1 (5)	5 (26)
25 – 29	20	12 (60)	3 (15)	1 (5)	4 (20)
30 + years	43	21 (49)	10 (23)	1 (2)	11 (26)
p value					0.3
2007					
< 20 years	5	3 (60)	0 (0)	0 (0)	2 (40)
20 – 24	20	16 (80)	1 (5)	0 (0)	3 (15)
25 – 29	14	8 (57)	3 (21)	1 (7)	2 (14)
30 + years	43	18 (42)	17 (40)	1 (2)	7 (16)
p value					0.09
2010					
< 20 years	10	4 (40)	0 (0)	0 (0)	6 (60)
20 – 24	24	13 (54)	2 (8)	0 (0)	9 (38)
25 – 29	27	18 (67)	4 (15)	0 (0)	5 (19)
30 + years	36	15 (42)	10 (28)	0 (0)	11 (31)
p value					0.07

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 406 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	33	24 (73)	1 (3)	1 (3)	7 (21)
2 to 4	41	20 (49)	9 (22)	1 (2)	11 (27)
5 to 9	12	4 (33)	3 (25)	1 (8)	4 (33)
10 +	2	0 (0)	0 (0)	0 (0)	2 (100)
p value					0.08
2007					
1	30	20 (67)	5 (17)	1 (3)	4 (13)
2 to 4	25	15 (60)	4 (16)	0 (0)	6 (24)
5 to 9	11	4 (36)	4 (36)	1 (9)	2 (18)
10 +	3	1 (33)	2 (67)	0 (0)	0 (0)
p value					0.4
2010					
1	57	33 (58)	7 (12)	0 (0)	17 (30)
2 to 4	21	8 (38)	6 (29)	0 (0)	7 (33)
5 to 9	13	6 (46)	3 (23)	0 (0)	4 (31)
10 +	6	3 (50)	0 (0)	0 (0)	3 (50)
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 407 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	58	42 (72)	5 (9)	1 (2)	10 (17)
Indigenous	36	10 (28)	8 (22)	2 (6)	16 (44)
p value					<0.001
2007					
Non-Indigenous	51	32 (63)	9 (18)	1 (2)	9 (18)
Indigenous	30	13 (43)	11 (37)	1 (2)	5 (17)
p value					0.2
2010					
Non-Indigenous	61	40 (66)	10 (16)	0 (0)	11 (18)
Indigenous	36	10 (28)	6 (17)	0 (0)	20 (56)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 408 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	70	42 (60)	7 (10)	3 (4)	18 (26)
Moderately accessible	5	2 (40)	0 (0)	0 (0)	3 (60)
Remote/very remote	15	6 (40)	5 (33)	0 (0)	4 (27)
p value					0.1
2007					
Highly accessible/accessible	63	38 (60)	13 (21)	2 (3)	10 (16)
Moderately accessible	2	2 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	10	2 (20)	6 (60)	0 (0)	2 (20)
p value					0.1
2010					
Highly accessible/accessible	88	47 (53)	15 (17)	0 (0)	26 (30)
Moderately accessible	3	1 (33)	0 (0)	0 (0)	2 (67)
Remote/very remote	6	2 (33)	1 (17)	0 (0)	3 (50)
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 409 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	87	47 (54)	12 (14)	3 (3)	25 (29)
Non-English	3	2 (67)	1 (33)	0 (0)	0 (0)
p value					0.6
2007					
English	78	43 (55)	20 (26)	2 (3)	13 (17)
Non-English	4	2 (50)	1 (25)	0 (0)	1 (25)
p value					1.0
2010					
English	91	48 (53)	15 (16)	0 (0)	28 (31)
Non-English	6	2 (33)	1 (17)	0 (0)	3 (50)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 410 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	31	5 (16)	5	2 (40)	36	7 (19)
Yes	22	11 (50)	1	1 (100)	23	12 (52)
Not sure	11	5 (45)	4	1 (25)	15	6 (40)
p value		0.02		0.4		0.03
2007						
No	29	3 (10)	4	1 (25)	33	4 (12)
Yes	18	9 (50)	--	--	18	9 (50)
Not sure	8	1 (13)	--	--	8	1 (13)
p value		0.006		--		0.007
2010						
No	41	13 (32)	2	0 (0)	43	13 (30)
Yes	27	14 (52)	2	1 (50)	29	15 (52)
Not sure	9	3 (33)	--	--	9	3 (33)
p value		0.2		0.3		0.2

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 411 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	93	5 (5)
Female	5	1 (20)
p value		0.2

† Excludes missing values.

Gonorrhoea

Table 412 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	93	1 (1)
Female	5	0 (0)
p value		0.8

† Excludes missing values.

Syphilis

Table 413 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	93	2 (2)	2 (2)	2 (2)
Female	4	0 (0)	0 (0)	0 (0)
p value		0.8	--	0.8

† Excludes missing values.

Methodological Notes

- Due to the small number of prisoners screened in the ACT, findings for this jurisdiction are included in the summary section only.
- Percentages over 1 have been rounded up to the nearest whole number while those less than 1 are indicated as '<1'.
- The label 'n/a' refers to survey items that were added or removed from previous years.
- The Accessibility/Remoteness Index of Australia (ARIA)² classification was developed in 1997 and is based on a continuous measure of remoteness developed by the National Key Centre for Social Applications of Geographical Information Systems (GISCA). In this classification, an ARIA category is allocated on the basis of the average ARIA index score (between 0 and 12) within an area (such as an SLA). The ARIA index score is based on the road distance from the closest service centres in each of four classes (as defined using 1996 census population data). ARIA index scores, and therefore ARIA categories, are capable of being updated over time as populations change. ARIA categorises areas into 5 groups as follows:
 1. Highly Accessible - relatively unrestricted accessibility to a wide range of goods and services and opportunities for social interaction.
 2. Accessible - some restrictions to accessibility of some goods, services and opportunities for social interaction.
 3. Moderately Accessible - significantly restricted accessibility of goods, services and opportunities for social interaction.
 4. Remote - very restricted accessibility of goods, services and opportunities for social interaction.
 5. Very Remote - very little accessibility of goods, services and opportunities for social interaction.

For the purpose of this report, 3 ARIA groupings were created: highly accessible + accessible, moderately accessible, and remote + very remote. Categories were allocated by using the postcode the individual had spent most time in during the 12 months before coming into prison.

- Living situation prior to prison was recorded for the first time in 2010. The classification used is based on that proposed by Mackenzie and Chamberlain¹⁸ which includes three categories in recognition of the diversity of homelessness:
 1. Primary homelessness is experienced by people without conventional accommodation (e.g. sleeping rough or in improvised dwellings);
 2. Secondary homelessness is experienced by people who frequently move from one temporary shelter to another (e.g. emergency accommodation, youth refuges, "couchsurfing");
 3. Tertiary homelessness is experienced by people staying in accommodation that falls below minimum community standards (e.g. boarding housing and caravan parks). This definition was adopted by the Commonwealth Advisory Committee on Homelessness in 2001 and is widely used in our sector.
- Hepatitis B immune status was determined in accordance with CDC guidelines - <http://www.cdc.gov/hepatitis/hbv/PDFs/SerologicChartv8.pdf> Participants with surface antibody levels above 10mIU/mL were considered to be immune to hepatitis B infection. In a limited number of cases hepatitis B surface antibody levels were not reported, vaccination conferred immunity to hepatitis B was established through a combination of self-report of

having received three doses of the hepatitis B vaccine and hepatitis B surface-antigen and hepatitis B core-antibody results. Analysis of self-reported hepatitis B vaccination and surface-antibody levels of above 10mIU/mL correlate reasonably well and so justified this approach.

Appendix 1 – Blood Tests, Test Kits and Testing Laboratories**Human Immunodeficiency Virus (HIV) Antibody & Antigen**

HIV Ag/Ab Combo Architect. ABBOTT (USA)

HIV Combi. ROCHE (USA)

ADVIA Centaur HIV Combo Assay. ROBION AG (Switzerland)

Hepatitis B Surface-Antibody

Anti-HBs Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis B Surface-Antigen

HBsAg Qualitative Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis B (IgG & IgM) Core-Antibody

Anti-HBc II Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis B e-Antibody

Anti-HBe Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis B e-Antigen

HBeAg Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis C Antibody

Anti-HCV Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Murex THCv. ABBOTT (USA)

Chiron Riba HCV 3.0 Immunoblot. NOVARTIS (USA)

***Treponema pallidum* Antibody**

TPLA test 2.0. SEKISUI (Japan)

Syphilis TP Architect. ABBOTT (USA)

Serodia *T. pallidum* Hemagglutination Assay. FUJIREBIO (Japan)

Macrovue Rapid Plasma Reagin Assay. BECTON-DICKISON (USA)

TrepoSpot Immunofluorescent. BIOMÉRIEUX (France)

***Chlamydia trachomatis* DNA**

COBAS TaqMan CT test 2.0. ROCHE (USA)

COBAS 4800. ROCHE (USA)

***Neisseria gonorrhoea* DNA**

COBAS Amplicore NG test. ROCHE (USA)

COBAS 4800. ROCHE (USA)

Testing Centres:

ACT ACT Pathology, Canberra

NSW Institute of Clinical Pathology and Medical Research, New South Wales

NT NT Government Pathology Service, Northern Territory

Qld Pathology Queensland, Queensland

SA Institute of Medical and Veterinary Science, Royal Adelaide Hospital, South Australia

Tas Royal Hobart Hospital Pathology Services, Tasmania

Vic Healthscope Pathology, Victoria

Melbourne Pathology, Victoria


WA PathWest Laboratory, Western Australia

2010 National Prison Entrants Bloodborne Viruses & Sexually Transmissible Infections Survey Questionnaire

- 14b. Which places did you inject in the **last month**?
(Tick all that apply)
- Prison
 Own home
 Friend's home
 Dealer's home
 Street, park or beach
 Car
 Public toilet
 Commercial "shooting" room
 MSIC (KX injecting centre in Sydney)
 Squat
 Other (specify) _____
- 14c. How often did you use a **new** sterile needle and syringe in the **last month**?
1. All injections
 2. Most of the time
 3. Half of the time
 4. Some of the time
 5. None of the time
- 14d. Tick all equipment that you used after anyone else in the **last month**?
- Spoon Toumiquet
 Water Drug solution / mix
 Filter Did not share any of above last month
- 14e. How many times **last month** did someone else **inject** you after injecting themselves or others?
1. More than 5 times
 2. 3 to 5 times
 3. Once or twice
 4. None
- 14f. How many times **last month** did you reuse a **needle & syringe** after someone else (including **sex partner**) had used it (even if it was cleaned)?
1. More than 5 times
 2. 3 to 5 times
 3. Twice
 4. Once
 5. None → go to Q15
- 14g. How many **different** people (including your sex partner) have used a needle before you in the **last month** (even if cleaned)?
1. More than 5 people
 2. 3 to 5 people
 3. 2 people
 4. 1 person
 5. Don't know how many
- 14h. Who were these people? (Tick all that apply)
- Regular sex partner
 Other sex partners
 Close friend
 Acquaintance
 Other (specify) _____
15. How many times **last month** did you get needles & syringes from a needle exchange?
1. Daily or almost daily
 2. A couple of times each week
 3. Less than weekly (1-4 times per month)
 4. Once last month
 5. Not in the last month
16. How many times **last month** did you get needles & syringes from a **pharmacy**?
1. Daily or almost daily
 2. A couple of times each week
 3. Less than weekly (2 to 5 times)
 4. Once last month
 5. Not in the last month
17. When was the **last time** you re-used a needle after someone else?
1. Last month
 2. In the last 2 to 6 months
 3. More than 6 months ago
 4. Never → go to Q19
18. Where was the **last place** you re-used a needle or syringe after someone else? (Tick one only)
- Prison
 Own home
 Friend's home
 Dealer's home
 Street, park or beach
 Car
 Public toilet
 Commercial "shooting" room
 MSIC (Kings Cross injecting centre Sydne)
 Squat
 Other (specify) _____
19. Have you **ever** participated in the yearly finger-prick survey at a needle exchange in the community?
1. Yes
 2. No
 3. Don't remember
20. Have you **ever** been on a methadone program?
1. Yes, on it now
 2. Yes, in the past
 3. No, never
21. Have you **ever** been on any other program (eg. naltrexone, buprenorphine or LAAM)?
1. Yes, am on it now
 2. Yes, in the past
 3. No, never
22. Have you **ever** had any other therapies for drug use (e.g. detox, counselling, Narcotics Anonymous)?
1. Yes
 2. No
23. Have you **ever** had hepatitis B infection?
1. Yes
 2. No
 3. Unsure
- 24a. Have you **ever** had hepatitis B vaccination?
1. Yes
 2. No → go to Q25a
 3. Unsure → go to Q25a
- 24b. If **yes**, how many injections have you had?
1. One 2. Two 3. 3 or more
- 25a. Have you ever been tested for HIV?
1. Yes, in the last year
 2. Yes, more than a year ago
 3. Never tested → go to Q26a
- 25b. If **yes**, what was the result of your **last** HIV test?
1. Did not have HIV
 2. I have HIV infection
 3. Don't know the result
 4. Declined to answer
- 26a. Have you been tested for hepatitis C?
1. Yes, in the last year
 2. Yes, more than a year ago
 3. Never tested → go to Q27
- 26b. If **yes**, what was the result of your **last** hepatitis C test?
1. Did not have hepatitis C → go to Q27
 2. I have hepatitis C
 3. Don't know result → go to Q27
- 26c. What year did you find out you had hepatitis C?
- 19/20
- 26d. Have you **ever** had treatment for hepatitis C?
(Tick all that apply)
1. No treatment → go to Q27
 2. Yes, Interferon
 3. Yes, Interferon + Ribavirin
 4. Other (specify) _____
- 26e. If **yes**, are you having treatment for hep C **now**?
1. Yes, Interferon
 2. Yes, Interferon + Ribavirin
 3. No, not currently on treatment
 4. Other (specify) _____
27. Have you had the cervical cancer vaccine (women only)?
1. Yes
 2. No
 3. Unsure
28. Do you identify as:
1. Heterosexual
 2. Bisexual
 3. Gay/lesbian
 4. Unsure
- 29a. How many **female** partners have you had sex with in the last 3 months?
- 29b. Did you use condoms with these partners?
- | | Never | Sometimes | Always |
|---------|----------------------|----------------------|----------------------|
| Regular | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| Casual | <input type="text"/> | <input type="text"/> | <input type="text"/> |
- 29c. How many **male** partners have you had sex with in the last 3 months?
- 29d. Did you use condoms with these partners?
- | | Never | Sometimes | Always |
|---------|----------------------|----------------------|----------------------|
| Regular | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| Casual | <input type="text"/> | <input type="text"/> | <input type="text"/> |
- 29e. Have you been paid for sex in the last 3 months? (include non-cash payments)
1. Yes
 2. No → end of questionnaire
- 29f. If **yes** to Q29e, did you use condoms (or dams) the last time you were paid for sex?
1. Yes → end of questionnaire
 2. No → end of questionnaire

References

1. *Prisoners in Australia. Catalogue No. 4517.0. Australian Bureau of Statistics. Canberra 2010.*
2. *Measuring Remoteness: Accessibility/Remoteness Index of Australia (ARIA). Occasional Paper New Series: Number 14. ISBN: 0 642 50327 3 Publications approval number 2518: Commonwealth Department of Health and Aged Care; 2001.*
3. Butler T, Levy M, Dolan K, Kaldor J. Drug use and its correlates in an Australian prisoner population. *Addiction Research and Theory.* 2003;11:89-101.
4. Gore S, Bird AG. Drugs in British prisons. *British Medical Journal.* 2000;316:1256-1257.
5. Butler T, Papanastasiou C. *National Prison Entrants' Bloodborne Virus and Risk Behaviour Survey Report 2004 & 2007. National Drug Research Institute (Curtin University) & National Centre in HIV Epidemiology and Clinical Research (University of New South Wales). ISBN: 1 74067 582 7. 2008.*
6. Butler T, Spencer J, Cui J, Vickery K, Zou J, Kaldor J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners - NSW, 1996. *Australian & New Zealand Journal of Public Health.* 1999;23:377-384.
7. Butler TG, Dolan KA, Ferson MJ, McGuinness LM, Brown PR, Robertson PW. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. *Medical Journal of Australia.* 1997;166:127-130.
8. Crofts N, Stewart T, Hearne P. Spread of Blood borne viruses among Australian prison entrants. *British Medical Journal.* 1996;310:285-288.
9. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. *European Journal of Epidemiology.* 2000;16:1043-1049.
10. Vescio MF, Longo B, Babudieri S, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. *Journal of Epidemiology and Community Health.* 2008;62:305-313.
11. Malliori M, Sypsa V, Psychogiou M, et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. *Addiction.* 1998;92:243-251.
12. Haber P, Parsons S, Harper S, White P, Rawlinson W, Lloyd A. Transmission of hepatitis C within Australian prisons. *Medical Journal of Australia.* 1999;171:31-33.
13. Post J, Dolan K, Whybin R, Carter I, Haber P, Lloyd A. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. *Medical Journal of Australia.* 2001;174:183-184.
14. Hellard ME, Aitken CK, Hocking JS. Tattooing in prisons - not such a pretty picture. *American Journal of Infection Control.* 2007;35:477-480.
15. Miller ER, Bi P, Ryan P. The prevalence of HCV antibody in South Australian prisoners. *Journal of Infection.* 2006;53:125-130.
16. *National Centre in HIV Epidemiology and Clinical Research. 2010 Annual Surveillance Report. HIV viral hepatitis and sexually transmissible infections in Australia. ISSN 1838-5559. University of New South Wales. 2010.*
17. *Australian NSP Survey. National Data Report 1995-2011. Kirby Institute, University of New South Wales. ISSN 1448-5915. 2011.*
18. *The Road Home. A national approach to reducing homelessness. Commonwealth of Australia 2008. ISBN: 978 1 921380 22 8.*



www.kirby.unsw.edu.au